<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='907'><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate; salmeterol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>fluticasone furoate; vilanterol</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>A 12-week study to compare the 24 h action to restore lung function with the combination of fluticasone furoate (FF) / vilanterol (VI), produced in the form of powder for inhalation and used by patients with chronic obstructive pulmonary disease (COPD), qd, and the combination of salmeterol / fluticasone propionate (FP), in the form of powder for inhalation, applied bid</ProtocolTitle><Reference>2010-021059-25; HZC113107</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="165373"/><TrialStartDate>FEBRUARY , 22, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Charcoal; Seretide Diskus; Seretide Diskus; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Reference>3106007; EudraCT 2012-00378-41; NCT01766843</Reference><Sponsor>Orion Corp</Sponsor><Trial id="104633"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ocular infection</Condition><Controls>prednisolone acetate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><EnrollmentCount>132</EnrollmentCount><Interventions>tobramycin + prednisolone acetate (ophthalmic), ISTA</Interventions><Patients>132</Patients><ProtocolAcronym/><ProtocolTitle>A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte</ProtocolTitle><Reference>ISTA-TP-CPK01; NCT00198523</Reference><Sponsor>ISTA Pharmaceuticals Inc</Sponsor><Trial id="10077"/><TrialStartDate>JULY     , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Retinopathy</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>9</EnrollmentCount><Interventions>aflibercept; aflibercept; triamcinolone acetonide; verteporfin</Interventions><Patients>9</Patients><ProtocolAcronym>PED</ProtocolAcronym><ProtocolTitle>A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes</ProtocolTitle><Reference>2012/1743; NCT01746875; PED</Reference><Sponsor>Norwegian University of Science and Technology (NTNU)</Sponsor><Trial id="101391"/><TrialStartDate>FEBRUARY , 28, 2014</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Atopic dermatitis</Condition><Controls>mometasone</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57631">auranofin + mometasone furoate (Sorafin dermatological formulation), Viralytics</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>Sorafin-AD</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>Phase II proof-of-concept trial of Sorafin-AD ointment versus topical mometasone in adults with atopic dermatitis</ProtocolTitle><Reference>PSX-AD-001</Reference><Sponsor>Viralytics Ltd</Sponsor><Trial id="69513"/><TrialStartDate>AUGUST   , 09, 2005</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>658</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone</Interventions><Patients>528</Patients><ProtocolAcronym>STAR</ProtocolAcronym><ProtocolTitle>A randomized, open-label, parallel-group study to compare the safety and efficacy of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma</ProtocolTitle><Reference>BY9010/M1-134; STAR</Reference><Sponsor>Takeda GmbH</Sponsor><Trial id="76911"/><TrialStartDate>NOVEMBER , 28, 2006</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12806">dexamethasone cipecilate</Drug><EnrollmentCount/><Interventions>dexamethasone cipecilate</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Phase III, parallel group, comparative trial of NS-126C and fluticasone propionate in patients with perennial allergic rhinitis</ProtocolTitle><Reference>JapicCTI-050155</Reference><Sponsor>Hisamitsu Pharmaceutical Co Inc, Nippon Shinyaku Co Ltd</Sponsor><Trial id="104452"/><TrialStartDate>OCTOBER  , 20, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Glucose; Insulin; Serum albumin (ALB); Serum corticosteroid-binding globulin (CBG); Serum cortisol</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>hydrocortisone</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><EnrollmentCount>14</EnrollmentCount><Interventions>dexamethasone; hydrocortisone (oral granules, adrenal insufficiency), Diurnal</Interventions><Patients>14</Patients><ProtocolAcronym/><ProtocolTitle>An Investigational Study of Hydrocortisone</ProtocolTitle><Reference>INFACORT 002; NCT01960530</Reference><Sponsor>Diurnal Ltd</Sponsor><Trial id="157428"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Xerophthalmia</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>722</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>722</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients</ProtocolTitle><Reference>C-10-078; NCT01276223</Reference><Sponsor>Alcon Research Ltd</Sponsor><Trial id="73801"/><TrialStartDate>FEBRUARY , 28, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>430</EnrollmentCount><Interventions>Relovair; fluticasone; fluticasone furoate</Interventions><Patients>430</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 microg qd With Fluticasone Propionate (FP) 250 microg bid and FP 100 microg bid in Well-Controlled Asthmatic Japanese Subjects</ProtocolTitle><Reference>201135; JapicCTI-142503; NCT02094937</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="178963"/><TrialStartDate>MARCH    , 27, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; serum cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>GW685698X</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>A phase II, multicenter, randomized, double-blind, placebo-controlled, incomplete block, three-way crossover study to determine the effect of repeat inhaled doses of GW685698X compared to fluticasone propionate, on airway responsiveness to adenosine 5'-monophosphate (AMP) in patients with mild asthma</ProtocolTitle><Reference>FFA10022</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="87425"/><TrialStartDate>SEPTEMBER, 11, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>360</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>360</Patients><ProtocolAcronym/><ProtocolTitle>Comparator Study Evaluating Patient Experience And Preference Of FFNS versus FPNS</ProtocolTitle><Reference>FFU105927; NCT00519636</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11559"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>calcipotriol + betamethasone dipropionate, LEO</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>An Exploratory, Open-Label, Intra-Individual, Active-Controlled Study Comparing the Efficacy and Safety of Betesil Versus Daivobet for the Treatment of Chronic Plaque Psoriasis</ProtocolTitle><Reference>08F/BET01; EudraCT 2008-005518-29</Reference><Sponsor>Laboratoires Genevrier SA</Sponsor><Trial id="118017"/><TrialStartDate>DECEMBER , 01, 2008</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Alopecia areata</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>minoxidil; tacrolimus; triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Study of the Safety and Efficacy Of Intralesional Steroid, Tacrolimus (0.1%) Ointment and Minoxidil (5%) in the Treatment of Alopecia Areata</ProtocolTitle><Reference>CTRI/2013/08/003880</Reference><Sponsor>Father Muller Med Coll</Sponsor><Trial id="154386"/><TrialStartDate>OCTOBER  , 12, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Retinal thickness</Biomarkers><Condition>Eale disease</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Clinical study about ophthalmic local administrations of triamcinolone acetonide for macular edema and/or retinal periphlebitis</ProtocolTitle><Reference>JPRN-UMIN000005778</Reference><Sponsor>Yamagata University</Sponsor><Trial id="121608"/><TrialStartDate>JULY     , 01, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Gastrointestinal disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><EnrollmentCount>2</EnrollmentCount><Interventions>orBec</Interventions><Patients>2</Patients><ProtocolAcronym/><ProtocolTitle>Study of orBec as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)</ProtocolTitle><Reference>BDP-GVHD-08; NCT01925950</Reference><Sponsor>Soligenix Inc</Sponsor><Trial id="151308"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Skin atrophy</Condition><Controls>Karison® Creme; mometasone furoate; nortriptyline HCl</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="56234">mometasone + nortriptyline (topical cream, psoriasis), CombinatoRx</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>CRx-191</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Phase I study of topical CRx-191 in normal healthy volunteers</ProtocolTitle><Reference>CRx-191-002; EudraCT Number: 2006-005903-33; NCT00544687</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="23649"/><TrialStartDate>SEPTEMBER, 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>130</EnrollmentCount><Interventions>Budenofalk; Entocort; Flagyl; Medrol; azathioprine; folic acid; infliximab; methotrexate; prednisolone</Interventions><Patients>130</Patients><ProtocolAcronym/><ProtocolTitle>The Ideal Management of Crohn's Disease: Top-Down Versus Step-Up Strategies - A Prospective, Controlled Trial in the Benelux</ProtocolTitle><Reference>ISRCTN61510219; NTR379</Reference><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><Trial id="120593"/><TrialStartDate>MAY      , 01, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>intraocular pressure</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60951">triamcinolone acetonide (controlled release/intravitreal injection/Verisome, diabetic macular edema), EyePoint</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>IBI-20089</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>An Open-Label, Dose-Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery</ProtocolTitle><Reference>ACTRN12608000603314</Reference><Sponsor>Icon Bioscience Inc</Sponsor><Trial id="120774"/><TrialStartDate>MAY      , 11, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Retinitis pigmentosa</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>87</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>87</Patients><ProtocolAcronym/><ProtocolTitle>Intravitreal Injection of Triamcinolone Acetonide in Retinitis</ProtocolTitle><Reference>IRCT201104266293N1</Reference><Sponsor>Tehran University of Medical Sciences</Sponsor><Trial id="122471"/><TrialStartDate>SEPTEMBER, 23, 2007</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Adrenocorticotropic Hormone; Hydrocortisone</Biomarkers><Condition>Ulcerative colitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>2</EnrollmentCount><Interventions>Entocort; hydrocortisone</Interventions><Patients>2</Patients><ProtocolAcronym/><ProtocolTitle>The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis</ProtocolTitle><Reference>H-30365; NCT00805285</Reference><Sponsor>University of Maryland</Sponsor><Trial id="193417"/><TrialStartDate>OCTOBER  , 31, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>6 beta-Hydroxycortisol; Hydrocortisone</Biomarkers><Condition>Asthma</Condition><Controls>albuterol; montelukast</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>111</EnrollmentCount><Interventions>Ellipta; albuterol; montelukast</Interventions><Patients>111</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-Pituitary-Adrenocortical Axis of Children Aged 5 to 11 Years With Asthma</ProtocolTitle><Reference>107118; NCT02483975</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="233443"/><TrialStartDate>OCTOBER  , 09, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Cortisol; Heart rate; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>GW-642444M; GW-685698X; fluticasone furoate + vilanterol</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects</ProtocolTitle><Reference>HZA105871; NCT00538057</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="23398"/><TrialStartDate>OCTOBER  , 02, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>1121</EnrollmentCount><Interventions>Alvesco</Interventions><Patients>1121</Patients><ProtocolAcronym>ACCEPT</ProtocolAcronym><ProtocolTitle>Asthma Care With Alvesco (Ciclesonide) in Primary Care in Adults</ProtocolTitle><Reference>ACCEPT; BY9010/CA-102; NCT00404547</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="22240"/><TrialStartDate>NOVEMBER , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CRP; cytokines</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="45643">prednisolone + paroxetine (rheumatoid arthritis, inflammation), CombinatoRx</Drug><EnrollmentCount>220</EnrollmentCount><Interventions>prednisolone + paroxetine (rheumatoid arthritis, inflammation), CombinatoRx</Interventions><Patients>220</Patients><ProtocolAcronym/><ProtocolTitle>A phase II, multicenter, randomized, blinded study of 14 weeks duration comparing the effect of CRx-139 plus DMARD therapy to that of steroid plus DMARD therapy using ACR-20 in subjects with active rheumatoid arthritis partially responsive to the DMARD</ProtocolTitle><Reference>CRx-139-002; CRx-139-RA; CZ::Protocol CRx-139-002; EudraCT 2004-004995-35; Protocol CRx-139-002</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="133649"/><TrialStartDate>FEBRUARY , 24, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls>prednisone; salbutamol, GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; prednisone; salbutamol, GlaxoSmithKline</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>Repeat Emergency Department Visits Among Patients With Asthma and COPD</ProtocolTitle><Reference>754754; NCT02499887</Reference><Sponsor>State University of New York</Sponsor><Trial id="235195"/><TrialStartDate>JANUARY  , 31, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>1568</Patients><ProtocolAcronym/><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="22103"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ulcerative proctitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>252</EnrollmentCount><Interventions>Rectabul; budesonide rectal suppository</Interventions><Patients>252</Patients><ProtocolAcronym/><ProtocolTitle>Novel budesonide suppository versus budesonide foam in acute ulcerative proctitis</ProtocolTitle><Reference>2016-001921-15; BUS-4/UCA</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="291869"/><TrialStartDate>MARCH    , 09, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Examine the Effect of Repeat Inhaled Doses of GW-870086X on Lung Function in Mild Asthmatic Male Subjects</ProtocolTitle><Reference>NCT00483899; SIG102335</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="22317"/><TrialStartDate>OCTOBER  , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>150</Patients><ProtocolAcronym/><ProtocolTitle>The Role Of Intra-Operative Peri-Articular Steroid Injection In Reducing Post-Operative Pain And Improving Knee Function After Total Knee Arthroplasty: a Prospective, Randomized, Controlled Trial</ProtocolTitle><Reference>ACTRN12609000345280; ANZCTR83890</Reference><Sponsor>Rhone-Poulenc Rorer Ltd</Sponsor><Trial id="134330"/><TrialStartDate>JUNE     , 01, 2009</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>288</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>288</Patients><ProtocolAcronym/><ProtocolTitle>A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>FFR30002; NCT00103454</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="13384"/><TrialStartDate>JANUARY  , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Choroidal neovascularization</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>photodynamic therapy; triamcinolone acetonide; verteporfin</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (In Combination With Intravitreal Triamcinolone Acetonide): A Prospective, Randomized, Comparative Study</ProtocolTitle><Reference>EudraCT 2005-000776-41</Reference><Sponsor>Medical University of Vienna</Sponsor><Trial id="139550"/><TrialStartDate>JUNE     , 22, 2005</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>4820</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>4820</Patients><ProtocolAcronym/><ProtocolTitle>A 12-Month, Open-Label, Randomized, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW-685698/vilanterol (VI, GW-642444) Inhalation Powder Delivered Once Daily via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma</ProtocolTitle><Reference>CCRN 997; UKCRN:13263</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="139569"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Spinal stenosis</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>lidocaine; triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Effect Of Pulsed Radiofrequency Treatment Of The Dorsal Root Ganglion In Spinal Stenosis With Intermittent Neurogenic Claudication</ProtocolTitle><Reference>KCT0000743</Reference><Sponsor>Asan Medical Center</Sponsor><Trial id="143635"/><TrialStartDate>OCTOBER  , 06, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic retinopathy</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>23</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>23</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Intravitreal Triamcinolone Acetonide before Pan Retinal Photocoagulation for Improvement of Visual Acuity and Macular Edema in Diabetic Retinopathy</ProtocolTitle><Reference>ACTRN12607000225415; HREC 356</Reference><Sponsor>Farabi Eye Hospital</Sponsor><Trial id="143664"/><TrialStartDate>NOVEMBER , 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>19</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>19</Patients><ProtocolAcronym/><ProtocolTitle>The Use of Intravitreal Injection of Triamcinolone Acetonide in Diabetic Patients to Reduce Diabetic Macular Edema</ProtocolTitle><Reference>ACTRN12613000249752</Reference><Sponsor>Suez Canal University</Sponsor><Trial id="138776"/><TrialStartDate>MARCH    , 25, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>intraocular pressure</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Tobradex</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="56575">dexamethasone + netilmicin (ophthalmic), SIFI</Drug><EnrollmentCount>103</EnrollmentCount><Interventions>Netildex</Interventions><Patients>103</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of the efficacy and safety of a new steroid-antibiotic ophthalmic gel as anti-inflammatory and antimicrobial topical treatment following microincisional vitreo-retinal surgery</ProtocolTitle><Reference>2008-005082-64</Reference><Sponsor>SIFI Societa Industria Farmaceutica Italiana SpA</Sponsor><Trial id="138949"/><TrialStartDate>OCTOBER  , 13, 2008</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Graft versus host disease</Condition><Controls/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>beclomethasone dipropionate; prednisone</Interventions><Patients>140</Patients><ProtocolAcronym>SUPPORTS</ProtocolAcronym><ProtocolTitle>Study of orBec With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)</ProtocolTitle><Reference>2010-022247-37; ACTRN12610000593033; BDP-GVHD-03; NCT00926575; SUPPORTS</Reference><Sponsor>Soligenix Inc</Sponsor><Trial id="58209"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Choroid disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Fluocinolone implant to treat macular degeneration</ProtocolTitle><Reference>01-EI-0058; 010058; NCT00008515</Reference><Sponsor>National Eye Institute</Sponsor><Trial id="4710"/><TrialStartDate>JANUARY  , 31, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort; budesonide; formoterol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>3316</EnrollmentCount><Interventions>PT-009</Interventions><Patients>2389</Patients><ProtocolAcronym>TELOS</ProtocolAcronym><ProtocolTitle>Study to Assess Efficacy and Safety of PT-009 Compared to PT-005, PT-008 and Symbicort Turbuhaler on Lung Function Over 24 Weeks in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Reference>2016-000154-34; D7820C00001; NCT02766608; PT009002; TELOS</Reference><Sponsor>AstraZeneca AB, Pearl Therapeutics Inc</Sponsor><Trial id="260435"/><TrialStartDate>MAY      , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ulcerative colitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Rectabul</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>Phase III study of AJG-511 in patients with active ulcerative colitis</ProtocolTitle><Reference>AJG511/CT1; JapicCTI-142704</Reference><Sponsor>EA Pharma Co Ltd</Sponsor><Trial id="215968"/><TrialStartDate>NOVEMBER , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>1113</EnrollmentCount><Interventions>Qvar</Interventions><Patients>1113</Patients><ProtocolAcronym/><ProtocolTitle>A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants &gt;/= 12 Years Old With Persistent Asthma</ProtocolTitle><Reference>2013-003397-27; BDB-AS-301; DRKS00005827; NCT02031640</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="167002"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Serum cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>A Study of GW-685698X in Healthy Japanese Male Subjects</ProtocolTitle><Reference>112018; HZA112018; NCT00972673</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="60174"/><TrialStartDate>SEPTEMBER, 24, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anterior chamber</Biomarkers><Condition>Cataract</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>EGP-437</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL</ProtocolTitle><Reference>EGP-437-005; NCT01602068</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="87599"/><TrialStartDate>MAY      , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Afamin; Afamin; Angiopoietin-2; Angiopoietin-2; Angiotensinogen; Angiotensinogen; Ankle motion; Blood pressure; Body Mass Index; Body height; Body temperature; C-C motif chemokine 22; C-C motif chemokine 22; Collagen type I trimeric cross-linked peptide; Dystrophin; Elbow motion; Fibrinogen gamma chain; Fibrinogen gamma chain; Glucose; Growth hormone receptor; Growth hormone receptor; Heart rate; Hydrocortisone; Insulin; Insulin; Insulin-like growth factor binding protein 2; Insulin-like growth factor binding protein 2; Insulin-like growth factor-binding protein 5; Insulin-like growth factor-binding protein 5; Integrin alpha-1; Integrin alpha-1; Integrin alpha1beta1; Integrin alpha1beta1; Interleukin-22 receptor subunit alpha-2; Interleukin-22 receptor subunit alpha-2; Intraocular pressure; Knee motion; Leptin; Leptin; Low affinity immunoglobulin epsilon Fc receptor; Low affinity immunoglobulin epsilon Fc receptor; Lymphocytes; Lymphotoxin-alpha; Lymphotoxin-alpha; Lymphotoxin-beta; Lymphotoxin-beta; Macrophage metalloelastase; Macrophage metalloelastase; Osteocalcin; Procollagen Type I N-terminal peptide; Respiratory frequency; Saposin-D; Saposin-D; Six-minute walk distance; Stromelysin-1; Stromelysin-1; T-lymphocyte surface antigen Ly-9; T-lymphocyte surface antigen Ly-9; Total body mass</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>prednisone; vamorolone; vamorolone</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="70712">vamorolone</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>vamorolone</Interventions><Patients>120</Patients><ProtocolAcronym>VISION DMD</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Reference>118942; 2017-002704-27; FDA IND 118942; NCT03439670; VBP15-004; VBP15-004-A1; VBP15-004-A2; VBP15-004-A3; VISION DMD</Reference><Sponsor>ReveraGen BioPharma Inc</Sponsor><Trial id="329964"/><TrialStartDate>JUNE     , 19, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="91606">budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Multiple-dose, Pharmacokinetics Study of 'SYN-006 HFA MDI' Administered Orally to Healthy Volunteers</ProtocolTitle><Reference>MCPK10002J1; NCT02165033</Reference><Sponsor>Benefit Biotechnology Co, Ltd, Intech Biopharm Ltd</Sponsor><Trial id="203681"/><TrialStartDate>NOVEMBER , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alkaline phosphatase; Blood pressure; Body temperature; Estradiol; Follicle-stimulating hormone; Glucose; Heart rate; Hydrocortisone; Luteinizing Hormone; Lymphocytes; PR interval; Prostate-specific antigen; QRS complex; QT interval; Sex hormone-binding globulin; Testosterone</Biomarkers><Condition>Bone metastases</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77410">dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>Oncocort</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Study investigating intravenously administrated Oncocort in patients with metastatic prostate cancer</ProtocolTitle><Reference>2016-003121-42; CHDR1635</Reference><Sponsor>Enceladus Pharmaceuticals</Sponsor><Trial id="291118"/><TrialStartDate>NOVEMBER , 28, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>547</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>547</Patients><ProtocolAcronym/><ProtocolTitle>Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>BDP-AR-306; NCT01783548</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="107743"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Herpesvirus infection</Condition><Controls>acyclovir</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><EnrollmentCount>1443</EnrollmentCount><Interventions>ME-609</Interventions><Patients>2437</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy And Safety Study Of ME-609 And Acyclovir For Treatment Of Herpes Simplex Labialis</ProtocolTitle><Reference>609-04; NCT00361881</Reference><Sponsor>Medivir AB</Sponsor><Trial id="11577"/><TrialStartDate>JULY     , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>formoterol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>1941</EnrollmentCount><Interventions>PT-009</Interventions><Patients>1941</Patients><ProtocolAcronym>Sophos</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of PT-009 Compared to PT-005 on COPD Exacerbations Over a 52 Weeks Period in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Reference>2016-000155-28; D7820C00002; NCT02727660; PT009003; Sophos</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="257369"/><TrialStartDate>APRIL    , 29, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume; Fractional concentration of exhaled nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>Relvar</Interventions><Patients>27</Patients><ProtocolAcronym/><ProtocolTitle>A Phase IIa, FF/VI Study to Measure FeNO in Asthmatic Patients</ProtocolTitle><Reference>201499; NCT02712047</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="256043"/><TrialStartDate>APRIL    , 29, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cortisol</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>474</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>450</Patients><ProtocolAcronym/><ProtocolTitle>Phase IV Fluticasone Furoate Nasal Spray (Veramyst) Long-Term Pediatric Growth Study</ProtocolTitle><Reference>EudraCT: 2007-005148-26; FFR101782; NCT00570492</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="14133"/><TrialStartDate>NOVEMBER , 26, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Corneal endothelium; Fundus of eye; Intraocular pressure; Visual acuity</Biomarkers><Condition>Ocular inflammation</Condition><Controls>prednisolone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><EnrollmentCount>194</EnrollmentCount><Interventions>IBI-10090</Interventions><Patients>194</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery</ProtocolTitle><Reference>C15-01; NCT02547623</Reference><Sponsor>Icon Bioscience Inc</Sponsor><Trial id="240288"/><TrialStartDate>NOVEMBER , 06, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>Zentacort</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>Investigation of the safety and efficacy of Budesonide (Zentacort capsules) in patients with Crohn's disease</ProtocolTitle><Reference>JapicCTI-184152</Reference><Sponsor>Zeria Pharmaceutical Co Ltd</Sponsor><Trial id="357577"/><TrialStartDate>SEPTEMBER, 30, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>CLS-1003; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Interventions><Patients>20</Patients><ProtocolAcronym>HULK</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema</ProtocolTitle><Reference>CLS1004-101; HULK; NCT02944240; NCT02949024</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="277937"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Macula retinae; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>64</Patients><ProtocolAcronym>TDMX Study</ProtocolAcronym><ProtocolTitle>Open-Label, Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Edema</ProtocolTitle><Reference>ACTRN12605000244606; NCT00148330; NHMRC project 402573; TDMX Study</Reference><Sponsor>University of Sydney</Sponsor><Trial id="177951"/><TrialStartDate>MAY      , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Patients>170</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Reference>NCT01011621; PRE/P/08-1</Reference><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><Trial id="180987"/><TrialStartDate>FEBRUARY , 28, 2010</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seborrheic dermatitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Patients>170</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Reference>NCT01011621; PRE/P/08-1</Reference><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><Trial id="180987"/><TrialStartDate>FEBRUARY , 28, 2010</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Fovea centralis</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation Of Durezol9415 For Macular Edema And Neovascular Disease</ProtocolTitle><Reference>JPRN-UMIN000001432; UMIN000001432</Reference><Sponsor>Yamagata University</Sponsor><Trial id="234454"/><TrialStartDate>NOVEMBER , 01, 2008</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>2020</EnrollmentCount><Interventions>Relovair; fluticasone furoate</Interventions><Patients>2019</Patients><ProtocolAcronym/><ProtocolTitle>Asthma Exacerbation Study</ProtocolTitle><Reference>106837; 2009-011461-84; HZA106837; JapicCTI-101072; NCT01086384</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="64836"/><TrialStartDate>FEBRUARY , 22, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>101</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>101</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 years)</ProtocolTitle><Reference>BY9010/AR-101; NCT00305461</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="22129"/><TrialStartDate>FEBRUARY , 28, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>397</EnrollmentCount><Interventions>canakinumab; canakinumab-LYO; canakinumab-PFS</Interventions><Patients>399</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients</ProtocolTitle><Reference>2010-024173-39; CACZ885H2361; NCT01356602</Reference><Sponsor>Novartis AG</Sponsor><Trial id="77484"/><TrialStartDate>MAY      , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>708</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>700</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Ciclesonide Versus Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid</ProtocolTitle><Reference>EFC6164; NCT00174720; XRP1526B/3031</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="22083"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>110</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>110</Patients><ProtocolAcronym/><ProtocolTitle>A 12-Week Study To Compare Lung Function Within 24 H With The Combination Of Fluticasone Furoate (FF)/Vilanterol (VI) Of 100/25 microg, qd, And A Combination Of Fluticasone Propionate/Salmeterol Of 250/50 microg, bid, In Patients With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>2010-023418-29; HZC113109</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="165358"/><TrialStartDate>APRIL    , 06, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>248</EnrollmentCount><Interventions>albuterol/salbutamol; fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>242</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma</ProtocolTitle><Reference>115283; FFA115283; NCT01436071</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="80899"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>338</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="197089"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>C-terminal telopeptide of collagen type I; Collagen type I trimeric cross-linked peptide; Plasma cortisol; Plasma insulin; Serum adiponectin; Serum glucose; Serum osteocalcin; Urine N terminal telopeptide of type I collagen (uNTX)</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59618">fosdagrocorat</Drug><EnrollmentCount>27</EnrollmentCount><Interventions>PF-04171327</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions</ProtocolTitle><Reference>A9391012; NCT01362673</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="77776"/><TrialStartDate>MAY      , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Glycated hemoglobin; Hydrocortisone</Biomarkers><Condition>Addisons disease</Condition><Controls>hydrocortisone</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Interventions><Patients>64</Patients><ProtocolAcronym>DC 06/02</ProtocolAcronym><ProtocolTitle>Once-Daily Oral Modified-Release Hydrocortisone in Patients With Adrenal Insufficiency</ProtocolTitle><Reference>104-07; DC 06/02; EudraCT: 2006-0007084-89; NCT00915343</Reference><Sponsor>Shire plc</Sponsor><Trial id="57668"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Bone Mineral Density (BMD); Lumbar spine bone mineral density</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>283</EnrollmentCount><Interventions>Relovair</Interventions><Patients>283</Patients><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Effect of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>102972; 2012-004801-28; HZC102972; NCT01957150</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157075"/><TrialStartDate>JANUARY  , 28, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>Symbicort Turbohaler; Viani</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>422</EnrollmentCount><Interventions>Relvar Ellipta</Interventions><Patients>422</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy study to evaluate fluticasone furoate/vilanterol inhalation powder delivered once daily via the Dry Powder Inhaler Ellipta compared with usual ICS/LABA maintenance therapy delivered by dry powder Inhaler in subjects with persistent asthma</ProtocolTitle><Reference>2014-000551-81; HZA116492</Reference><Sponsor>GlaxoSmithKline Research &amp; Development Ltd</Sponsor><Trial id="309224"/><TrialStartDate>AUGUST   , 01, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood cell count; Thyroid-stimulating hormone</Biomarkers><Condition>Vulvar intraepithelial neoplasia</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>clobetasol; tacrolimus</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus</ProtocolTitle><Reference>NCT00757874; STJUSTINEH</Reference><Sponsor>CHU de Quebec-Universite Laval</Sponsor><Trial id="198682"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ataxia telangiectasia</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>EryDex</Interventions><Patients>180</Patients><ProtocolAcronym>ATTeST</ProtocolAcronym><ProtocolTitle>EDS in Ataxia Telangiectasia Patients</ProtocolTitle><Reference>115929; 2015-005241-31; ATTeST; CTRI/2017/02/007912; IEDAT-02-2015; NCT02770807</Reference><Sponsor>EryDel SPA</Sponsor><Trial id="260767"/><TrialStartDate>MARCH    , 02, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Blood pressure; Diastolic blood pressure; Glucose; Heart rate; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>CHF-5993; HFA-pressurised Metered Dose Inhaler; NEXThaler Dry Powder Inhaler; Valved Holding Chamber</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF-5993 in Healthy Volunteers</ProtocolTitle><Reference>2015-005198-19; CCD-05993BA1-01; NCT02743013</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="258618"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Adrenal gland hypofunction</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>Infacort</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Treatment of Adrenal Insufficiency in Children</ProtocolTitle><Reference>2014-002265-30; INFACORT-003; NCT02720952</Reference><Sponsor>Diurnal Ltd</Sponsor><Trial id="256755"/><TrialStartDate>MARCH    , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Atrophy</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>17</EnrollmentCount><Interventions>Medidur FA</Interventions><Patients>17</Patients><ProtocolAcronym/><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy</ProtocolTitle><Reference>C-01-08-004; NCT00695318</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="32426"/><TrialStartDate>DECEMBER , 01, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Heart rate; Heart rate; Serum cortisol; Serum potassium</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>Relovair</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Effects of Fluticasone Furoate and GW-642444-M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment</ProtocolTitle><Reference>111789; NCT01266941</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="73503"/><TrialStartDate>OCTOBER  , 18, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>GW-642444; fluticasone furoate; fluticasone furoate/GW-642444</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW-642444 Are Processed by the Body in Healthy Subjects</ProtocolTitle><Reference>102934; NCT01299558</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="75477"/><TrialStartDate>MAY      , 17, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Blood platelets; Neutrophils</Biomarkers><Condition>Graft versus host disease</Condition><Controls>Medrol; Rayos</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>439</EnrollmentCount><Interventions>Medrol; Rayos; itacitinib</Interventions><Patients>439</Patients><ProtocolAcronym>GRAVITAS-301</ProtocolAcronym><ProtocolTitle>A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease</ProtocolTitle><Reference>2017-000538-78; GRAVITAS-301; INCB 39110-301; INCB39110-301; NCT03139604</Reference><Sponsor>Incyte Corp, MEDPACE SINGAPORE PTE LTD</Sponsor><Trial id="297219"/><TrialStartDate>JUNE     , 08, 2017</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood flow; Cephalic vein; Radial artery</Biomarkers><Condition>Fistula</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Nanocort</Interventions><Patients>30</Patients><ProtocolAcronym>LIPMAT</ProtocolAcronym><ProtocolTitle>Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation</ProtocolTitle><Reference>2015-002488-40; LIPMAT; LIPMAT; NCT02495662</Reference><Sponsor>Leiden University Medical Center</Sponsor><Trial id="234690"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1; Peak Expiratory Flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><EnrollmentCount>421</EnrollmentCount><Interventions>fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>421</Patients><ProtocolAcronym>ILA115938</ProtocolAcronym><ProtocolTitle>Evaluate the Safety, Efficacy and Dose Response of GSK-573719 in Combination With Fluticasone Furoate in Subjects With Asthma</ProtocolTitle><Reference>115938; ILA115938; ILA115938; NCT01573624</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="86335"/><TrialStartDate>APRIL    , 03, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume; Inspiratory capacity</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount/><Interventions>PT-009; PT-010</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>To Assess the Efficacy and Safety of PT-010 Compared to PT-009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>NCT03081247; PT010017</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="290987"/><TrialStartDate>APRIL    , 16, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study to Compare Fluticasone Furoate (FF) Single-strip Inhaler With FF Two-strip Inhaler and With FF/Vilanterol Combination</ProtocolTitle><Reference>115440; NCT01485445</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="82997"/><TrialStartDate>DECEMBER , 21, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Arthralgia</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>526</EnrollmentCount><Interventions>CINGAL</Interventions><Patients>526</Patients><ProtocolAcronym/><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-up</ProtocolTitle><Reference>2017-003205-18; CINGAL 17-02; NCT03390036</Reference><Sponsor>Anika Therapeutics Inc</Sponsor><Trial id="324751"/><TrialStartDate>DECEMBER , 07, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Enteritis</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>SGX-201</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>A Dose-Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer</ProtocolTitle><Reference>1R43CA141968-01; BDP-ENT-01; NCT01073384</Reference><Sponsor>Soligenix Inc</Sponsor><Trial id="64387"/><TrialStartDate>DECEMBER , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Bone mineral density; Lumbar spine bone mineral density</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>PT-003; PT-009; PT-010; symbicort</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Safety and Tolerability of PT-010, PT-009 and PT-003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>NCT02536508; NCT03313570; PT010008</Reference><Sponsor>AstraZeneca plc, Pearl Therapeutics Inc</Sponsor><Trial id="239329"/><TrialStartDate>AUGUST   , 10, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Adrenal gland hypofunction</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>Infacort</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration</ProtocolTitle><Reference>2016-001388-36; INFACORT 006; NCT03178214</Reference><Sponsor>Diurnal Ltd</Sponsor><Trial id="300900"/><TrialStartDate>MAY      , 22, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Chronic sinusitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="103922">mometasone furoate (sustained release transmucosal formulation, chronic sinusitis), Lyra Therapeutics</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>mometasone</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>480 Biomedical Sinus Drug Depot</ProtocolTitle><Reference>480MFSDD2016-001; NCT02942186; NCT02967731</Reference><Sponsor>Lyra Therapeutics</Sponsor><Trial id="280158"/><TrialStartDate>JUNE     , 06, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls>mometasone (nasal/ dermatological)</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>125</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>125</Patients><ProtocolAcronym/><ProtocolTitle>Long Term Safety Of GW-685698X Via Nasal Biopsy</ProtocolTitle><Reference>FFR104503; NCT00224523</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="12096"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>288</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>285</Patients><ProtocolAcronym/><ProtocolTitle>Study In Adults And Adolescents With Seasonal Allergic Rhinitis</ProtocolTitle><Reference>FFR103184; NCT00225823</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="12097"/><TrialStartDate>MAY      , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cortisol</Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>FX-006</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of FX-006 in Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>FX006-2011-002; NCT01487200</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="83055"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Aspartate aminotransferase; Bicarbonates; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Erythrocytes; Glucose; Heart; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lung; Mean corpuscular hemoglobin; Nitrite; Phosphate; Potassium; Skin; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea nitrogen; Uric acid; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Psoriasis</Condition><Controls>betamethasone valerate</Controls><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="112485">SEGRA (topical, plaque psoriasis), Leo Pharma</Drug><EnrollmentCount>13</EnrollmentCount><Interventions>LEO-134310</Interventions><Patients>13</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis</ProtocolTitle><Reference>2018-000140-26; LP0155-1375; NCT03669757</Reference><Sponsor>LEO Pharma A/S</Sponsor><Trial id="353433"/><TrialStartDate>SEPTEMBER, 27, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>ACR20; ACR50; ACR70; Joint swelling; Joint tenderness</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>prednisone (oral, delayed release), Horizon/Mundipharma</Interventions><Patients>350</Patients><ProtocolAcronym>CAPRA-2</ProtocolAcronym><ProtocolTitle>Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra) Therapy in Patients With Active Rheumatoid Arthritis</ProtocolTitle><Reference>CAPRA-2; EudraCT-Number: 2007-003508-36; NCT00650078; NP01-007</Reference><Sponsor>Horizon Pharma plc</Sponsor><Trial id="9663"/><TrialStartDate>MARCH    , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Skin</Biomarkers><Condition>Psoriasis</Condition><Controls>calcipotriene + betamethasone dipropionate; calcipotriol; clobetasol; prednicarbate</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="46177">mapracorat</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>mapracorat</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Open Psoriasis Plaque Test to Evaluate Efficacy of Different Comparator to Mapracorat</ProtocolTitle><Reference>1404003; 16599; 2012-004171-39; NCT03399526</Reference><Sponsor>Bayer AG</Sponsor><Trial id="325659"/><TrialStartDate>FEBRUARY , 11, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>160</EnrollmentCount><Interventions>OTO-104</Interventions><Patients>160</Patients><ProtocolAcronym/><ProtocolTitle>Phase III Study of OTO-104 in Subjects With Unilateral Meniere's Disease</ProtocolTitle><Reference>104-201811; NCT03664674</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="352993"/><TrialStartDate>AUGUST   , 27, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>serum cortisol</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>loratadine; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis</ProtocolTitle><Reference>2014-004646-98; NCT01154153; TRICA_L_04286</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="67836"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls>Lucentis</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount/><Interventions>Iluvien; Lucentis</Interventions><Patients/><ProtocolAcronym>CASSIE</ProtocolAcronym><ProtocolTitle>Randomized, Control Trial on Combined Iluvien and Lucentis for Diabetic Macular Oedema</ProtocolTitle><Reference>CASSIE; NCT03784443; P78912</Reference><Sponsor>Imperial College London</Sponsor><Trial id="364319"/><TrialStartDate>SEPTEMBER, 01, 2019</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>377</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>377</Patients><ProtocolAcronym/><ProtocolTitle>Comparator Study Evaluating Patient Preference Of FFNS versus FPNS</ProtocolTitle><Reference>FFU105924; NCT00539006</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11295"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>clobetasol propionate foam, Connetics</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>triamcinolone</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails</ProtocolTitle><Reference>NCT01703325; Si599/2010</Reference><Sponsor>Mahidol University</Sponsor><Trial id="94221"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Pemphigoid</Condition><Controls>Dermovate; orabase</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Reference>00UAD; NCT03878771</Reference><Sponsor>Beni-Suef University</Sponsor><Trial id="373754"/><TrialStartDate>MARCH    , 13, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Mouth ulcer</Condition><Controls>Dermovate; orabase</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Reference>00UAD; NCT03878771</Reference><Sponsor>Beni-Suef University</Sponsor><Trial id="373754"/><TrialStartDate>MARCH    , 13, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced Vital Capacity; Fukutin-related protein; Maximal expiratory pressure; Maximal inspiratory mouth pressure</Biomarkers><Condition>Limb girdle muscular dystrophy</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>deflazacort</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>A Study of Deflazacort (Emflaza) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)</ProtocolTitle><Reference>NCT03783923; PTCEMF-GD-004-LGMD</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="364440"/><TrialStartDate>MAY      , 15, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>6 beta-Hydroxycortisol; Hydrocortisone</Biomarkers><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>58</EnrollmentCount><Interventions>clarithromycin; deflazacort; deflazacort; rifampin</Interventions><Patients>58</Patients><ProtocolAcronym/><ProtocolTitle>Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single-Dose Pharmacokinetics of Deflazacort</ProtocolTitle><Reference>MP-104-CL-025; NCT02286635</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="215408"/><TrialStartDate>NOVEMBER , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="61788">glucocorticoid receptor agonists (immune disorders, inflammatory diseases), Bristol-Myers Squibb</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>BMS-791826; prednisolone</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males</ProtocolTitle><Reference>IM125-001; NCT03198013</Reference><Sponsor>Bristol-Myers Squibb Co</Sponsor><Trial id="303059"/><TrialStartDate>NOVEMBER , 11, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><EnrollmentCount/><Interventions>GK-664-S</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A Phase III Clinical Study of GK-664S in Plaque Psoriasis Patients</ProtocolTitle><Reference>JapicCTI-152858</Reference><Sponsor>Maruho Co Ltd</Sponsor><Trial id="226223"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Lichen</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>betamethasone; triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Positive Controlled, Parallel, Phase II Trial To Evaluate The Efficacy And Safety Of Betamethasone Injection In The Local Blockage Treatment Of Oral Erosion Lichen Planus</ProtocolTitle><Reference>ChiCTR-TRC-11001225</Reference><Sponsor>Sichuan University</Sponsor><Trial id="91441"/><TrialStartDate>JUNE     , 01, 2010</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Ear pressure</Biomarkers><Condition>Middle ear disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>91</EnrollmentCount><Interventions>Azmacort</Interventions><Patients>91</Patients><ProtocolAcronym/><ProtocolTitle>Short-Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays</ProtocolTitle><Reference>103-04; IST4008; NCT00279916; XRG5029C/4008</Reference><Sponsor>Mayo Clinic Foundation</Sponsor><Trial id="11760"/><TrialStartDate>SEPTEMBER, 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume in 1 s; Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls>Flixotide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>510</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>510</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 200, 400, 600 and 800 microg Administered qd in the Morning and Fluticasone Propionate 500 microg bid via Diskus Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (= 12 years old) with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy</ProtocolTitle><Reference>EudraCT 2005-001122-87; FFA20003</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="117748"/><TrialStartDate>SEPTEMBER, 19, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>9</EnrollmentCount><Interventions>aflibercept; aflibercept; triamcinolone acetonide; verteporfin</Interventions><Patients>9</Patients><ProtocolAcronym>PED</ProtocolAcronym><ProtocolTitle>A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes</ProtocolTitle><Reference>2012/1743; NCT01746875; PED</Reference><Sponsor>Norwegian University of Science and Technology (NTNU)</Sponsor><Trial id="101391"/><TrialStartDate>FEBRUARY , 28, 2014</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls>bevacizumab; triamcinolone acetonide; verteporfin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount/><Interventions>bevacizumab; verteporfin</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Combined PDT and Intravitreal Bevacizumab versus Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD</ProtocolTitle><Reference>8542; NCT00370539</Reference><Sponsor>Shaheed Beheshti Medical University</Sponsor><Trial id="33340"/><TrialStartDate>SEPTEMBER, 30, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Pigment epithelium-derived factor; Retinal thickness; Vascular endothelial growth factor; Vascular endothelial growth factors</Biomarkers><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide; verteporfin</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized Controlled Trial of Intravitreal Bevacizumab Monotherapy Versus Triple Therapy With Half Fluence Verteporfin Photodynamic Therapy and Intravitreal Bevacizumab and Triamcinolone Acetonide for the Treatment of Neovascular Age-Related Macular Degeneration</ProtocolTitle><Reference>CUHK_CCT00272; ChiCTR-TRC-10001137</Reference><Sponsor>Hong Kong Eye Hospital</Sponsor><Trial id="94644"/><TrialStartDate>AUGUST   , 26, 2010</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>431</EnrollmentCount><Interventions>budesonide; ciclesonide</Interventions><Patients>403</Patients><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, double-dummy, parallel-group study to investigate the efficacy and safety of ciclesonide compared with budesonide in adolescents with severe asthma</ProtocolTitle><Reference>EudraCT No: 2004-001233-41</Reference><Sponsor>Takeda GmbH</Sponsor><Trial id="76905"/><TrialStartDate>FEBRUARY , 12, 2007</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Vitiligo</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo</ProtocolTitle><Reference>H12-02140; NCT01766609</Reference><Sponsor>University of British Columbia</Sponsor><Trial id="104547"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; FVC</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>456</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>456</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid</ProtocolTitle><Reference>EFC6163; NCT00174733; XRP1526B/3030</Reference><Sponsor>Sanofi SA, Takeda Pharmaceuticals International GmbH</Sponsor><Trial id="22084"/><TrialStartDate>JULY     , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Hypertrophic skin disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>5-fluorouracil; bleomycin; triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Intralesional Bleomycin in Comparision to Combination of Intralesional 5-Fluorouracil and Triamcinolone Acetonide in Patients of Keloid and Hypertrophic Scars: A Randomized, Open-Labelled, Comparative Study</ProtocolTitle><Reference>CTRI/2013/11/004155</Reference><Sponsor>Government Medical College, Bhavnagar</Sponsor><Trial id="162474"/><TrialStartDate>MARCH    , 01, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64584">PF-4308515</Drug><EnrollmentCount>58</EnrollmentCount><Interventions>PF-04308515</Interventions><Patients>58</Patients><ProtocolAcronym/><ProtocolTitle>Multiple-Dose Escalation Trial Of PF-04308515 In Healthy Volunteers</ProtocolTitle><Reference>B0861002; NCT01101932</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="65603"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls>Entocort</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>ciprofloxacin; metronidazole; trimethoprim</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>A Pilot, Randomized Study to Compare Antibiotic Therapy (Ciprofloxacin, Trimethoprim and Metronidazole) with Standard Therapy (Budesonide) in the Treatment of Active Crohns Disease</ProtocolTitle><Reference>UKCRN 13163</Reference><Sponsor>Royal Liverpool and Broadgreen University Hospitals NHS Trust</Sponsor><Trial id="116894"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; PEF</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>164</EnrollmentCount><Interventions>salmeterol; triamcinolone acetonide</Interventions><Patients>164</Patients><ProtocolAcronym>SCOS</ProtocolAcronym><ProtocolTitle>A 28-week, randomized, triple-blinded, placebo-controlled, parallel-group study to assess the effectiveness of long-acting beta-2-agonist, salmeterol monotherapy versus continued therapy with inhaled corticosteroids (ICS) in patients with persistent asthma</ProtocolTitle><Reference>SCOS</Reference><Sponsor>University of California</Sponsor><Trial id="76806"/><TrialStartDate>FEBRUARY , 28, 1997</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>651</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>651</Patients><ProtocolAcronym/><ProtocolTitle>A phase IV, open-label study to assess the safety and efficacy of Nasacort in patients with seasonal and perennial allergic rhinitis</ProtocolTitle><Reference>XRG5029C/4005</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="89194"/><TrialStartDate>MARCH    , 22, 2002</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls>budesonide (inhaled formulations), AstraZeneca</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>476</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>476</Patients><ProtocolAcronym/><ProtocolTitle>A phase IV, multicenter, randomized, single-blind, active-controlled, parallel group study to assess the safety and efficacy of Nasacort compared to Rhinocort Aqua in patients with seasonal allergic rhinitis</ProtocolTitle><Reference>XRG5029C/4007</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="91058"/><TrialStartDate>FEBRUARY , 12, 2003</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Skin allergy</Condition><Controls>methylprednisolone aceponate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>82</EnrollmentCount><Interventions>clobetasol propionate foam, Connetics</Interventions><Patients>82</Patients><ProtocolAcronym/><ProtocolTitle>Randomized Study on the Effectiveness, Safety and Acceptability Of Clobetasol Propionate Foam-cooled (OLUX) in Comparison With Cream Aceponato Methylprednisolone in the Treatment of Allergic Contact Dermatitis</ProtocolTitle><Reference>EudraCT 2008-004331-38; olux 01/08</Reference><Sponsor>Mipharm SpA</Sponsor><Trial id="117327"/><TrialStartDate>AUGUST   , 28, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate Opthalmic Emulsion in the Treatment of Postoperative Inflammation</ProtocolTitle><Reference>NCT00407225; SJE2079/2-01-PC</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21570"/><TrialStartDate>DECEMBER , 31, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>237</EnrollmentCount><Interventions>cetirizine; fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>237</Patients><ProtocolAcronym/><ProtocolTitle>A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study of Intranasal Fluticasone Once Daily Compared with Once-Daily Cetirizine in the Treatment of Seasonal Allergic Rhinitis</ProtocolTitle><Reference>FNM40072</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="153743"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>440</EnrollmentCount><Interventions>Qvar</Interventions><Patients>440</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Two Doses of Qvar by Breath Operated and Metered Dose Inhalers in Asthmatic Children</ProtocolTitle><Reference>IXR-302-25-197; NCT00094016</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="22290"/><TrialStartDate>OCTOBER  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Dermatitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="64063">triamcinolone acetonide (DuraPeel cream, dermatitis/psoriasis), Nuvo Research</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>triamcinolone acetonide (DuraPeel cream, dermatitis), Nuvo Research</Interventions><Patients>56</Patients><ProtocolAcronym>TAC-202</ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis</ProtocolTitle><Reference>NCT00890968; TAC-202; TAC-202</Reference><Sponsor>ZARS Pharma Inc</Sponsor><Trial id="88586"/><TrialStartDate>APRIL    , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Choroidal neovascularization</Condition><Controls>verteporfin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>triamcinolone acetonide; verteporfin</Interventions><Patients>400</Patients><ProtocolAcronym>TPDT</ProtocolAcronym><ProtocolTitle>The Safety and Efficacy of Posterior Juxta-scleral (40 mg) or Intra-vitreal (4 mg) Triamcinolone Acetonide, in Addition to Verteporfin Photodynamic Therapy for Choroidal Neovascularization (CNV), in Age-related Macular Degeneration (AMD): A Randomized, Controlled Trial</ProtocolTitle><Reference>ISRCTN81615611; NRR Pub ID N0503172670 (03428); TPDT</Reference><Sponsor>Newcastle Upon Tyne Hospitals NHS Trust</Sponsor><Trial id="122573"/><TrialStartDate>OCTOBER  , 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="83838">budesonide (controlled release/inhaled/AKITA, adult asthma), Vectura</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>budesonide (controlled release/inhaled/AKITA, adult asthma),  Activaero</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>An Open-Label Randomized Pilot Trial to Evaluate Tolerability, Safety and Applicability of AKITA Inhaled Budesonide Suspension in Children aged 3 to 11 years with Mild to Moderate Asthma</ProtocolTitle><Reference>Acti-SCIPE-001; EudraCT 2010-023981-27</Reference><Sponsor>Activaero GmbH</Sponsor><Trial id="118612"/><TrialStartDate>MARCH    , 08, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus</ProtocolTitle><Reference>3106008; EUDRACT 2012-003782-18; NCT01856621</Reference><Sponsor>Orion Corp</Sponsor><Trial id="132070"/><TrialStartDate>MAY      , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>transpupillary thermal rherapy; triamcinolone acetonide</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration</ProtocolTitle><Reference>ISRCTN74123635</Reference><Sponsor>Asociacion Para Evitar la Ceguera en Mexico</Sponsor><Trial id="122141"/><TrialStartDate>FEBRUARY , 01, 2004</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>triamcinolone acetonide; verteporfin</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>A Pilot Study to Examine the Safety and Efficacy of Posterior Juxtascleral Triamcinolone Acetonide Administration, in Addition to Visudyne Photoynamic Therapy for Predominantly Classic Choroidal Neovascularization Secondary to Age Related Macular Degeneration: An Open-Label, Randomized, Active-Controlled Trial</ProtocolTitle><Reference>EudraCT 2005-002466-11; version125/05/05</Reference><Sponsor>Kings College Hospital NHS Trust</Sponsor><Trial id="142831"/><TrialStartDate>JANUARY  , 03, 2006</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls>ranibizumab</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>ranibizumab; triamcinolone acetonide</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Combination therapy for DME</ProtocolTitle><Reference>UMIN000021630</Reference><Sponsor>Mie University School of Medicine</Sponsor><Trial id="256819"/><TrialStartDate>FEBRUARY , 01, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Eosinophils; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort Turbuhaler</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>1800</EnrollmentCount><Interventions>PT-003; PT-009; PT-010</Interventions><Patients>1900</Patients><ProtocolAcronym>KRONOS</ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multicenter Study to Assess the Efficacy and Safety of PT-010, PT-003, and PT-009 Compared With Symbicort Turbuhaler</ProtocolTitle><Reference>JapicCTI-184079; KRONOS; NCT02497001; PT010006</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="234795"/><TrialStartDate>AUGUST   , 10, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>budesonide (inhaled formulations), AstraZeneca; procaterol hydrochloride (Meptin Air)</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="91606">budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Bioavailability Study of SYN-006, Pulmicort pMDI and Meptin Air in Healthy Adult</ProtocolTitle><Reference>MCPK09003J1; NCT02165046</Reference><Sponsor>Intech Biopharm Ltd</Sponsor><Trial id="197305"/><TrialStartDate>FEBRUARY , 29, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Interventions><Patients>150</Patients><ProtocolAcronym/><ProtocolTitle>Phase II study of Efficacy and Safety of SJE-2079 in the Treatment for Diabetic Macular Edema</ProtocolTitle><Reference>JPRN-UMIN000005648</Reference><Sponsor>Senju Usa Inc</Sponsor><Trial id="124785"/><TrialStartDate>OCTOBER  , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume; Hydrocortisone; PR interval; Peak expiratory flow rate; QRS complex; QT interval</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Single-Dose GW-685698X Magnesium Stearate Study In Asthmatic Patients</ProtocolTitle><Reference>HZA108799; NCT00444509</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="22276"/><TrialStartDate>FEBRUARY , 17, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>To Determine the Efficacy of Subacromial Bursa Corticosteroid Injection in Stroke Patients With Periarticular Shoulder Disorder</ProtocolTitle><Reference>AJIRB-MED-CT4-09-124; KCT0000104</Reference><Sponsor>Ajou University Hospital</Sponsor><Trial id="127285"/><TrialStartDate>AUGUST   , 20, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>End stage renal disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>deflazacort</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>A Single-Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics</ProtocolTitle><Reference>MP-104-CL-024; NCT02286622</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="215407"/><TrialStartDate>DECEMBER , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>208</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>208</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Safety of Repeat Administration of FX-006 Administered to Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>FX006-2016-011; NCT03046446</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="287683"/><TrialStartDate>FEBRUARY , 21, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Lichen</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>An Evaluation of The Assistant Efficacy of Periodontal Treatment for The Oral Erosion Lichen Planus and The Post-Treatment</ProtocolTitle><Reference>ChiCTR-TRC-13004128</Reference><Sponsor>Sichuan University</Sponsor><Trial id="168620"/><TrialStartDate>APRIL    , 01, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Herpesvirus infection</Condition><Controls>acyclovir</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><EnrollmentCount>201</EnrollmentCount><Interventions>ME-609</Interventions><Patients>201</Patients><ProtocolAcronym/><ProtocolTitle>Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients</ProtocolTitle><Reference>609-06; NCT00735761</Reference><Sponsor>Medivir AB</Sponsor><Trial id="23402"/><TrialStartDate>DECEMBER , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cytokine</Biomarkers><Condition>Ulcerative colitis</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Periappendiceal Injection of Steroids in Ulcerative Colitis</ProtocolTitle><Reference>CTRI/2012/04/002605; Project number: P-130</Reference><Sponsor>Postgraduate Institute of Medical Education and Research</Sponsor><Trial id="128187"/><TrialStartDate>JULY     , 01, 2012</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness Intra-articular Corticosteroid</ProtocolTitle><Reference>IIA- 3131- AR; NCT01851278</Reference><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><Trial id="129636"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Carbomix granules; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>129</EnrollmentCount><Interventions>Carbomix granules; fluticasone propionate + salmeterol xinafoate; fluticasone propionate + salmeterol xinafoate</Interventions><Patients>129</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus</ProtocolTitle><Reference>3106009; NCT02162485</Reference><Sponsor>Orion Corp</Sponsor><Trial id="196211"/><TrialStartDate>JUNE     , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>102</EnrollmentCount><Interventions>GW-685698</Interventions><Patients>102</Patients><ProtocolAcronym/><ProtocolTitle>A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis</ProtocolTitle><Reference>2015-004888-37; FFR111158; NCT00730756</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="22961"/><TrialStartDate>MARCH    , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Collagen; Lymphocytes</Biomarkers><Condition>Colitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>106</EnrollmentCount><Interventions>budesonide</Interventions><Patients>106</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide for Induction of Remission in Incomplete Microscopical Colitis</ProtocolTitle><Reference>2013-001912-31; BUG-3/MIC; NCT02142634</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="188822"/><TrialStartDate>MAY      , 31, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Avamys; Relovair</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Reference>HZA102940; NCT00625196</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="23384"/><TrialStartDate>FEBRUARY , 27, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Patients>105</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, Randomized, Three Parallel-Groups to Estimate the Safety and Efficacy of Triamcinolone Acetonide Associated Laser, the Laser Associated Bevacizumab Versus Laser Alone for the Treatment of Diffuse Diabetic Macular Edema</ProtocolTitle><Reference>ALBA2009; EudraCT 2009-014654-15</Reference><Sponsor>Roche Holding AG, Sanofi SA</Sponsor><Trial id="130318"/><TrialStartDate>JULY     , 07, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume in 1 s (FEV1); Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>612</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>609</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW-642444) in Adult and Adolescent Asthmatics</ProtocolTitle><Reference>106827; 2010-019590-15; HZA106827; NCT01165138; P/119/2011</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="68324"/><TrialStartDate>AUGUST   , 20, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Lichen</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="111733">clobetasol propionate  patch (intraoral, bio-adhesive, oral lichen planus), Dermtreat Aps</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>Rivelin-CLO</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>Intra-oral Treatment of OLP With Rivelin-CLO Patches</ProtocolTitle><Reference>2017-002193-40; DT-001-R-004; NCT03592342</Reference><Sponsor>AFYX Therapeutics</Sponsor><Trial id="346927"/><TrialStartDate>JUNE     , 28, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Dystrophin; Muscle; Six-minute walk distance</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>deflazacort; prednisone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>ataluren</Interventions><Patients>230</Patients><ProtocolAcronym>ACT DMD</ProtocolAcronym><ProtocolTitle>Phase III Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy</ProtocolTitle><Reference>2012-004527-20; 2017-001223-49; 431; 68; ACT DMD; IND Number Number: 68,431; NCT01826487; PTC124-GD-020-DMD</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="119769"/><TrialStartDate>MARCH    , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intra-ocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount/><Interventions>triamcinolone acetonide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Randomized, Controlled Trial of Intravitreal Triamcinolone in Patients with Diabetic Macular edema Refractory to Laser Treatment</ProtocolTitle><Reference>ISRCTN90614292; N0192133909</Reference><Sponsor>Department of Health</Sponsor><Trial id="135441"/><TrialStartDate>NOVEMBER , 28, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>288</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>288</Patients><ProtocolAcronym/><ProtocolTitle>Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)</ProtocolTitle><Reference>FFR104861; NCT00197262</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="13577"/><TrialStartDate>AUGUST   , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount/><Interventions>grid laser photocoagulation treatment; triamcinolone acetonide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>The Safety and Efficacy of Combined Subtenon Triamcinolone and Grid Laser Photocoagulation as Primary Treatment for Diabetic Macular Edema - A Pilot Study</ProtocolTitle><Reference>CUHK_CCT00130; ChiCTR-TRC-09000743</Reference><Sponsor>Chinese University of Hong Kong</Sponsor><Trial id="135786"/><TrialStartDate>JUNE     , 09, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>fexofenadine; fluticasone furoate</Interventions><Patients>1000</Patients><ProtocolAcronym/><ProtocolTitle>Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine</ProtocolTitle><Reference>2015-004885-27; FFU109045; NCT00435461</Reference><Sponsor>GlaxoSmithKline Inc</Sponsor><Trial id="13581"/><TrialStartDate>DECEMBER , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62431">budesonide + azelastine (intranasal Captisol-enabled, allergic rhinitis), Sedor Pharmaceuticals</Drug><EnrollmentCount>108</EnrollmentCount><Interventions>Astelin; CDX-313; Rhinocort Aqua</Interventions><Patients>108</Patients><ProtocolAcronym/><ProtocolTitle>Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis</ProtocolTitle><Reference>CDX313CT001; NCT00940953; P2DS07001</Reference><Sponsor>Ligand Pharmaceuticals Inc</Sponsor><Trial id="58894"/><TrialStartDate>FEBRUARY , 29, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Glucose; Heart rate; Peak expiratory flow rate; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>Pulmicort Turbuhaler; Serevent Diskus</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>Busal</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>A study to compare the blood concentration of budesonide and the bronchodilatory effect after administration of the following study drugs: Budesonide-Salmeterol DPI capsule 75-25 microg, Budesonide-Salmeterol DPI capsule 75-12.5 microg, Budesonide-Salmeterol DPI capsule 75-6.25 microg delivered by the Axahaler versus Serevent Diskus 50 microg + Pulmicort Turbuhaler 100 microg co-administration in asthmatic children</ProtocolTitle><Reference>2017-003330-91; BUSAL-II-17-1</Reference><Sponsor>Laboratoires SMB SA</Sponsor><Trial id="337272"/><TrialStartDate>NOVEMBER , 29, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Heart rate; Hydrocortisone; Potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>GW-642444-M; fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>An open-label, non-randomized, pharmacokinetic and safety study of repeat-doses of fluticasone furoate and GW-42444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment</ProtocolTitle><Reference>2010-020157-13; HZA111789</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="257760"/><TrialStartDate>SEPTEMBER, 20, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Heart rate; Hydrocortisone; Potassium</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>GW-642444-M; fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>An open-label, non-randomized, pharmacokinetic and safety study of repeat-doses of fluticasone furoate and GW-42444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment</ProtocolTitle><Reference>2010-020157-13; HZA111789</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="257760"/><TrialStartDate>SEPTEMBER, 20, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>65</EnrollmentCount><Interventions>GW-685698</Interventions><Patients>65</Patients><ProtocolAcronym/><ProtocolTitle>Study Of Perennial Allergic Rhinitis</ProtocolTitle><Reference>FFR100688; JapicCTI-050024; NCT00358475</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="13878"/><TrialStartDate>JUNE     , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Peak nasal inspiratory flow; Peak nasal inspiratory flow</Biomarkers><Condition>Allergic rhinitis</Condition><Controls>fexofenadine</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>680</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>680</Patients><ProtocolAcronym/><ProtocolTitle>Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine</ProtocolTitle><Reference>2015-004873-34; FFU109047; NCT00502775</Reference><Sponsor>GlaxoSmithKline Inc</Sponsor><Trial id="13883"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume in 1 s</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>49</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Qvar Versus Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients</ProtocolTitle><Reference>IXR-402-4-196; NCT00071552</Reference><Sponsor>IVAX Research Inc, Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="22588"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Eosinophils; FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1626</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate</Interventions><Patients>1626</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>102871; HZC102871; NCT01009463</Reference><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><Trial id="61703"/><TrialStartDate>SEPTEMBER, 25, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><EnrollmentCount>625</EnrollmentCount><Interventions>Airexar Spiromax; fluticasone</Interventions><Patients>1363</Patients><ProtocolAcronym/><ProtocolTitle>Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma</ProtocolTitle><Reference>2014-001149-25; FSS-AS-301; NCT02139644</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="187642"/><TrialStartDate>MAY      , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Glucose; PR interval; Peak expiratory flow rate; QRS complex; QT interval</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>870</EnrollmentCount><Interventions>ELLIPTA dry powder inhaler; Ellipta</Interventions><Patients>870</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma</ProtocolTitle><Reference>107116; 2016-004086-87; CTR20181312; HZA107116; JapicCTI-183937; NCT03248128</Reference><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><Trial id="308779"/><TrialStartDate>OCTOBER  , 20, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Blepharoconjunctivitis</Condition><Controls>AzaSite; dexamethasone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55854">azithromycin + dexamethasone (sustained release, DuraSite), InSite</Drug><EnrollmentCount/><Interventions>AzaSite Plus</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis</ProtocolTitle><Reference>C-07-502-003; NCT00754949</Reference><Sponsor>InSite Vision Inc</Sponsor><Trial id="28944"/><TrialStartDate>SEPTEMBER, 16, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1; Heart rate; Plasma glucose; Plasma potassium</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>AeroChamber Plus; Foster; Qvar; formoterol fumarate (Atimos)</Interventions><Patients>60</Patients><ProtocolAcronym>ADO pMDI</ProtocolAcronym><ProtocolTitle>Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients</ProtocolTitle><Reference>2011-005108-14; ADO pMDI; CCD-1104-PR-0062; NCT01803087</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="113665"/><TrialStartDate>FEBRUARY , 29, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>85</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; budesonide</Interventions><Patients>85</Patients><ProtocolAcronym/><ProtocolTitle>To Compare the Clinical Effects of Beclomethasone Dipropionate MDI With Spacer and Budesonide MDI With Spacer in the Treatment of Children With Mild Persistent Asthma Aged 7 to 15 Years</ProtocolTitle><Reference>CTRI/2013/03/003495</Reference><Sponsor>Department of Pharmacology, PGIMER</Sponsor><Trial id="156545"/><TrialStartDate>NOVEMBER , 04, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Fluocinolone implant to treat macular degeneration</ProtocolTitle><Reference>01-EI-0058; 010058; NCT00008515</Reference><Sponsor>National Eye Institute</Sponsor><Trial id="4710"/><TrialStartDate>JANUARY  , 31, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Retina</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide; vitrectomy</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Vitrectomy combined with IVTA for DME</ProtocolTitle><Reference>UMIN000017250</Reference><Sponsor>Tohoku University</Sponsor><Trial id="228441"/><TrialStartDate>MAY      , 01, 2015</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Carbon monoxide diffusing capacity</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>95</EnrollmentCount><Interventions>Anoro Ellipta; Arnuity Ellipta; hyper polarized xenon-129 MRI</Interventions><Patients>95</Patients><ProtocolAcronym/><ProtocolTitle>Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics</ProtocolTitle><Reference>19352; NCT03002389</Reference><Sponsor>University of Virginia</Sponsor><Trial id="283200"/><TrialStartDate>NOVEMBER , 05, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Chalazion</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>5-fluorouracil; 5-fluorouracil; incision and curettage; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>120</Patients><ProtocolAcronym>CTS</ProtocolAcronym><ProtocolTitle>Chalazia Treatment Study</ProtocolTitle><Reference>42336; 42336-D; CTS; NCT02025023; STUDY00003748</Reference><Sponsor>University of Washington</Sponsor><Trial id="165479"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>1226</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Patients>1224</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>112207; 2009-013067-19; HZC112207; JapicCTI-101097; NCT01054885</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="63564"/><TrialStartDate>OCTOBER  , 19, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Cortisol; FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1031</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Patients>1030</Patients><ProtocolAcronym/><ProtocolTitle>A 6-Month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>112206; HZC112206; JapicCTI-101096; NCT01053988</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="63573"/><TrialStartDate>OCTOBER  , 05, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Xerophthalmia</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>BOL-303242X</Interventions><Patients>350</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Safety and Efficacy of BOL-303242X Ophthalmic Suspension in Dry Eye Syndrome</ProtocolTitle><Reference>637; EudraCT: 2010-018441-61; NCT01163643</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="68287"/><TrialStartDate>JULY     , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>PT-009; PT-010; Symbicort Turbohaler</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety Study of PT-010 in Healthy Subjects</ProtocolTitle><Reference>NCT02189304; PT010002-00</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="204168"/><TrialStartDate>JUNE     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Dermatitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>clobetasol propionate</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Dermatitis</ProtocolTitle><Reference>NCT00828464; U0280-401</Reference><Sponsor>Stiefel</Sponsor><Trial id="55280"/><TrialStartDate>OCTOBER  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>Foster; Foster; Tiotropium Respimat</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>1433</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>1433</Patients><ProtocolAcronym>TRIGGER</ProtocolAcronym><ProtocolTitle>Triple in Asthma High Strength Versus ICS/LABA HS and Tiotropium</ProtocolTitle><Reference>2015-000717-40; CCD-05993AB2-02; NCT02676089; TRIGGER</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="252801"/><TrialStartDate>APRIL    , 06, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>408</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>408</Patients><ProtocolAcronym/><ProtocolTitle>A 24-week study to evaluate the effect of fluticasone furoate/vilanterol 100/25 microg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>2010-023091-10; HZC113108</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="220553"/><TrialStartDate>APRIL    , 05, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure</Biomarkers><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>241</Patients><ProtocolAcronym/><ProtocolTitle>Second, Phase III Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Reference>NCT02089113; OTX-14-003</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="178013"/><TrialStartDate>APRIL    , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Airway resistance; Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume; Lung; Lung clearance index; Partial pressure of oxygen</Biomarkers><Condition>Asthma</Condition><Controls>Relvar Ellipta</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>Abriff</Interventions><Patients>105</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar Ellipta DPI on Ventilation Heterogeneity in Asthma</ProtocolTitle><Reference>2015-000801-38; KFL3502; NCT02753712</Reference><Sponsor>Mundipharma International Corp Ltd</Sponsor><Trial id="259438"/><TrialStartDate>JUNE     , 15, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>PT-009; budesonide; formoterol</Interventions><Patients>180</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of PT-009, PT-008, and PT-005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>NCT02196077; PT009001</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="205952"/><TrialStartDate>AUGUST   , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>PT-009; budesonide; formoterol</Interventions><Patients>180</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of PT-009, PT-008, and PT-005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>NCT02196077; PT009001</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="205952"/><TrialStartDate>AUGUST   , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Nasal polyps</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Compare the Effects of Fluticasone Furoate Nasal Spray versus Placebo in Patients With Nasal Polypoid Disease</ProtocolTitle><Reference>NA_00029405; NCT01013701</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="61959"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Xerophthalmia</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>43</EnrollmentCount><Interventions>OTX-DP</Interventions><Patients>43</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye</ProtocolTitle><Reference>NCT02468700; OTX-14-006</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="231838"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Central cornea; Intraocular pressure; Macula retinae</Biomarkers><Condition>Ocular infection</Condition><Controls>Moxeza; nepafenac; prednisolone acetate</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="95157">triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Harrow Health</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>TriMoxiVanc; TriMoxiVanc; nepafenac</Interventions><Patients>66</Patients><ProtocolAcronym/><ProtocolTitle>Dropless Versus Standard Drops Contralateral Eye Study</ProtocolTitle><Reference>CEP 14-002; NCT02515045</Reference><Sponsor>Carolina Eyecare Physicians, LLC</Sponsor><Trial id="236566"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Dystrophin</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>deflazacort</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort</ProtocolTitle><Reference>MP-104-CL-022OLE; NCT02295748</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="216535"/><TrialStartDate>DECEMBER , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Colitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>92</EnrollmentCount><Interventions>budesonide; mesalazine</Interventions><Patients>92</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide Capsules Versus Mesalazine Granules Versus Placebo in Collagenous Colitis</ProtocolTitle><Reference>2006-004159-39; BUC-60/COC; NCT00450086</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="19193"/><TrialStartDate>MARCH    , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>2020</EnrollmentCount><Interventions>Relovair; fluticasone furoate</Interventions><Patients>2019</Patients><ProtocolAcronym/><ProtocolTitle>Asthma Exacerbation Study</ProtocolTitle><Reference>106837; 2009-011461-84; HZA106837; JapicCTI-101072; NCT01086384</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="64836"/><TrialStartDate>FEBRUARY , 22, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body surface area</Biomarkers><Condition>Psoriasis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><EnrollmentCount>213</EnrollmentCount><Interventions>Bryhali</Interventions><Patients>213</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis</ProtocolTitle><Reference>NCT02515097; V01-122A-302</Reference><Sponsor>Bausch Health Companies Inc</Sponsor><Trial id="236598"/><TrialStartDate>NOVEMBER , 10, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>142</EnrollmentCount><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide; triamcinolone acetonide</Interventions><Patients>65</Patients><ProtocolAcronym>ATEMD</ProtocolAcronym><ProtocolTitle>Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema</ProtocolTitle><Reference>108/08; ATEMD; NCT00737971</Reference><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><Trial id="24389"/><TrialStartDate>AUGUST   , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>480</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Patients>480</Patients><ProtocolAcronym/><ProtocolTitle>Beclomethasone dipropionate HFA in adult and adolescent subjects with persistent asthma</ProtocolTitle><Reference>APC-1000-02; NCT03834012</Reference><Sponsor>Adamis Pharmaceuticals Corp</Sponsor><Trial id="369472"/><TrialStartDate>FEBRUARY , 28, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>CHF-5993; hydrofluoroalkane 134-a pressurized-metered dose inhaler (HFA pMDI)</Interventions><Patients>24</Patients><ProtocolAcronym>Triple study</ProtocolAcronym><ProtocolTitle>Pharmacokineticsof the active components of anextrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G)delivered via a hydrofluoroalkane 134-a pressurized-metered dose inhaler (HFA pMDI) in Chinese healthy adults</ProtocolTitle><Reference>ChiCTR1800019095; Triple study</Reference><Sponsor>Chiesi Farmaceutici SpA, West China Hospital</Sponsor><Trial id="358796"/><TrialStartDate>OCTOBER  , 29, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Blood pressure; Carbon dioxide; Chlorides; Creatine kinase; Creatinine; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Hydrocortisone; Ketones; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; Potassium; Sodium; Total protein; Urea; Urea nitrogen; Uric acid; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>187</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>187</Patients><ProtocolAcronym/><ProtocolTitle>A Long-term Safety Study of Fluticasone Furoate (FF)/GW-642444 in Japanese Subjects With COPD</ProtocolTitle><Reference>114156; JapicCTI-101342; NCT01192191</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="230954"/><TrialStartDate>AUGUST   , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>338</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="197089"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Ocular inflammation</Condition><Controls>prednisolone acetate</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>Durezol</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate versus Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery</ProtocolTitle><Reference>NCT01244334; SEMC 5/2009-011</Reference><Sponsor>Cincinnati Eye Institute</Sponsor><Trial id="72412"/><TrialStartDate>MARCH    , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular pain</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>OTX-DP</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Reference>NCT01666210; OTX-12-002</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="90260"/><TrialStartDate>OCTOBER  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Reference>NCT01550471; RC#5401</Reference><Sponsor>West Penn Allegheny Health System Inc</Sponsor><Trial id="86234"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Body temperature; Bone mineral density; Calcium; Carbon dioxide; Chlorine; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Forced expiratory volume; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; Phosphorus; Potassium; Sodium; Systolic blood pressure; Urea nitrogen; Uric acid; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Ellipta; umeclidinium bromide</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1058</EnrollmentCount><Interventions>Elebrato Ellipta</Interventions><Patients>1055</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>200812; 2015-005212-14; JapicCTI-163329; NCT02729051</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="257588"/><TrialStartDate>JUNE     , 29, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Allergic conjunctivitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56186">ciclosporin + prednisolone (allergic conjunctivitis), CombinatoRx/Fovea</Drug><EnrollmentCount>716</EnrollmentCount><Interventions>cyclosporine; cyclosporine + prednisolone (allergic conjunctivitis), CombinatoRx/Fovea; prednisolone</Interventions><Patients>716</Patients><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Efficacy of Administration of Cyclosporine (Low-Dose and High-Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis</ProtocolTitle><Reference>10-003-03; FOV1101/CLIN202; NCT01120132</Reference><Sponsor>Fovea Pharmaceuticals SA</Sponsor><Trial id="66292"/><TrialStartDate>MAY      , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Blood pressure; Calcium; Carbon dioxide; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; FEV1; Glucose; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; PEF; Phosphorus; Potassium; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Urea; Uric acid; Urinary protein; cortisol; gamma-Glutamyltransferase</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>627</EnrollmentCount><Interventions>fluticasone; fluticasone furoate</Interventions><Patients>627</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy</ProtocolTitle><Reference>2007-004458-98; FFA109684; NCT00603746</Reference><Sponsor>GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline plc</Sponsor><Trial id="22441"/><TrialStartDate>DECEMBER , 01, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Colitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>budesonide</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide for Maintenance Treatment of Collagenous Colitis</ProtocolTitle><Reference>MIMIC; NCT00180076</Reference><Sponsor>University of Dresden</Sponsor><Trial id="64504"/><TrialStartDate>JULY     , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>474</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>470</Patients><ProtocolAcronym/><ProtocolTitle>Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)</ProtocolTitle><Reference>BDP-AR-302; NCT01134705</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="66890"/><TrialStartDate>MAY      , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cytokines; Neutrophils</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>budesonide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="29656">TPI-1020</Drug><EnrollmentCount>62</EnrollmentCount><Interventions>TPI-1020 </Interventions><Patients>62</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability and PD Activity of Inhaled TPI-1020 Versus Inhaled Budesonide in COPD Patients</ProtocolTitle><Reference>NCT00483743; TPI 1020-203</Reference><Sponsor>Pharmaxis Ltd</Sponsor><Trial id="3700"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Antral follicles; Blood pressure; Body Mass Index; Bone mineral density; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Testosterone/Androstenedione ratio; Total cholesterol; Triglycerides</Biomarkers><Condition>Congenital adrenal hyperplasia</Condition><Controls>cortisone acetate; dexamethasone; hydrocortisone; prednisolone; prednisone</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>Plenadren</Interventions><Patients>150</Patients><ProtocolAcronym>CareOnTIME</ProtocolAcronym><ProtocolTitle>Innovative Treatment in Congenital Adrenal Hyperplasia</ProtocolTitle><Reference>140/16; CareOnTIME; NCT03760835</Reference><Sponsor>Universita degli Studi di Napoli Federico II</Sponsor><Trial id="362194"/><TrialStartDate>AUGUST   , 11, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Eosinophils</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>budesonide</Interventions><Patients>200</Patients><ProtocolAcronym>ORBIT2</ProtocolAcronym><ProtocolTitle>An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)</ProtocolTitle><Reference>NCT02736409; ORBIT2; SHP621-302</Reference><Sponsor>Shire plc</Sponsor><Trial id="258090"/><TrialStartDate>APRIL    , 29, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Patients>20</Patients><ProtocolAcronym>FAVOR</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina</ProtocolTitle><Reference>C-01-08-006; FAVOR; NCT00770770</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="30143"/><TrialStartDate>MAY      , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Contact dermatitis</Condition><Controls>vehicle ointment (paraffin oil/soft white paraffin)</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59469">triamcinolone acetonide (topical, dermatoses, AzoneTS), Echo</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>Clarelux; Durhalieve; Protopic; glycerol</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of glycerol, two topical steroids, and a topical immune modulator against skin irritation</ProtocolTitle><Reference>2008-001678-34; NCT00779792; WA+TR_1</Reference><Sponsor>Odense University Hospital</Sponsor><Trial id="31700"/><TrialStartDate>SEPTEMBER, 30, 2008</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Eczema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>GK-664-S</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>A Open-Label, Phase III, Multicenter, Parallel Group Study to Evaluate Efficacy and Safety Study of GK-664-S in Subjects With Moderate-to-Severe Scalp Eczema Dermatitis Except for Seborrheic Dermatitis</ProtocolTitle><Reference>JapicCTI-184247</Reference><Sponsor>Maruho Co Ltd</Sponsor><Trial id="366908"/><TrialStartDate>DECEMBER , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Heart rate; Potassium; QT interval; Serum cortisol; Whole blood potassium</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Relovair PD PK in Chinese Healthy Subjects</ProtocolTitle><Reference>115199; NCT01711463</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="95532"/><TrialStartDate>DECEMBER , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount/><Interventions>Ellipta inhaler; fluticasone furoate + umeclidinium + vilanterol (dry powder inhaled, COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; salbutamol, GlaxoSmithKline; umeclidinium bromide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>205165; NCT02731846</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="257690"/><TrialStartDate>JUNE     , 30, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; FEV1; Glucose; Heart rate; Hematocrit; Hemoglobin; Interleukin-8; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Myeloperoxidase; Neutrophils; Potassium; Reticulocytes; Sodium; Systolic blood pressure; Total protein; gamma-Glutamyltransferase</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effect of GW-870086-X on Allergen Challenge in Mild Asthmatics</ProtocolTitle><Reference>110762; 2007-005791-14; NCT00857857</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="48265"/><TrialStartDate>FEBRUARY , 16, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure; Retina</Biomarkers><Condition>Pain</Condition><Controls>Prednefrin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="112786">Difluprednate (ophthalmic solution, ocular inflammation/ocular pain), Laboratorios Sophia</Drug><EnrollmentCount>178</EnrollmentCount><Interventions>PRO-145</Interventions><Patients>178</Patients><ProtocolAcronym>PRO-145/III</ProtocolAcronym><ProtocolTitle>Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification</ProtocolTitle><Reference>NCT03693989; PRO-145/III; SOPH145-0716 / III</Reference><Sponsor>Laboratorios Sophia</Sponsor><Trial id="355334"/><TrialStartDate>OCTOBER  , 01, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>2000</EnrollmentCount><Interventions>Allermist</Interventions><Patients>2000</Patients><ProtocolAcronym/><ProtocolTitle>Drug Use Investigation for Allermist</ProtocolTitle><Reference>113407; NCT01376206</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="78401"/><TrialStartDate>DECEMBER , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Atopic dermatitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46177">mapracorat</Drug><EnrollmentCount>263</EnrollmentCount><Interventions>mapracorat</Interventions><Patients>263</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Different Concentrations of ZK-245186 in Atopic Dermatitis (AD)</ProtocolTitle><Reference>1403380; 15267; NCT01228513</Reference><Sponsor>Bayer AG</Sponsor><Trial id="71668"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>828</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>828</Patients><ProtocolAcronym/><ProtocolTitle>A Study To Assess The Efficacy Of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 Microg Once-Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 Microg Twice-daily In Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>077855 and 050703; 116974; NCT01706328; RLV116974</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="94705"/><TrialStartDate>OCTOBER  , 15, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Reference>116524; NCT01725685</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="97979"/><TrialStartDate>NOVEMBER , 08, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Reference>116524; NCT01725685</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="97979"/><TrialStartDate>NOVEMBER , 08, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>141</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>141</Patients><ProtocolAcronym/><ProtocolTitle>A 6-Month Extension Study of OTO-104 in Meniere's Disease</ProtocolTitle><Reference>104-201610; 2016-000766-29; NCT02768662</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="260634"/><TrialStartDate>AUGUST   , 31, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>176</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>174</Patients><ProtocolAcronym>AVERTS-2</ProtocolAcronym><ProtocolTitle>Study of OTO-104 in Subjects With Unilateral Meniere's Disease</ProtocolTitle><Reference>104-201508; 2015-004496-71; AVERTS-2; NCT02717442</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="256498"/><TrialStartDate>MARCH    , 31, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>Monovisc</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>CINGAL</Interventions><Patients>60</Patients><ProtocolAcronym>EEFFEK</ProtocolAcronym><ProtocolTitle>Early Effect of Cingal Compared to Monovisc in Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>CIN-401; EEFFEK; NCT03062787</Reference><Sponsor>Pharmascience Inc</Sponsor><Trial id="289267"/><TrialStartDate>APRIL    , 05, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>8564</EnrollmentCount><Interventions>PT-003; PT-009; PT-010</Interventions><Patients>8564</Patients><ProtocolAcronym>Ethos</ProtocolAcronym><ProtocolTitle>Study to Assess the Efficacy and Safety of PT-010 Relative to PT-003 and PT-009 in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Reference>118313; 2014-005671-92; Ethos; JapicCTI-184078; NCT02465567; PT010005</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="231627"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>FVC</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>GW-685698X; fluticasone propionate</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>A Randomised, Double-blind, Placebo-controlled, 6-way Cross-over Design Study to Investigate the Effect of 250 microg Single Inhaled Doses of GW-685698X and Fluticasone Propionate on Airway Responsiveness to Adenosine 5’-monophosphate (AMP) Challenge in Mild Asthmatic Patients</ProtocolTitle><Reference>FFA10027</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="87519"/><TrialStartDate>APRIL    , 23, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Glucose; Heart rate; PR interval; Peak expiratory flow rate; Potassium; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>Perforomist</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>67</EnrollmentCount><Interventions>CHF-1531</Interventions><Patients>67</Patients><ProtocolAcronym>FLASH</ProtocolAcronym><ProtocolTitle>A Dose-Ranging Study of CHF-1531 in Asthmatic Subjects</ProtocolTitle><Reference>CCD-05993AA3-03; FLASH; NCT03086460</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="291496"/><TrialStartDate>SEPTEMBER, 08, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>Dermovate; Diprosone; Elocon; Locoid</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>Enstilar</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Vasoconstriction Trial With LEO-90100 Aerosol Foam</ProtocolTitle><Reference>LP0053-1276; NCT02973776</Reference><Sponsor>LEO Pharma A/S</Sponsor><Trial id="280409"/><TrialStartDate>DECEMBER , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Patients>474</Patients><ProtocolAcronym/><ProtocolTitle>An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2 to 5 Years With Perennial Allergic Rhinitis</ProtocolTitle><Reference>NCT00132925; XRG5029C_3502</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="12107"/><TrialStartDate>NOVEMBER , 30, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Aspartate aminotransferase; Bicarbonates; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Erythrocytes; Glucose; Heart; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lung; Mean corpuscular hemoglobin; Nitrite; Phosphate; Potassium; Skin; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea nitrogen; Uric acid; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Psoriasis</Condition><Controls>betamethasone valerate</Controls><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><EnrollmentCount>13</EnrollmentCount><Interventions>LEO-134310</Interventions><Patients>13</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis</ProtocolTitle><Reference>2018-000140-26; LP0155-1375; NCT03669757</Reference><Sponsor>LEO Pharma A/S</Sponsor><Trial id="353433"/><TrialStartDate>SEPTEMBER, 27, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Arthralgia</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>576</EnrollmentCount><Interventions>CINGAL</Interventions><Patients>576</Patients><ProtocolAcronym/><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide</ProtocolTitle><Reference>2017-000355-46; CINGAL 16-02; NCT03191903</Reference><Sponsor>Anika Therapeutics Inc</Sponsor><Trial id="301892"/><TrialStartDate>MAY      , 25, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Anterior chamber</Biomarkers><Condition>Uveitis</Condition><Controls>prednisolone acetate ophthalmic</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>251</EnrollmentCount><Interventions>EGP-437; EyeGate II Drug Delivery System (EGDS); ocular iontophoresis</Interventions><Patients>251</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis</ProtocolTitle><Reference>EGP-437-006; NCT02517619</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="236849"/><TrialStartDate>JANUARY  , 16, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Estimated glomerular filtration rate; Synovial membrane</Biomarkers><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>FX-006</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Effect of FX-006 on Synovial Inflammation in Patients With osteoarthritis (OA) of the Knee</ProtocolTitle><Reference>FX006-2017-014; NCT03529942</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="340019"/><TrialStartDate>APRIL    , 24, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body surface area; Hydrocortisone</Biomarkers><Condition>Psoriasis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>IDP-122</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis</ProtocolTitle><Reference>NCT03987763; V01-122A-401</Reference><Sponsor>Bausch Health Americas, Inc.</Sponsor><Trial id="384836"/><TrialStartDate>JUNE     , 08, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA</ProtocolTitle><Reference>NCT03895840; STUDY00142926</Reference><Sponsor>University of Kansas Medical Center</Sponsor><Trial id="375286"/><TrialStartDate>MARCH    , 19, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount/><Interventions>Fibrin Glue; triamcinolone acetonide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A randomized trial for the evaluation of Triamcinolone Acetonide and Fibrin Glue in the prevention of seroma formation after axillary dissection</ProtocolTitle><Reference>2011/02145</Reference><Sponsor>Tan Tock Seng Hospital</Sponsor><Trial id="161209"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition/><Controls>PT-007; PT-008</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><EnrollmentCount>91</EnrollmentCount><Interventions>PT-027</Interventions><Patients>91</Patients><ProtocolAcronym>LOGAN</ProtocolAcronym><ProtocolTitle>A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT-007 and PT-008 Administered Separately</ProtocolTitle><Reference>D6930C00003; LOGAN; NCT03772223</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="363124"/><TrialStartDate>JANUARY  , 21, 2019</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition/><Controls>ciclesonide (metered dose inhaler), Nycomed</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>BI-54903; butylated hydroxytoluene</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI-54903 XX Via Respimat Soft MistTM Inhaler B in Healthy Male Subjects</ProtocolTitle><Reference>1256.1; NCT02221375</Reference><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><Trial id="208595"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>219</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>438</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery</ProtocolTitle><Reference>NCT00430092; ST-601A-002b</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21685"/><TrialStartDate>JANUARY  , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>CYP3A4; Hydrocortisone</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects</ProtocolTitle><Reference>113477; NCT01000597</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="61354"/><TrialStartDate>SEPTEMBER, 17, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood cells; C-reactive protein; Cortisol/Creatinine ratio; Glucose; Hydrocortisone; Interleukin-6; Nitric oxide; Tumor necrosis factor</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>prednisolone</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>Qvar</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Does Extra-Fine Hydrofluoroalkane-Beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?</ProtocolTitle><Reference>2008-005909-19; NCT00921921; PAW002</Reference><Sponsor>University of Dundee</Sponsor><Trial id="58085"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Cortisol; Diastolic blood pressure; FEV1; Fasting glucose; Potassium; Pulse rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>Relovair</Interventions><Patients>54</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of Three Doses of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo</ProtocolTitle><Reference>110946; NCT01072149</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="64307"/><TrialStartDate>JANUARY  , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; mometasone (nasal)</Interventions><Patients>300</Patients><ProtocolAcronym/><ProtocolTitle>Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays</ProtocolTitle><Reference>201474; NCT02397915</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="225253"/><TrialStartDate>MARCH    , 26, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Bacterial infection</Condition><Controls>prednisolone acetate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><EnrollmentCount>132</EnrollmentCount><Interventions>tobramycin + prednisolone acetate (ophthalmic), ISTA</Interventions><Patients>132</Patients><ProtocolAcronym/><ProtocolTitle>A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte</ProtocolTitle><Reference>ISTA-TP-CPK01; NCT00198523</Reference><Sponsor>ISTA Pharmaceuticals Inc</Sponsor><Trial id="10077"/><TrialStartDate>JULY     , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ulcerative colitis</Condition><Controls>mesalazine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>343</EnrollmentCount><Interventions>Uceris</Interventions><Patients>343</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)</ProtocolTitle><Reference>2006-005377-22; BUC-57/UCA; NCT00747110</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="187399"/><TrialStartDate>OCTOBER  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular Pressure</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Intracameral different dosage triamcinolone acetonide preventing anterior uveitis after pediatric cataract surgery</ProtocolTitle><Reference>ChiCTR-TRC-13003465</Reference><Sponsor>Beijing Shijitan Hospital</Sponsor><Trial id="151509"/><TrialStartDate>SEPTEMBER, 02, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="56749">784568</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>GW-784568-X</Interventions><Patients>69</Patients><ProtocolAcronym/><ProtocolTitle>Effects Of Single Doses Of GW-784568-X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber</ProtocolTitle><Reference>BGS105049; NCT00404586</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="14031"/><TrialStartDate>SEPTEMBER, 11, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>76</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>76</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema</ProtocolTitle><Reference>8126; NCT00369863</Reference><Sponsor>Shaheed Beheshti Medical University</Sponsor><Trial id="166045"/><TrialStartDate>JUNE     , 30, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Unidentified indication</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64584">PF-4308515</Drug><EnrollmentCount>27</EnrollmentCount><Interventions>PF-04308515</Interventions><Patients>27</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I, Single Dose-Escalation Study of PF-04308515 in Healthy Volunteers</ProtocolTitle><Reference>B0861001; NCT00990015</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="60956"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-peptide; Plasma glucose; Plasma insulin</Biomarkers><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64584">PF-4308515</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>PF-04308515; prednisone</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate</ProtocolTitle><Reference>B0861004; NCT01199029</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="70171"/><TrialStartDate>AUGUST   , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>ACTH; CRP; HgbA1c; IOP; lipid; platelet</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><EnrollmentCount>616</EnrollmentCount><Interventions>CRx-102</Interventions><Patients>616</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Multicenter, One-Year Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of CRx-102 in Subjects with Active Rheumatoid Arthritis</ProtocolTitle><Reference>CRx-102-007E; EudraCT 2007-004399-38</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="125078"/><TrialStartDate>APRIL    , 18, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls>BETABIOPTAL</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="56575">dexamethasone + netilmicin (ophthalmic), SIFI</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>dexamethasone + netilmicin (ophthalmic), SIFI</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Topical Steroid/antibiotic Association Treatments Following Phacoemulsification Cataract Extraction</ProtocolTitle><Reference>033/SI; EudraCT 2006-003305-13</Reference><Sponsor>SIFI Societa Industria Farmaceutica Italiana SpA</Sponsor><Trial id="118314"/><TrialStartDate>AUGUST   , 01, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>Phacoemulsification; Trabeculectomy; triamcinolone acetonide</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, parallel and Controlled study to Evaluate Inhibition effect of different doses of triamcinolone acetonide in inhibiting anterior uveitis after combined phacoemulsification and trabeculectomy</ProtocolTitle><Reference>ChiCTR-TRC-12002314</Reference><Sponsor>Beijing Shijitan Hospital</Sponsor><Trial id="98799"/><TrialStartDate>JANUARY  , 01, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cortisol; Creatinine; FEV1</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone + salmeterol</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48419">ciclesonide + formoterol (inhaled, asthma), Altana/sanofi-aventis</Drug><EnrollmentCount>160</EnrollmentCount><Interventions>ciclesonide + formoterol (inhaled, asthma), Altana/sanofi-aventis</Interventions><Patients>160</Patients><ProtocolAcronym>EXCITED</ProtocolAcronym><ProtocolTitle>Comparison of the Efficacy of a Fixed Combination of Ciclesonide and Formoterol versus a Fixed Combination of Fluticasone and Salmeterol</ProtocolTitle><Reference>BY9010/M1-502; EXCITED; EudraCT 2004-002983-80</Reference><Sponsor>Mainz University Hospital, Takeda GmbH</Sponsor><Trial id="116883"/><TrialStartDate>FEBRUARY , 14, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Escherichia coli infection</Condition><Controls>Entocort</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>ciprofloxacin; metronidazole; trimethoprim</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>A Pilot, Randomized Study to Compare Antibiotic Therapy (Ciprofloxacin, Trimethoprim and Metronidazole) with Standard Therapy (Budesonide) in the Treatment of Active Crohns Disease</ProtocolTitle><Reference>UKCRN 13163</Reference><Sponsor>Royal Liverpool and Broadgreen University Hospitals NHS Trust</Sponsor><Trial id="116894"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55108">triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Sustained Triamcinolone Release for Inhibition of Diabetic macular Edema. A phase I, safety and tolerability study of tramiconolone acetonide (intravitreal implant) for the potential treatment of diabteic macular edema.</ProtocolTitle><Reference>STRIDE</Reference><Sponsor>SurModics Inc</Sponsor><Trial id="5034"/><TrialStartDate>JUNE     , 30, 2005</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Contact dermatitis</Condition><Controls>methylprednisolone aceponate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>82</EnrollmentCount><Interventions>clobetasol propionate foam, Connetics</Interventions><Patients>82</Patients><ProtocolAcronym/><ProtocolTitle>Randomized Study on the Effectiveness, Safety and Acceptability Of Clobetasol Propionate Foam-cooled (OLUX) in Comparison With Cream Aceponato Methylprednisolone in the Treatment of Allergic Contact Dermatitis</ProtocolTitle><Reference>EudraCT 2008-004331-38; olux 01/08</Reference><Sponsor>Mipharm SpA</Sponsor><Trial id="117327"/><TrialStartDate>AUGUST   , 28, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>430</EnrollmentCount><Interventions>Relovair; fluticasone; fluticasone furoate</Interventions><Patients>430</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 microg qd With Fluticasone Propionate (FP) 250 microg bid and FP 100 microg bid in Well-Controlled Asthmatic Japanese Subjects</ProtocolTitle><Reference>201135; JapicCTI-142503; NCT02094937</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="178963"/><TrialStartDate>MARCH    , 27, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Xerophthalmia</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="66735">DE-110</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>DE-110</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease</ProtocolTitle><Reference>30-002; NCT01239069</Reference><Sponsor>Santen Inc</Sponsor><Trial id="72186"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>700</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>700</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 25, 50, 100, and 200 microg Administered Once Daily in the Morning and Fluticasone Propionate 100 microg bid via Diskus Inhalation Powder compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (&gt;/= 12 years old) with Persistent Asthma Symptomatic on Non-ICS Therapy</ProtocolTitle><Reference>2005-001123-11; FFA100240</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="118070"/><TrialStartDate>AUGUST   , 24, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls>budesonide + formoterol fumarate, AstraZeneca</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Interventions><Patients>216</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III, Randomized, Parallel-roup, Open Study to Compare the Therapeutic Efficacy and Safety of SMB Budesonide-Salmeterol DPI Capsule 150/25 microg bid Delivered by the Axahaler Versus Symbicort Turbuhaler 200/12 microg bid Over 12 Weeks in Moderate to Severe Persistent Asthmatic Patients</ProtocolTitle><Reference>BUSAL-III-08-1; EudraCT 2008-004833-70</Reference><Sponsor>Laboratoires SMB SA</Sponsor><Trial id="118139"/><TrialStartDate>JANUARY  , 16, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Adhesive capsulitis</Condition><Controls>lidocaine; triamcinolone acetonide</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>hydrodilatation; lidocaine; triamcinolone acetonide</Interventions><Patients>64</Patients><ProtocolAcronym/><ProtocolTitle>Hydrodilatation with corticosteroid versus corticosteroid injection alone in adhesive capsulitis of shoulder</ProtocolTitle><Reference>AJIRB-MED-CT4-10-104; KCT0002006</Reference><Sponsor>Ajou University Hospital</Sponsor><Trial id="268407"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>bevacizumab; laser photocoagulation; triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym>TRIMADE</ProtocolAcronym><ProtocolTitle>Triple Therapy for Diabetic Macular Edema: Intravitreal Bevacizumab, Triamcinolone Acetonide and Macular Photocoagulation</ProtocolTitle><Reference>ChiCTR-TNC-09000606; TRIMADE</Reference><Sponsor>Sorocaba Eye Bank</Sponsor><Trial id="92537"/><TrialStartDate>JANUARY  , 01, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood glucose level; Blood pressure; Hemoglobin A1c (HbA1c); Intraocular pressure</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Injection of Triamicinolone Acetonide Into the Sub-Tenon Capsule for Treatment of Macular Edema</ProtocolTitle><Reference>JPRN-UMIN000000907</Reference><Sponsor>University Of Tokyo, Graduate School Of Medicine</Sponsor><Trial id="122358"/><TrialStartDate>APRIL    , 01, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>beclomethasone dipropionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount/><Interventions>BTR-15</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, comparative, dose-confirmation study of BTR-15 to target pediatric asthma patients</ProtocolTitle><Reference>JapicCTI-090805</Reference><Sponsor>Teijin Pharma Ltd</Sponsor><Trial id="122480"/><TrialStartDate>JULY     , 23, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="103843">DSXS-1538b</Drug><EnrollmentCount>3</EnrollmentCount><Interventions>DSXS-1538b</Interventions><Patients>3</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product</ProtocolTitle><Reference>DSXS 1538B; NCT02933502</Reference><Sponsor>Taro Pharmaceuticals USA Inc</Sponsor><Trial id="275506"/><TrialStartDate>JULY     , 11, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>intraoccular pressure</Biomarkers><Condition>Glaucoma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>110</EnrollmentCount><Interventions>5-fluorouracil; triamcinolone acetonide</Interventions><Patients>110</Patients><ProtocolAcronym/><ProtocolTitle>Prospective Study into the Effect of an Intraocular Injection of a Steroid in the Prevention of Glaucoma Drainage Surgery Failure After Cataract Surgery</ProtocolTitle><Reference>ACTRN12611000336987; U1111-1120-4139</Reference><Sponsor>Royal Victorian Eye and Ear Hospital</Sponsor><Trial id="123904"/><TrialStartDate>MAY      , 31, 2011</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>Ultravate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>Jemdel</Interventions><Patients>150</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis</ProtocolTitle><Reference>NCT02785185; V01-122A-203</Reference><Sponsor>Bausch Health Companies Inc</Sponsor><Trial id="262106"/><TrialStartDate>JUNE     , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Ultibro Breezhaler</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>1532</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>1532</Patients><ProtocolAcronym>TRIBUTE</ProtocolAcronym><ProtocolTitle>A Two-arm, Parallel-Group Study of Fixed Combination of CHF-5993 Versus Ultibro in COPD Patients</ProtocolTitle><Reference>2014-001704-22; CCD-05993AA1-08; NCT02579850; TRIBUTE</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="243510"/><TrialStartDate>MAY      , 29, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Scleritis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase I, Dose-Varying Study</ProtocolTitle><Reference>1R01FD003910; EGP-IST-001; NCT01059955</Reference><Sponsor>University of Pennsylvania</Sponsor><Trial id="63816"/><TrialStartDate>JANUARY  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls>Avamys; Relovair</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Reference>HZA102940; NCT00625196</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="23384"/><TrialStartDate>FEBRUARY , 27, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis</ProtocolTitle><Reference>NCT00407056; SJE2079/3-02-PC</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21749"/><TrialStartDate>AUGUST   , 31, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; Forced Vital Capacity; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>budesonide</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>249</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 years)</ProtocolTitle><Reference>BY9010/M1-136; NCT00163384</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="22072"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Xerophthalmia</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>89</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>105</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye</ProtocolTitle><Reference>EGP-437-002; NCT00765804</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="31793"/><TrialStartDate>OCTOBER  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls>bupivacaine, AstraZeneca</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>Randomized Controlled Trial of Transforaminal Injections for Sciatica</ProtocolTitle><Reference>06/12/13/3/01; ACTRN12608000401358; ANZCTR82969</Reference><Sponsor>Newcastle Bone and Joint institute</Sponsor><Trial id="135001"/><TrialStartDate>FEBRUARY , 01, 2007</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Heart rate; QT interval</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi; charcoal block; pressurized metered dose inhaler</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF-5993 pMDI Combination in Healthy Volunteers</ProtocolTitle><Reference>CCD-05993AB2-01; NCT02359292</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="221592"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>prednisone; salbutamol, GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; prednisone; salbutamol, GlaxoSmithKline</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>Repeat Emergency Department Visits Among Patients With Asthma and COPD</ProtocolTitle><Reference>754754; NCT02499887</Reference><Sponsor>State University of New York</Sponsor><Trial id="235195"/><TrialStartDate>JANUARY  , 31, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Proliferative diabetic retinopathy</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>panretinal photocoagulation; triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy</ProtocolTitle><Reference>310/05; NCT00443521</Reference><Sponsor>University of Sao Paulo</Sponsor><Trial id="165786"/><TrialStartDate>MARCH    , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount/><Interventions>Macular focal laser photocoagulation; Vitrectomy; triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema</ProtocolTitle><Reference>2006-05-029; NCT00371410</Reference><Sponsor>Samsung Medical Center (SMC)</Sponsor><Trial id="165530"/><TrialStartDate>APRIL    , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intra occular pressure (IOP)</Biomarkers><Condition>Pain</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon; moxifloxacin (ophthalmic), Alcon</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Trial in Patients With Steroid Responsive Inflammatory Ocular Conditions. Clinical Trial Is to Study Efficacy, Safety and Tolerability of Moxifloxacin HCL + Difluprednate Ophthalmic Solution Versus Moxifloxacin HCL + Dexamethasone Phosphate Eye Drops</ProtocolTitle><Reference>AJ/SC/12/2009; CTRI/2010/091/001121</Reference><Sponsor>Ajanta Pharma Ltd</Sponsor><Trial id="132784"/><TrialStartDate>AUGUST   , 10, 2010</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Atopic dermatitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46177">mapracorat</Drug><EnrollmentCount>23</EnrollmentCount><Interventions>mapracorat</Interventions><Patients>23</Patients><ProtocolAcronym/><ProtocolTitle>HPA Axis Study in Adults</ProtocolTitle><Reference>1403161; 1403161; NCT01408511</Reference><Sponsor>Bayer AG, Intendis GmbH</Sponsor><Trial id="79784"/><TrialStartDate>JULY     , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Study to assess the effect of fluticasone furoate on growth rate in children aged 5 to 11</ProtocolTitle><Reference>2015-000841-22; HZA107112</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="253752"/><TrialStartDate>AUGUST   , 04, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>17-alpha-hydroxyprogesterone; Androgens; Androstenedione; Testosterone</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>Infacort</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Extension Study for Patients Entered Into Study Infacort 003</ProtocolTitle><Reference>2015-000458-40; INFACORT 004; NCT02733367</Reference><Sponsor>Diurnal Ltd</Sponsor><Trial id="257842"/><TrialStartDate>MARCH    , 04, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Graft versus host disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; methotrexate; tacrolimus</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematological Cancer</ProtocolTitle><Reference>2079.00; NCI-2009-01544; NCT00489203</Reference><Sponsor>Fred Hutchinson Cancer Research Center</Sponsor><Trial id="58495"/><TrialStartDate>APRIL    , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>301</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>301</Patients><ProtocolAcronym/><ProtocolTitle>Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>FFR106080; NCT00289198</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="14192"/><TrialStartDate>FEBRUARY , 28, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>23</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>23</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Intravitreal Triamcinolone Acetonide before Pan Retinal Photocoagulation for Improvement of Visual Acuity and Macular Edema in Diabetic Retinopathy</ProtocolTitle><Reference>ACTRN12607000225415; HREC 356</Reference><Sponsor>Farabi Eye Hospital</Sponsor><Trial id="143664"/><TrialStartDate>NOVEMBER , 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls>fluticasone furoate</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>fluticasone furoate; oxymetazoline; oxymetazoline</Interventions><Patients>64</Patients><ProtocolAcronym/><ProtocolTitle>A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa</ProtocolTitle><Reference>15059B; NCT00584987</Reference><Sponsor>University of Chicago</Sponsor><Trial id="14092"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>800</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>800</Patients><ProtocolAcronym/><ProtocolTitle>A 12-Week Study to Evaluate the 24-h Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 microg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 microg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>EudraCT: 2012-003106-27; RLV116974</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="142783"/><TrialStartDate>NOVEMBER , 01, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="116385">beclomethasone dipropionate (oral dual release tablet, Crohn’s disease), Soligenix</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>beclomethasone dipropionate (oral dual release), Soligenix/Sigma-Tau</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>SGX-203 for The Treatment of Pediatric Crohn's Disease</ProtocolTitle><Reference>BDP-PCD-01</Reference><Sponsor>Soligenix Inc</Sponsor><Trial id="125927"/><TrialStartDate>MAY      , 15, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Addisons disease</Condition><Controls>hydrocortisone</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>Infacort</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Pharmacokinetics of Infacort Versus Immediate-release Hydrocortisone</ProtocolTitle><Reference>2013-000260-28; INFACORT 001; NCT02777268</Reference><Sponsor>Diurnal Ltd</Sponsor><Trial id="261362"/><TrialStartDate>JULY     , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>110</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>110</Patients><ProtocolAcronym/><ProtocolTitle>Daily versus as-needed use of fluticasone furoate nasal spray in patients with allergic rhinitis: A randomized, controlled trial</ProtocolTitle><Reference>TCTR20170310002</Reference><Sponsor>Mahidol University, Siriraj Hospital</Sponsor><Trial id="290776"/><TrialStartDate>JUNE     , 01, 2017</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>369</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>369</Patients><ProtocolAcronym/><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Reference>790; NCT01591161</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="87111"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>369</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>369</Patients><ProtocolAcronym/><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Reference>790; NCT01591161</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="87111"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Multiple myeloma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12806">dexamethasone cipecilate</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>dexamethasone cipecilate; doxorubicin (liposomal, STEALTH), Alza; thalidomide</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life</ProtocolTitle><Reference>Doxil; NCT00222105</Reference><Sponsor>University of Kansas</Sponsor><Trial id="48539"/><TrialStartDate>NOVEMBER , 30, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1226</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Patients>1224</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>112207; 2009-013067-19; HZC112207; JapicCTI-101097; NCT01054885</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="63564"/><TrialStartDate>OCTOBER  , 19, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; Forced Vital Capacity</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>480</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>480</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of ciclesonide versus fluticasone propionate in patients with mild to moderate asthma (12 to 75 years)</ProtocolTitle><Reference>2004-001072-39; BY9010/M1-142; NCT00163423</Reference><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><Trial id="22040"/><TrialStartDate>NOVEMBER , 30, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>310</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>310</Patients><ProtocolAcronym/><ProtocolTitle>Study of FX-006 versus Normal Saline in Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>FX006-2014-006; NCT02116972</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="182577"/><TrialStartDate>APRIL    , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1</EnrollmentCount><Interventions>budesonide + formoterol fumarate, AstraZeneca; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Patients>1</Patients><ProtocolAcronym/><ProtocolTitle>Evidence Synthesis and Mixed Treatment Comparison of Efficacy of Treatments for the Maintenance of COPD</ProtocolTitle><Reference>200342</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="158632"/><TrialStartDate>JULY     , 01, 2013</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Forced expiratory volume in 1 s</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Fostair; Spiriva; Spiriva; beclometasone dipropionate + formoterol fumarate + tiotropium bromide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>3686</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>2691</Patients><ProtocolAcronym>TRINITY</ProtocolAcronym><ProtocolTitle>Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>2013-000063-91; CCD-1208-PR-0090; NCT01911364; TRINITY</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="148190"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>9</ArmCount><Biomarkers/><Condition>Retinopathy</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Kenalog; flurbiprofen (Froben); guttae prednisolone (Pred Forte); triamcinolone acetonide</Interventions><Patients>40</Patients><ProtocolAcronym>AOT</ProtocolAcronym><ProtocolTitle>Triamcinolone acetonide to prevent PVR in eyes undergoing vitreoretinal surgery for open globe trauma</ProtocolTitle><Reference>2007-005138-35; AOT; CHAD1024</Reference><Sponsor>Moorfields Eye Hospital</Sponsor><Trial id="133460"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Fatigue</Condition><Controls>prednisone</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>62</EnrollmentCount><Interventions>Rayos</Interventions><Patients>62</Patients><ProtocolAcronym>RIFLE</ProtocolAcronym><ProtocolTitle>A Crossover Study to Compare Rayos to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE</ProtocolTitle><Reference>AMP-002; NCT03098823; RIFLE</Reference><Sponsor>Ampel BioSolutions, LLC</Sponsor><Trial id="294933"/><TrialStartDate>SEPTEMBER, 12, 2017</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Long Term Safety Trial of Z-102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis</ProtocolTitle><Reference>NCT01612377; Z102-009</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="88095"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>165</EnrollmentCount><Interventions>OTO-104</Interventions><Patients>165</Patients><ProtocolAcronym>AVERTS-1</ProtocolAcronym><ProtocolTitle>Study of OTO-104 in Subjects With Unilateral Meniere's Disease</ProtocolTitle><Reference>104-201506; AVERTS-1; NCT02612337</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="246584"/><TrialStartDate>OCTOBER  , 27, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide injectable suspension</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>484</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>484</Patients><ProtocolAcronym/><ProtocolTitle>Study of FX-006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>2014-005329-11; FX006-2014-008; NCT02357459</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="221476"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide (Kenalog)</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>81</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>81</Patients><ProtocolAcronym/><ProtocolTitle>Study to Characterize the PK and Local Extent and Duration of Exposure From FX-006 in Patients With OA of the Knee</ProtocolTitle><Reference>FX006-2015-009; NCT02637323</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="249253"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Calprotectin; Cytokines</Biomarkers><Condition>Crohns disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>B-FAHF-2; Entocort EC</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Safety, Tolerability and Efficacy of Oral B-FAHF-2 in Mild-to-Moderate Crohns Disease</ProtocolTitle><Reference>0266-3308; GCO 19-0125; NCT03992469</Reference><Sponsor>Mount Sinai School of Medicine</Sponsor><Trial id="385284"/><TrialStartDate>JULY     , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>TNF-alpha</Biomarkers><Condition>Peripheral vascular disease</Condition><Controls>methylprednisolone (Pfizer)</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>21</EnrollmentCount><Interventions>prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos</Interventions><Patients>21</Patients><ProtocolAcronym>DELIVER</ProtocolAcronym><ProtocolTitle>A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort</ProtocolTitle><Reference>DELIVER; NCT01647685; NL39717.018.12</Reference><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><Trial id="89428"/><TrialStartDate>MAY      , 31, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Herpes simplex virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><EnrollmentCount>54</EnrollmentCount><Interventions>aciclovir + hydrocortisone (dermatological), Medivir</Interventions><Patients>54</Patients><ProtocolAcronym/><ProtocolTitle>An Open-label, Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6 to 11 Years Old</ProtocolTitle><Reference>MP 800; NCT01574612</Reference><Sponsor>Meda Pharmaceuticals Ltd</Sponsor><Trial id="86381"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Relovair; Spiriva</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>1479</EnrollmentCount><Interventions>CHF-5993</Interventions><Patients>1479</Patients><ProtocolAcronym>Tristar</ProtocolAcronym><ProtocolTitle>Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>2014-001487-35; CCD-05993AA1-07; NCT02467452; Tristar</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="231716"/><TrialStartDate>MAY      , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>111</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon; prednisolone acetate</Interventions><Patients>110</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis</ProtocolTitle><Reference>C-10-034; NCT01201798</Reference><Sponsor>Alcon Research Ltd</Sponsor><Trial id="70332"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><EnrollmentCount>33</EnrollmentCount><Interventions>Prevacid; budesonide (oral, eosinophilic esophagitis), Meritage</Interventions><Patients>33</Patients><ProtocolAcronym/><ProtocolTitle>Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis</ProtocolTitle><Reference>NCT00638456; VPI-106-01</Reference><Sponsor>University of California San Diego</Sponsor><Trial id="57129"/><TrialStartDate>FEBRUARY , 29, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Cortisol; Hemoglobin; Mean corpuscular volume; Urea nitrogen; gamma-Glutamyltransferase</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>99</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>99</Patients><ProtocolAcronym/><ProtocolTitle>Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study In Pediatric Subjects With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>BDP-AR-307; NCT01697956</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="93137"/><TrialStartDate>OCTOBER  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>OTO-104</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>OTO-104 for Meniere's Disease</ProtocolTitle><Reference>104-200901; NCT01084525</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="64740"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992; beclomethasone dipropionate + formoterol fumarate + CHF-5992; cimetidine</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Drug-drug Interaction Study of CHF-5993 With Cimetidine</ProtocolTitle><Reference>2013-005491-18; CCD-05993AA1-12; NCT02287272</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="215420"/><TrialStartDate>MAY      , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Eosinophils; FEV1; Neutrophils</Biomarkers><Condition>Asthma</Condition><Controls>budesonide (inhaled formulations), AstraZeneca</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>27</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>The Study Will Evaluate the Efficacy of AZD-5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen</ProtocolTitle><Reference>D2340C00005; NCT01225549</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="71513"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Vitreous humor disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>EyeGate II drug delivery system; dexamethasone</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy</ProtocolTitle><Reference>EGP-437-010; NCT02644694</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="250160"/><TrialStartDate>MARCH    , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Vitamin D deficiency</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>408</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; vitamin D3</Interventions><Patients>408</Patients><ProtocolAcronym>VIDA</ProtocolAcronym><ProtocolTitle>Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma</ProtocolTitle><Reference>1U10HL098115; ASTHMANET 001; NCT01248065; VIDA</Reference><Sponsor>Milton S. Hershey Medical Center</Sponsor><Trial id="188785"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Reference>200284; NCT01962467</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157921"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89013">fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis), GlaxoSmithKline</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Reference>200284; NCT01962467</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157921"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89013">fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis), GlaxoSmithKline</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Reference>200284; NCT01962467</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157921"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>calcipotriol betamethasone (Defubao)</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="96651">clobetasol propionate + tretinoin (topical/ointment, psoriasis vulgaris), Jiangsu Zeyuan Pharmaceutical</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>Jinniuer</Interventions><Patients>240</Patients><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, single-blind, positive controlled trials that assess the effect, safety and cost in patients with mild to moderate psoriasis vulgaris and compare fufangbingsuanlvbeitasuo (Jinniuer) ointment to gaibosanchunbeitamisong (Defubao) ointment</ProtocolTitle><Reference>ChiCTR-IPR-16008126</Reference><Sponsor>Curegen (Jiangsu) Pharmaceuticals Inc, The First Hospital Of China Medical University</Sponsor><Trial id="256863"/><TrialStartDate>APRIL    , 17, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Ulcerative proctitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>265</EnrollmentCount><Interventions>Rectabul</Interventions><Patients>265</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Reference>BUCF3001; NCT01008410</Reference><Sponsor>Bausch Health Companies Inc</Sponsor><Trial id="62013"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cortisol</Biomarkers><Condition>Asthma</Condition><Controls>prednisolone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>185</EnrollmentCount><Interventions>Relovair</Interventions><Patients>73</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of the Effects of Inhaled Fluticasone Furoate/GW-642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis</ProtocolTitle><Reference>106851; HZA106851; NCT01086410</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="64852"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Antral follicles; Blood pressure; Body Mass Index; Bone mineral density; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Testosterone/Androstenedione ratio; Total cholesterol; Triglycerides</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>cortisone acetate; dexamethasone; hydrocortisone; prednisolone; prednisone</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>Plenadren</Interventions><Patients>150</Patients><ProtocolAcronym>CareOnTIME</ProtocolAcronym><ProtocolTitle>Innovative Treatment in Congenital Adrenal Hyperplasia</ProtocolTitle><Reference>140/16; CareOnTIME; NCT03760835</Reference><Sponsor>Universita degli Studi di Napoli Federico II</Sponsor><Trial id="362194"/><TrialStartDate>AUGUST   , 11, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Arterial stiffness; Ejection fraction; Left atrial ejection fraction; Left atrium; Left ventricle; Pulmonary artery; Pulse Wave Transit Time; Pulse wave velocity; Right ventricle; Right ventricular ejection fraction; Stroke volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>Relovair</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Relovair Lung Deflation Study</ProtocolTitle><Reference>116601; 2012-000927-42; HZC116601; NCT01691885</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="92645"/><TrialStartDate>NOVEMBER , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><EnrollmentCount>51</EnrollmentCount><Interventions>CRx-102</Interventions><Patients>51</Patients><ProtocolAcronym>MARS-1</ProtocolAcronym><ProtocolTitle>Multicenter Study to Evaluate CRx-102 versus Each of Its Components to Treat Active Rheumatoid Arthritis</ProtocolTitle><Reference>CRx-102-007; MARS-1; NCT00551707</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="5373"/><TrialStartDate>OCTOBER  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>340</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>340</Patients><ProtocolAcronym/><ProtocolTitle>Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)</ProtocolTitle><Reference>BDP-AR-301; NCT01024608</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="62468"/><TrialStartDate>DECEMBER , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure; Leukocyte count</Biomarkers><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>438</EnrollmentCount><Interventions>OTX-DP</Interventions><Patients>438</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Reference>NCT02736175; OTX-15-003</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="258056"/><TrialStartDate>OCTOBER  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Blepharitis</Condition><Controls>azithromycin (ophthalmic sustained release, DuraSite), InSite; dexamethasone (sustained release, DuraSite), InSite</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55854">azithromycin + dexamethasone (sustained release, DuraSite), InSite</Drug><EnrollmentCount>917</EnrollmentCount><Interventions>azithromycin + dexamethasone (sustained release, DuraSite), InSite</Interventions><Patients>907</Patients><ProtocolAcronym>DOUBle</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis</ProtocolTitle><Reference>C-10-502-004; DOUBle; NCT01408082</Reference><Sponsor>InSite Vision Inc</Sponsor><Trial id="79770"/><TrialStartDate>OCTOBER  , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Blood glucose; FEV1; Heart rate; Serum cortisol; Serum potassium; Urine cortisol</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>GSK-961081 + fluticasone propionate (COPD), GlaxoSmithKline; batefenterol succinate; batefenterol succinate; fluticasone; fluticasone</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>An Investigation of the Pharmacokinetics of GSK-961081 and Fluticasone Propionate in Healthy Volunteers</ProtocolTitle><Reference>113423; NCT01449799</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="81468"/><TrialStartDate>JULY     , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>A study to see if it is safe to give a new asthma controller drug and a new asthma reliever drug together (called fluticasone furoate/vilanterol) to 5 to 11 year old children with asthma</ProtocolTitle><Reference>2012-000754-55; HZA112777</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="211035"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Choroid; Oxygen saturation; Retina; Transcriptional regulator ERG</Biomarkers><Condition>Retinitis pigmentosa</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19 mg) in Patients with Retinitis Pigmentosa</ProtocolTitle><Reference>2016-002523-28; KHAK1001</Reference><Sponsor>Moorfields Eye Hospital</Sponsor><Trial id="328923"/><TrialStartDate>SEPTEMBER, 16, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Heart rate; Potassium; QT interval; Serum cortisol; Whole blood potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Relovair PD PK in Chinese Healthy Subjects</ProtocolTitle><Reference>115199; NCT01711463</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="95532"/><TrialStartDate>DECEMBER , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>34</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>34</Patients><ProtocolAcronym/><ProtocolTitle>Open-Label Study of OTO-104 in Subjects With Meniere's Disease</ProtocolTitle><Reference>104-201505; NCT02740387</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="258351"/><TrialStartDate>JUNE     , 30, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Joint swelling; Joint tenderness</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>methylprednisolone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>330</EnrollmentCount><Interventions>Nanocort</Interventions><Patients>330</Patients><ProtocolAcronym/><ProtocolTitle>To Evaluate The Efficacy And Safety Of Sunpharma-1505 Compared With Reference-1505 In Subjects With Active Rheumatoid Arthritis</ProtocolTitle><Reference>2015-002924-17; CLR_15_05; NCT02534896</Reference><Sponsor>Sun Pharmaceutical Industries Ltd</Sponsor><Trial id="238910"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure; Retina</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Prednefrin</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="112786">Difluprednate (ophthalmic solution, ocular inflammation/ocular pain), Laboratorios Sophia</Drug><EnrollmentCount>178</EnrollmentCount><Interventions>PRO-145</Interventions><Patients>178</Patients><ProtocolAcronym>PRO-145/III</ProtocolAcronym><ProtocolTitle>Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification</ProtocolTitle><Reference>NCT03693989; PRO-145/III; SOPH145-0716 / III</Reference><Sponsor>Laboratorios Sophia</Sponsor><Trial id="355334"/><TrialStartDate>OCTOBER  , 01, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>153</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>153</Patients><ProtocolAcronym>PALADIN</ProtocolAcronym><ProtocolTitle>Phase IV IOP Signals Associated With Iluvien</ProtocolTitle><Reference>M-01-15-004; NCT02424019; PALADIN</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="227463"/><TrialStartDate>MAY      , 06, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>17-alpha-hydroxyprogesterone; Adrenocorticotropic hormone; Blood pressure; Body Mass Index; Body temperature; C-terminal telopeptide of collagen type I; Corticosterone; Cortodoxone; Glucose; Heart rate; High-density lipoprotein cholesterol; Hydrocortisone; Insulin; Low-density lipoprotein cholesterol; Muscle strength; Osteocalcin; Procollagen Type I N-terminal peptide; Respiratory frequency; Six-minute walk distance; Testosterone; Total body mass; Total cholesterol; Triglycerides</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="70712">vamorolone</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>vamorolone</Interventions><Patients>48</Patients><ProtocolAcronym>VISION-DMD</ProtocolAcronym><ProtocolTitle>Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Reference>2017-003568-10; NCT03038399; VBP15-LTE; VISION-DMD</Reference><Sponsor>ReveraGen BioPharma Inc</Sponsor><Trial id="287053"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Eosinophils</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><EnrollmentCount>82</EnrollmentCount><Interventions>budesonide (oral, eosinophilic esophagitis), Meritage</Interventions><Patients>71</Patients><ProtocolAcronym>PEER</ProtocolAcronym><ProtocolTitle>Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis</ProtocolTitle><Reference>MPI-101-01; NCT00762073; PEER</Reference><Sponsor>Shire plc</Sponsor><Trial id="42073"/><TrialStartDate>NOVEMBER , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>189</EnrollmentCount><Interventions>OTO-104</Interventions><Patients>189</Patients><ProtocolAcronym/><ProtocolTitle>A 6-Month Extension Study of OTO-104 in Meniere's Disease</ProtocolTitle><Reference>104-201509; NCT02706730</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="255564"/><TrialStartDate>FEBRUARY , 29, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Wet age related macular degeneration</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Azmacort; photodynamic therapy (PDT)</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration</ProtocolTitle><Reference>05-EI-0064; 050064; NCT00100009</Reference><Sponsor>National Eye Institute</Sponsor><Trial id="95955"/><TrialStartDate>DECEMBER , 09, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Heart rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><EnrollmentCount>63</EnrollmentCount><Interventions>batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Interventions><Patients>63</Patients><ProtocolAcronym/><ProtocolTitle>Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>201546; NCT02573870</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="243854"/><TrialStartDate>DECEMBER , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study to Compare Fluticasone Furoate (FF) Single-strip Inhaler With FF Two-strip Inhaler and With FF/Vilanterol Combination</ProtocolTitle><Reference>115440; NCT01485445</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="82997"/><TrialStartDate>DECEMBER , 21, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>99mTc; beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients</ProtocolTitle><Reference>2016-001088-35; CCD-05993AA1-15; NCT02975843</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="280709"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Duchenne dystrophy</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>29</EnrollmentCount><Interventions>Emflaza</Interventions><Patients>29</Patients><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, double-blind, randomized, parallel-group, placebo-controlled study of deflazacort for the treatment of patients with Duchenne muscular dystrophy (DMD)</ProtocolTitle><Reference>MP-104-NM-002</Reference><Sponsor>Marathon Pharmaceuticals LLC</Sponsor><Trial id="332308"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>27</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>27</Patients><ProtocolAcronym/><ProtocolTitle>AZD-5423 Multiple Ascending Dose Study</ProtocolTitle><Reference>D2340C00002; EudraCT No: 2009-016611-38; NCT01037504</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="63153"/><TrialStartDate>JANUARY  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anterior chamber</Biomarkers><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>101</EnrollmentCount><Interventions>EyeGate; dexamethasone</Interventions><Patients>101</Patients><ProtocolAcronym/><ProtocolTitle>Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery</ProtocolTitle><Reference>EGP-437-009; NCT03180255</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="301426"/><TrialStartDate>JULY     , 26, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>Seretide; Seretide; charcoal</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>charcoal; fluticasone propionate + salmeterol xinafoate; fluticasone propionate + salmeterol xinafoate</Interventions><Patients>64</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Reference>3106010; NCT03060044</Reference><Sponsor>Orion Corp</Sponsor><Trial id="289048"/><TrialStartDate>JULY     , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV / FVC ratio; Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>30</Patients><ProtocolAcronym>STORM</ProtocolAcronym><ProtocolTitle>Lung Deposition of TRIMBOW pMDI in Healthy Volunteers, Asthmatic and COPD Patients</ProtocolTitle><Reference>2017-005030-29; CLI-05993AA1-20; NCT03795350; STORM</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="365704"/><TrialStartDate>JANUARY  , 14, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>576</EnrollmentCount><Interventions>CINGAL</Interventions><Patients>576</Patients><ProtocolAcronym/><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide</ProtocolTitle><Reference>2017-000355-46; CINGAL 16-02; NCT03191903</Reference><Sponsor>Anika Therapeutics Inc</Sponsor><Trial id="301892"/><TrialStartDate>MAY      , 25, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>Seretide Diskus</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>fluticasone propionate + salmeterol xinafoate</Interventions><Patients>64</Patients><ProtocolAcronym>SAIMI</ProtocolAcronym><ProtocolTitle>Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Reference>3106012; NCT03238482; SAIMI</Reference><Sponsor>Orion Corp</Sponsor><Trial id="307440"/><TrialStartDate>AUGUST   , 16, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body height; Bone mineral density; Total body mass</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount/><Interventions>Emflaza</Interventions><Patients/><ProtocolAcronym>PTCEMF</ProtocolAcronym><ProtocolTitle>A Phase III Study of Emflaza (Deflazacort) in Patients With Duchenne Muscular Dystrophy</ProtocolTitle><Reference>NCT03642145; PTCEMF; PTCEMF-GD-003</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="351212"/><TrialStartDate>OCTOBER  , 31, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>17</EnrollmentCount><Interventions>Arnuity; Breo; Ellipta</Interventions><Patients>17</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Vilanterol on Methacholine Challenge Results</ProtocolTitle><Reference>NCT03315000; VIL-2017</Reference><Sponsor>University of Saskatchewan</Sponsor><Trial id="316341"/><TrialStartDate>OCTOBER  , 13, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>17</EnrollmentCount><Interventions>Arnuity; Breo; Ellipta</Interventions><Patients>17</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Vilanterol on Methacholine Challenge Results</ProtocolTitle><Reference>NCT03315000; VIL-2017</Reference><Sponsor>University of Saskatchewan</Sponsor><Trial id="316341"/><TrialStartDate>OCTOBER  , 13, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD-5423 When Administered in Different Ways</ProtocolTitle><Reference>D2340C00008; NCT01310322</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="75917"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Atopic dermatitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46177">mapracorat</Drug><EnrollmentCount>197</EnrollmentCount><Interventions>mapracorat</Interventions><Patients>197</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)</ProtocolTitle><Reference>1403440; 15616; 2010-024279-14; NCT01359787</Reference><Sponsor>Bayer AG</Sponsor><Trial id="77700"/><TrialStartDate>MAY      , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Ulcerative proctitis</Condition><Controls>mesalazine</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>320</EnrollmentCount><Interventions>Rectabul; Rectabul; mesalazine</Interventions><Patients>320</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide versus Mesalazine versus Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis</ProtocolTitle><Reference>2012-003362-41; BUS-2/UCA; NCT01966783</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="238809"/><TrialStartDate>SEPTEMBER, 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Blepharitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91859">fluticasone (ocular inflammation, pain), Nicox Ophthalmics</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>NCX-4251</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Safety and Tolerability of NCX-4251 for the Treatment of Acute Exacerbations of Blepharitis</ProtocolTitle><Reference>NCT03926026; NCX-4251-01</Reference><Sponsor>NicOx SA, Nicox Ophthalmics Inc</Sponsor><Trial id="318225"/><TrialStartDate>MARCH    , 18, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body height; Total body mass</Biomarkers><Condition>Esophageal disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>budesonide</Interventions><Patients>60</Patients><ProtocolAcronym>OVB in EA</ProtocolAcronym><ProtocolTitle>Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair</ProtocolTitle><Reference>NCT03999008; OVB IN EA; OVB in EA</Reference><Sponsor>CHU de Quebec-Universite Laval</Sponsor><Trial id="386068"/><TrialStartDate>JUNE     , 01, 2020</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>5</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>5</Patients><ProtocolAcronym/><ProtocolTitle>A non-randomized, open-label, two period crossover study in healthy adult male subjects to determine the excretion balance and pharmacokinetics of [14C]-GW-685698, administered as single doses of oral and intravenous infusion</ProtocolTitle><Reference>FFR10008</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="202329"/><TrialStartDate>NOVEMBER , 17, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition/><Controls>PT-007; PT-008</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><EnrollmentCount>91</EnrollmentCount><Interventions>PT-027</Interventions><Patients>91</Patients><ProtocolAcronym>LOGAN</ProtocolAcronym><ProtocolTitle>A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT-007 and PT-008 Administered Separately</ProtocolTitle><Reference>D6930C00003; LOGAN; NCT03772223</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="363124"/><TrialStartDate>JANUARY  , 21, 2019</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>deflazacort</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers</ProtocolTitle><Reference>MP-104-CL-026; NCT02485431</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="233499"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>219</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>438</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery</ProtocolTitle><Reference>NCT00429923; ST-601A-002a</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21683"/><TrialStartDate>JANUARY  , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Intraocular pressure; Macula retinae; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>1127</EnrollmentCount><Interventions>Azmacort; bevacizumab; bromfenac; bromfenac; dexamethasone; dexamethasone</Interventions><Patients>1127</Patients><ProtocolAcronym>PREMED</ProtocolAcronym><ProtocolTitle>Prevention of Macular Edema After Cataract Surgery</ProtocolTitle><Reference>2012-004873-14; NCT01774474; NL42463.068.12; NL_42463; PREMED</Reference><Sponsor>Maastricht University Medical Center, University Eye Clinic Maastricht</Sponsor><Trial id="105848"/><TrialStartDate>JULY     , 10, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Ear pressure</Biomarkers><Condition>Rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>91</EnrollmentCount><Interventions>Azmacort</Interventions><Patients>91</Patients><ProtocolAcronym/><ProtocolTitle>Short-Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays</ProtocolTitle><Reference>103-04; IST4008; NCT00279916; XRG5029C/4008</Reference><Sponsor>Mayo Clinic Foundation</Sponsor><Trial id="11760"/><TrialStartDate>SEPTEMBER, 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1 (forced expiratory volume in 1 s); PEF (peak expiratory flow)</Biomarkers><Condition>Asthma</Condition><Controls>Flixotide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>700</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>700</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 100, 200, 300 and 400 microg Administered qd in the Morning and Fluticasone Propionate 250 microg bid via Diskus Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (= 12 years old) with Persistent Asthma Symptomatic on Low-Dose ICS Therapy</ProtocolTitle><Reference>2005-001124-36; FFA20002; FFA20003</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="117759"/><TrialStartDate>SEPTEMBER, 19, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Xerophthalmia</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>198</EnrollmentCount><Interventions>EGP-437</Interventions><Patients>198</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye</ProtocolTitle><Reference>EGP-437-003; NCT01129856</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="66663"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls>prednisolone acetate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery</ProtocolTitle><Reference>C-10-004; NCT01124045</Reference><Sponsor>Alcon Research Ltd</Sponsor><Trial id="66419"/><TrialStartDate>AUGUST   , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Body height</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>fluticasone furoate; montelukast; salbutamol</Interventions><Patients>450</Patients><ProtocolAcronym/><ProtocolTitle>Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Pediatric Subjects With Asthma Over a Year</ProtocolTitle><Reference>114971; 2016-002551-22; HZA114971; NCT02889809; P/276/2016</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="271148"/><TrialStartDate>OCTOBER  , 20, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Cortisol; Creatinine; Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone propionate; salmeterol</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>An Open-label Study to Compare Systemic Side Effects of High Dose Fluticasone/Salmeterol with that of High Dose Ciclesonide/Salmeterol in Symptomatic Asthmatics</ProtocolTitle><Reference>AcadMed CTU03/05; EudraCT 2006-002450-30</Reference><Sponsor>Hull and East Yorkshire Hospitals NHS Trust</Sponsor><Trial id="116685"/><TrialStartDate>JULY     , 12, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Patients>37</Patients><ProtocolAcronym>FAME</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema</ProtocolTitle><Reference>C-01-06-002; FAME; NCT00490815</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="4360"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Intranasal Steroids and the Nasal Ocular Response</ProtocolTitle><Reference>15061B; NCT00473915</Reference><Sponsor>University of Chicago</Sponsor><Trial id="11749"/><TrialStartDate>APRIL    , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca; budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB; salmeterol</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II, Randomized, Partially-blinded, Crossover Study to Evaluate the Systemic Effect of Two Doses of the SMB Budesonide-salmeterol DPI Fixed-dose Combination Capsule (300/25 microg bid and 150/25 microg bid) Delivered by the Axahaler Versus Pulmicort Turbohaler 400 microg bid and Serevent Diskus 50 microg bid Versus Placebo in Mild Persistent Asthmatic Patients</ProtocolTitle><Reference>BUSAL-II-10-2; EudraCT 2010-020794-16</Reference><Sponsor>Laboratoires SMB SA</Sponsor><Trial id="118182"/><TrialStartDate>OCTOBER  , 15, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus</ProtocolTitle><Reference>3106008; EUDRACT 2012-003782-18; NCT01856621</Reference><Sponsor>Orion Corp</Sponsor><Trial id="132070"/><TrialStartDate>MAY      , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Choroidal neovascularization</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>triamcinolone acetonide; verteporfin</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>A Pilot Study to Examine the Safety and Efficacy of Posterior Juxtascleral Triamcinolone Acetonide Administration, in Addition to Visudyne Photoynamic Therapy for Predominantly Classic Choroidal Neovascularization Secondary to Age Related Macular Degeneration: An Open-Label, Randomized, Active-Controlled Trial</ProtocolTitle><Reference>EudraCT 2005-002466-11; version125/05/05</Reference><Sponsor>Kings College Hospital NHS Trust</Sponsor><Trial id="142831"/><TrialStartDate>JANUARY  , 03, 2006</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Esophagus tumor</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>A RCT of Local Steroid Injection for Prevention of Post-ESD Esophageal Stenosis</ProtocolTitle><Reference>JPRN-UMIN000006327</Reference><Sponsor>Keiyukai Sapporo Hospital</Sponsor><Trial id="122329"/><TrialStartDate>FEBRUARY , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>intraoccular pressure</Biomarkers><Condition>Cataract</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>110</EnrollmentCount><Interventions>5-fluorouracil; triamcinolone acetonide</Interventions><Patients>110</Patients><ProtocolAcronym/><ProtocolTitle>Prospective Study into the Effect of an Intraocular Injection of a Steroid in the Prevention of Glaucoma Drainage Surgery Failure After Cataract Surgery</ProtocolTitle><Reference>ACTRN12611000336987; U1111-1120-4139</Reference><Sponsor>Royal Victorian Eye and Ear Hospital</Sponsor><Trial id="123904"/><TrialStartDate>MAY      , 31, 2011</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Central cornea; Intraocular pressure; Macula retinae</Biomarkers><Condition>Ocular disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="95157">triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Harrow Health</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>Imprimis Less Drops; PredKeterolac; triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Imprimis</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Dropless Versus Less Drops Pharmaceutical Regimens After Cataract Surgery</ProtocolTitle><Reference>BF-2015-011; NCT02819908</Reference><Sponsor>Eye Center of North Florida</Sponsor><Trial id="264759"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount>7</EnrollmentCount><Interventions>methotrexate; methylprednisolone; prednisone; prednisone; triamcinolone acetonide</Interventions><Patients>7</Patients><ProtocolAcronym>UVEXATE</ProtocolAcronym><ProtocolTitle>Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis</ProtocolTitle><Reference>NCT00918554; P070140; UVEXATE</Reference><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><Trial id="169537"/><TrialStartDate>SEPTEMBER, 30, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Arm circumference</Biomarkers><Condition>Lymphedema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>66</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide</Interventions><Patients>66</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Effectiveness of Corticosteroid Preparation in Sympathetic Ganglion Block on Lymphedema</ProtocolTitle><Reference>2010-0206; KCT0000300</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="127593"/><TrialStartDate>APRIL    , 30, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>261</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>261</Patients><ProtocolAcronym/><ProtocolTitle>Study FFR116364, a Placebo-Controlled Study of GW-685698X in Pediatric Subjects With Perennial Allergic Rhinitis</ProtocolTitle><Reference>116364; FFR116364; JapicCTI-121888; NCT01630135</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="88789"/><TrialStartDate>JUNE     , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Diastolic blood pressure; Heart rate; Peak expiratory flow rate; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Repeat Dose GW-685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Subjects</ProtocolTitle><Reference>HZA102928; NCT00522678</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="23655"/><TrialStartDate>FEBRUARY , 15, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Avamys; Relovair</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Reference>HZA102940; NCT00625196</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="23384"/><TrialStartDate>FEBRUARY , 27, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Panretinal photocoagulation; triamcinolone acetonide</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Controlled Trial on Therapeutic Effects of Sub-Tenons Capsule Injection of Triamcinolone Acetonide in Prevention of Occurrence and Inhibition of Progression of Diabetic Macular Edema Caused by Panretinal Photocoagulation</ProtocolTitle><Reference>JPRN-C000000455</Reference><Sponsor>Kyoto University</Sponsor><Trial id="136114"/><TrialStartDate>JULY     , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Respiratory disorder</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>1568</Patients><ProtocolAcronym/><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="22103"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation</ProtocolTitle><Reference>NCT00406341; SJE2079/3-03</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21568"/><TrialStartDate>APRIL    , 30, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><EnrollmentCount>172</EnrollmentCount><Interventions>IBI-10090</Interventions><Patients>172</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of IBI-10090 in Ocular Surgery Patients</ProtocolTitle><Reference>C11-01; NCT01606735</Reference><Sponsor>Icon Bioscience Inc</Sponsor><Trial id="87882"/><TrialStartDate>APRIL    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls>triamcinolone acetonide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>481</EnrollmentCount><Interventions>fluticasone</Interventions><Patients>451</Patients><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the safety and efficacy of fluticasone propionate aqueous spray and triamcinolone acetonide  aqueous nasal spray in patients with seasonal allergic rhinitis</ProtocolTitle><Reference>FLTA4007</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="87544"/><TrialStartDate>AUGUST   , 11, 1997</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>415</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>415</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Two Doses of Qvar versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids</ProtocolTitle><Reference>IXR-301-4-197; NCT00109668</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="22589"/><TrialStartDate>JULY     , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>PARI BOY inhalation system; budesonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="83838">budesonide (controlled release/inhaled/AKITA, adult asthma), Vectura</Drug><EnrollmentCount>702</EnrollmentCount><Interventions>VR-475 inhalation system; budesonide</Interventions><Patients>702</Patients><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two doses of nebulised budesonide delivered by the VR475 Inhalation System, with an open-label comparison to conventionally nebulized budesonide, in patients with uncontrolled asthma despite treatment with high dose inhaled corticosteroid and at least a second controller (GINA Step 4) and those receiving oral corticosteroid (GINA Step 5)</ProtocolTitle><Reference>2015-000353-20; 2015-CT0310; PHRR160330-001192; VR475/3/001</Reference><Sponsor>Syneos Health Inc, Vectura Group plc</Sponsor><Trial id="253447"/><TrialStartDate>OCTOBER  , 01, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Carpal tunnel syndrome</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>triamcinolone acetonide; wrist splint</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of steroid injection and wrist splint in carpal tunnel syndrome</ProtocolTitle><Reference>6/10/12/90/پ; IRCT2012110210799N3</Reference><Sponsor>Yasouj University of Medical Sciences and Health Services</Sponsor><Trial id="139713"/><TrialStartDate>NOVEMBER , 30, 2012</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>162</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>162</Patients><ProtocolAcronym/><ProtocolTitle>A Multicenter, randomized controlled Clinical Trial of Early Vitrectomy for Diffuse Diabetic Macular Edema</ProtocolTitle><Reference>JPRN-UMIN000008957</Reference><Sponsor>Kagoshima University</Sponsor><Trial id="138006"/><TrialStartDate>OCTOBER  , 01, 2012</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Bone mineral density; Prothrombin time</Biomarkers><Condition>Autoimmune hepatitis</Condition><Controls/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount/><Interventions>Entocort</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis</ProtocolTitle><Reference>07-003586; BUDESONIDE; NCT00587119</Reference><Sponsor>Mayo Clinic Foundation</Sponsor><Trial id="201346"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Fovea centralis; Macula retinae; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>pars plana vitrectomy; triamcinolone acetonide</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized Controlled Trial of Triamcinolone Intravitreal Injection Versus Vitrectomy for Diabetic Macular Edema</ProtocolTitle><Reference>JPRN-C000000432</Reference><Sponsor>Kagoshima University</Sponsor><Trial id="142064"/><TrialStartDate>JUNE     , 01, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW-685698X Aqueous Nasal Spray Or Placebo Nasal Spray</ProtocolTitle><Reference>FFR101747; NCT00109486</Reference><Sponsor>GlaxoSmithKline Inc</Sponsor><Trial id="14025"/><TrialStartDate>APRIL    , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Glucose; High-density lipoprotein cholesterol</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>86</EnrollmentCount><Interventions>hydrocortisone</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>An open, multicenter, phase IIIb, long-term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency</ProtocolTitle><Reference>2008-003990-42; DC08/01</Reference><Sponsor>DuoCort Pharma AB</Sponsor><Trial id="142192"/><TrialStartDate>JULY     , 28, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood flow; Cephalic vein; Radial artery</Biomarkers><Condition>Kidney dialysis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Nanocort</Interventions><Patients>30</Patients><ProtocolAcronym>LIPMAT</ProtocolAcronym><ProtocolTitle>Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation</ProtocolTitle><Reference>2015-002488-40; LIPMAT; LIPMAT; NCT02495662</Reference><Sponsor>Leiden University Medical Center</Sponsor><Trial id="234690"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>108</EnrollmentCount><Interventions>PPA-904; Photodynamic therapy; bevacizumab; bevacizumab; triamcinolone acetonide</Interventions><Patients>108</Patients><ProtocolAcronym/><ProtocolTitle>Phase III, Clinical Trial Multicenter, Randomized for the Evaluation of the Safety and Efficacy of the Combined Treatment of Intravitreal Triamcinolone and Photodynamic Therapy Versus Intravitreal Bevacizumab and Photodynamic Therapy Versus Intravitreal Bevacizumab for the Treatment of Neo-Vascular Maculopathy Type Retinal Angiomatous Prolipheration (RAP)</ProtocolTitle><Reference>EudraCT 2008-001468-34; HLS01/2008</Reference><Sponsor>Ospedale Luigi Sacco Azienda Ospedaliera Polo Universitario, Polo Universitario</Sponsor><Trial id="142760"/><TrialStartDate>NOVEMBER , 20, 2008</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Arthralgia</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>94</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>94</Patients><ProtocolAcronym/><ProtocolTitle>Blind intra-articular injection with low- and high-dose corticosteroid in adhesive capsulitis: a randomized, double-blind, controlled trial</ProtocolTitle><Reference>AJIRB-MED-CT4-15-005; KCT0001451</Reference><Sponsor>Ajou University Hospital</Sponsor><Trial id="227263"/><TrialStartDate>APRIL    , 20, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Calprotectin; Insulin-like Growth Factor 1</Biomarkers><Condition>Crohns disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>22</EnrollmentCount><Interventions>Entocort; Nutropin AQ; prednisone</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Growth Hormone Therapy in Pediatric Crohn's Disease</ProtocolTitle><Reference>CCHMC IRB #: 04-12-06; IND # 71,344; NCT00109473</Reference><Sponsor>Cincinnati Children's Hospital Medical Center</Sponsor><Trial id="157135"/><TrialStartDate>APRIL    , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56234">mometasone + nortriptyline (topical cream, psoriasis), CombinatoRx</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>CRx-191</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Study of CRx-191 to assess activity in plaque psoriasis</ProtocolTitle><Reference>CRx-191-001; Eudra CT #: 2006-005848-87; NCT00557739</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="36819"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Atopic dermatitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46177">mapracorat</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>mapracorat</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>HPA Axis Study in Japanese Adults</ProtocolTitle><Reference>1403460; 15519; NCT01407510</Reference><Sponsor>Bayer AG</Sponsor><Trial id="79701"/><TrialStartDate>MAY      , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; FEV1; Glucose; Heart rate; Hematocrit; Hemoglobin; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; PEF; Phosphorus; Potassium; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Urea nitrogen; Uric acid; cortisol; gamma-Glutamyltransferase</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>622</EnrollmentCount><Interventions>fluticasone; fluticasone furoate</Interventions><Patients>207</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-dose ICS Therapy</ProtocolTitle><Reference>2007-004459-13; FFA109685; NCT00603278</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="88126"/><TrialStartDate>DECEMBER , 20, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Bursitis</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>Treatments for Non - Septic Olecranon Bursitis: Choosing among Observation, Aspiration and Aspiration with Steroid Injection</ProtocolTitle><Reference>KCT0001525; MJH-14-086</Reference><Sponsor>Myongji Hospital</Sponsor><Trial id="232350"/><TrialStartDate>FEBRUARY , 17, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular Pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>45</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>45</Patients><ProtocolAcronym/><ProtocolTitle>Intracameral different dosage triamcinolone acetonide preventing anterior uveitis after uveitic cataract</ProtocolTitle><Reference>ChiCTR-TRC-13003466</Reference><Sponsor>Beijing Shijitan Hospital</Sponsor><Trial id="151518"/><TrialStartDate>SEPTEMBER, 01, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>53</EnrollmentCount><Interventions>Qvar; darunavir; ritonavir</Interventions><Patients>53</Patients><ProtocolAcronym/><ProtocolTitle>Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers</ProtocolTitle><Reference>09-CC-0186; 090186; NCT00936793</Reference><Sponsor>National Institutes of Health</Sponsor><Trial id="58697"/><TrialStartDate>JULY     , 06, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Crohns disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>123</EnrollmentCount><Interventions>Entocort</Interventions><Patients>108</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of Entocort for Children With Mild to Moderate Crohn's Disease</ProtocolTitle><Reference>2011-003743-22; D9422C00001; NCT01444092</Reference><Sponsor>Perrigo Co plc</Sponsor><Trial id="81223"/><TrialStartDate>NOVEMBER , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>127</EnrollmentCount><Interventions>fluticasone furoate; fluticasone propionate</Interventions><Patients>127</Patients><ProtocolAcronym/><ProtocolTitle>Fluticasone Nasal Spray Patient Preference Study</ProtocolTitle><Reference>FFU108556; NCT00398476</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="13880"/><TrialStartDate>DECEMBER , 01, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Histamine; Tryptase</Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Veramyst; olopatadine</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms</ProtocolTitle><Reference>09-287-B; NCT01007253</Reference><Sponsor>University of Chicago</Sponsor><Trial id="61731"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>250</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>250</Patients><ProtocolAcronym/><ProtocolTitle>Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery</ProtocolTitle><Reference>663; NCT01230125</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="71760"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory flow ; Forced expiratory volume; Hydrocortisone; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>Alvesco</Interventions><Patients>1000</Patients><ProtocolAcronym>BALLOON</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 years)</ProtocolTitle><Reference>2005-001242-17; BALLOON; BY9010/M1-207; NCT00163449</Reference><Sponsor>ALTANA AG, AstraZeneca plc</Sponsor><Trial id="22042"/><TrialStartDate>NOVEMBER , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>IBI-10090</Interventions><Patients>42</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients</ProtocolTitle><Reference>C10-01; NCT01214174</Reference><Sponsor>Icon Bioscience Inc</Sponsor><Trial id="70911"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><EnrollmentCount>394</EnrollmentCount><Interventions>Dexycu</Interventions><Patients>394</Patients><ProtocolAcronym/><ProtocolTitle>The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery</ProtocolTitle><Reference>C13-04; NCT02006888</Reference><Sponsor>Icon Bioscience Inc</Sponsor><Trial id="163346"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>PT-009; PT-010; Symbicort Turbohaler</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety Study of PT-010 in Healthy Subjects</ProtocolTitle><Reference>NCT02189304; PT010002-00</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="204168"/><TrialStartDate>JUNE     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ear disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64095">dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>FST-201</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>FST-201 In The Treatment of Acute Fungal Otitis Externa</ProtocolTitle><Reference>FST201-AFOE-02; NCT00945646</Reference><Sponsor>Shire plc</Sponsor><Trial id="59122"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Glucose</Biomarkers><Condition>Non-insulin dependent diabetes</Condition><Controls>triamcinolone acetonide injectable suspension (Kenalog)</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>33</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>33</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Effects of FX-006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes</ProtocolTitle><Reference>FX006-2015-010; NCT02762370</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="260068"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Heart rate</Biomarkers><Condition>Lateral epicondylitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, prospective, double-blind, in parallel-groups, randomized, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of betamethasone valerate 2.25 mg medicated plaster in patients with chronic lateral epicondylitis (tennis elbow)</ProtocolTitle><Reference>14I-BMT09; 2014-004119-35</Reference><Sponsor>Institut Biochimique SA</Sponsor><Trial id="269724"/><TrialStartDate>MARCH    , 03, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="114745">halobetasol propionate (0.05% topical foam, plaque psoriasis), Mayne Pharma</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>halobetasol propionate</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12 to 17 With Plaque Psoriasis</ProtocolTitle><Reference>122-0551-209; NCT03992261</Reference><Sponsor>Mayne Pharma Group Ltd</Sponsor><Trial id="385266"/><TrialStartDate>JUNE     , 14, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Knee stiffness</Biomarkers><Condition>Pain</Condition><Controls>triamcinolone acetonide injectable suspension</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>484</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>484</Patients><ProtocolAcronym/><ProtocolTitle>Study of FX-006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>2014-005329-11; FX006-2014-008; NCT02357459</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="221476"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Central cornea; Intraocular pressure; Macula retinae</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Moxeza; nepafenac; prednisolone acetate</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="95157">triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Harrow Health</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>TriMoxiVanc; TriMoxiVanc; nepafenac</Interventions><Patients>66</Patients><ProtocolAcronym/><ProtocolTitle>Dropless Versus Standard Drops Contralateral Eye Study</ProtocolTitle><Reference>CEP 14-002; NCT02515045</Reference><Sponsor>Carolina Eyecare Physicians, LLC</Sponsor><Trial id="236566"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>hsCRP</Biomarkers><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>136</EnrollmentCount><Interventions>canakinumab</Interventions><Patients>136</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Canakinumab (ACZ-885) in Patients With Frequent Flares for Whom Non-steroidal Anti-Inflammatory Drug (NSAIDs) and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective</ProtocolTitle><Reference>2010-024172-26; CACZ885H2358; NCT01362608</Reference><Sponsor>Novartis AG</Sponsor><Trial id="77770"/><TrialStartDate>JUNE     , 20, 2011</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>GTPase KRas</Biomarkers><Condition>Adenocarcinoma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>123</EnrollmentCount><Interventions>clobetasol; regorafenib</Interventions><Patients>123</Patients><ProtocolAcronym>ReDOS</ProtocolAcronym><ProtocolTitle>Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer</ProtocolTitle><Reference>NCI-2015-00011; NCT02368886; P30CA015083; RU021407I; ReDOS</Reference><Sponsor>Academic and Community Cancer Research United</Sponsor><Trial id="222641"/><TrialStartDate>MARCH    , 27, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>1080</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>1050</Patients><ProtocolAcronym>RAINBOW</ProtocolAcronym><ProtocolTitle>A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6 to 11 years) With Asthma</ProtocolTitle><Reference>BY9010/M1-209; NCT00384189; RAINBOW; U1111-1172-2297</Reference><Sponsor>Takeda GmbH</Sponsor><Trial id="22308"/><TrialStartDate>SEPTEMBER, 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Interleukin-13; Interleukin-17D; Protein S100-A1</Biomarkers><Condition>Atopic dermatitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>betamethasone; clobetasol propionate foam, Connetics; pimecrolimus</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)</ProtocolTitle><Reference>EXP-1184; NCT02376049</Reference><Sponsor>LEO Pharma A/S</Sponsor><Trial id="223294"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>193</EnrollmentCount><Interventions>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate; prednisolone (oral suspension, inflammation), Taro Pharmaceuticals</Interventions><Patients>193</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis</ProtocolTitle><Reference>EGP-437-004; NCT01505088</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="83808"/><TrialStartDate>DECEMBER , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Fovea centralis; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls>Lucentis</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>Avastin; Lucentis; triamcinolone acetonide</Interventions><Patients>460</Patients><ProtocolAcronym>TOPAZ</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO</ProtocolTitle><Reference>2017-002089-37; CLS1003-302; CTRI/2018/05/014044; NCT03203447; TOPAZ</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="303712"/><TrialStartDate>MARCH    , 05, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>98</EnrollmentCount><Interventions>Qvar; glycopyrronium bromide (inhaled, COPD), Chiesi</Interventions><Patients>98</Patients><ProtocolAcronym>ELITRA</ProtocolAcronym><ProtocolTitle>Efficacy of LAMA Added to ICS in Treatment of Asthma</ProtocolTitle><Reference>2014-001442-16; CCD-05993AB1-02; CCD-5993AB1-02; ELITRA; NCT02296411</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="216299"/><TrialStartDate>NOVEMBER , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>592</EnrollmentCount><Interventions>Enbrel; Enbrel; Enbrel + Primolux; Primolux</Interventions><Patients>592</Patients><ProtocolAcronym/><ProtocolTitle>Evaluate Efficacy and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis</ProtocolTitle><Reference>20080470; NCT01235442</Reference><Sponsor>Amgen Inc</Sponsor><Trial id="71945"/><TrialStartDate>SEPTEMBER, 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>inhaled corticosteroids therapy; long acting beta 2-agonist therapy; long acting bronchodilator therapy</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>4233</EnrollmentCount><Interventions>Relvar Ellipta</Interventions><Patients>4233</Patients><ProtocolAcronym>Salford Lung Study 2</ProtocolAcronym><ProtocolTitle>An Effectiveness Study Comparing Fluticasone Furoate (FF, GW-685698)/Vilanterol (VI, GW-642444) With Standard Treatment in Asthma</ProtocolTitle><Reference>115150; 2011-005553-31; HZA115150; NCT01706198; Salford Lung Study 2</Reference><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline plc</Sponsor><Trial id="94845"/><TrialStartDate>NOVEMBER , 01, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Graft versus host disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>242</EnrollmentCount><Interventions>Budenofalk</Interventions><Patients>94</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation</ProtocolTitle><Reference>NCT00180089; PROGAST</Reference><Sponsor>Dresden University of Technology</Sponsor><Trial id="77387"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>107</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>BDP-AR-304; NCT01133626</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="66887"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>beclomethasone dipropionate, (CFC-free), Teva</Interventions><Patients>25</Patients><ProtocolAcronym>PVSD-ICS</ProtocolAcronym><ProtocolTitle>The predictive value of the acute effect of beclomethasone-dipropionate on a mannitol challenge test for the outcome of longterm treatment with beclomethasone-dipropionate in childhood asthma</ProtocolTitle><Reference>2016-002276-27; PVSD-ICS; PVSD-ICS</Reference><Sponsor>Medisch Spectrum Twente Enschede</Sponsor><Trial id="267741"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89013">fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis), GlaxoSmithKline</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Reference>200284; NCT01962467</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157921"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cortisol; FEV1; PEF</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>669</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>575</Patients><ProtocolAcronym/><ProtocolTitle>A Study of GW-685698X 100 microg Administered Once-Daily Either in the Morning or the Evening and GW-685698X 250 microg Administered Once-Daily in the Evening Via Diskhaler for 28 Days in Subjects With Persistent Bronchial Asthma</ProtocolTitle><Reference>FFA20001; NCT01499446</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="83590"/><TrialStartDate>SEPTEMBER, 30, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1; cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>750</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>744</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 years)</ProtocolTitle><Reference>2004-000825-31; BY9010/M1-206; NCT00163462</Reference><Sponsor>AstraZeneca plc, Takeda Pharmaceutical Co Ltd</Sponsor><Trial id="22091"/><TrialStartDate>OCTOBER  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Bilirubin; Blood platelets; Calcium; Creatine kinase; Creatinine; Gamma-glutamyltranspeptidase 1; Glucose; Leukocyte count; Phosphorus; Potassium; Sodium; Total cholesterol</Biomarkers><Condition>Multiple myeloma</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77410">dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>35</Patients><ProtocolAcronym>AMETHYST</ProtocolAcronym><ProtocolTitle>An Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma</ProtocolTitle><Reference>14-097; 2014-005137-32; AMETHYST; NCT03033316</Reference><Sponsor>Enceladus Pharmaceuticals</Sponsor><Trial id="294570"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>Ellipta dry powder inhaler; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Bronchodilator Effect of a Single-Dose of Fluticasone Furoate (FF)/Vilanterol (VI) 100/25 microg Combination When Administered in Adult Patients With Asthma</ProtocolTitle><Reference>116592; NCT01837316</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="123588"/><TrialStartDate>OCTOBER  , 21, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Rectosigmoiditis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>265</EnrollmentCount><Interventions>Rectabul</Interventions><Patients>265</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Reference>BUCF3001; NCT01008410</Reference><Sponsor>Bausch Health Companies Inc</Sponsor><Trial id="62013"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Netildex eye drops solution; bromfenac</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56575">dexamethasone + netilmicin (ophthalmic), SIFI</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>Netildex; XanterGel; bromfenac</Interventions><Patients>180</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-Inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction</ProtocolTitle><Reference>044-SI; 2016-002138-63; NCT02973880</Reference><Sponsor>SIFI Societa Industria Farmaceutica Italiana SpA</Sponsor><Trial id="280555"/><TrialStartDate>OCTOBER  , 15, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>415</EnrollmentCount><Interventions>BOL-303242X</Interventions><Patients>415</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of BOL-303242X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery</ProtocolTitle><Reference>2009-011913-26; 588; NCT00905450</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="55690"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)</ProtocolTitle><Reference>NCT00616993; ST-601-004</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="22504"/><TrialStartDate>JANUARY  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + vilanterol</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>Randomized Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW-642444M) Combination and FF on an Allergen Induced Asthmatic Response</ProtocolTitle><Reference>113090; NCT01128569</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="66839"/><TrialStartDate>JANUARY  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Adenosine Monophosphate; Forced expiratory volume; Slow vital capacity</Biomarkers><Condition>Asthma</Condition><Controls>Ventolin; fluticasone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>Ventolin; ciclesonide</Interventions><Patients>37</Patients><ProtocolAcronym/><ProtocolTitle>Responsiveness of Lower Airways in Adult Patients (18 to 60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate</ProtocolTitle><Reference>BY9010/NL-101; ISRCTN37115189; NCT00306163; NTR711</Reference><Sponsor>AstraZeneca plc, Byk Nederland BV</Sponsor><Trial id="22406"/><TrialStartDate>MAY      , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Staphylococcus aureus infection</Condition><Controls>clobetasol propionate foam, Connetics</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>Altabax; clobetasol propionate foam, Connetics</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Treatment of Staphylococcus Aureus Colonization in Hand Eczema</ProtocolTitle><Reference>GCO 11-0038; NCT01591785</Reference><Sponsor>Mount Sinai School of Medicine</Sponsor><Trial id="87172"/><TrialStartDate>JANUARY  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide (Kenalog-40)</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>229</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>229</Patients><ProtocolAcronym/><ProtocolTitle>Study of FX-006 in Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>FX006-2011-001; NCT01487161</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="83071"/><TrialStartDate>JUNE     , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>487</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>487</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR</ProtocolTitle><Reference>BDP-AR-201; NCT00854360</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="47773"/><TrialStartDate>MARCH    , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Fostair</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>366</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>366</Patients><ProtocolAcronym>TRI-D</ProtocolAcronym><ProtocolTitle>Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>2017-004405-41; CLI-05993BA1-02; NCT03590379; TRI-D</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="346870"/><TrialStartDate>JUNE     , 15, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; vilanterol</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler</ProtocolTitle><Reference>102932; NCT01213849</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="71284"/><TrialStartDate>OCTOBER  , 04, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C5a anaphylatoxin chemotactic receptor; Complement receptor type 1; Cytokines; Forced expiratory volume; Integrin alpha-IIb; Integrin alpha-M; Interleukin-1 beta; Interleukin-13; Interleukin-17A; Interleukin-8; Leukocyte elastase; Neutrophil extracellular trap; Neutrophils; Resistin</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Relvar Ellipta</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>Spiolto Respimat</Interventions><Patients>80</Patients><ProtocolAcronym>INCOGNITO</ProtocolAcronym><ProtocolTitle>Investigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol</ProtocolTitle><Reference>2016-004473-41; 2016RC22; INCOGNITO; NCT03152149</Reference><Sponsor>University of Dundee</Sponsor><Trial id="299300"/><TrialStartDate>JUNE     , 01, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>99mTc; beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients</ProtocolTitle><Reference>2016-001088-35; CCD-05993AA1-15; NCT02975843</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="280709"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Globulins; Glucose; Hematocrit; Hemoglobin; Ketones; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; PR interval; Phosphate; Potassium; QRS complex; QT interval; Respiratory frequency; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea; Uric acid; Urinary specific gravity; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>batefenterol succinate; batefenterol succinate + fluticasone furoate; fluticasone furoate; fluticasone furoate + vilanterol trifenatate; fluticasone furoate + vilanterol trifenatate</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>GSK-961081 Alone and With Fluticasone Furoate (FF), Phase I (PhI), Single-Dose Regimen (SD), Repeat-Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)</ProtocolTitle><Reference>201958; NCT02666287</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="251911"/><TrialStartDate>JANUARY  , 27, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>Diastolic blood pressure; Forced expiratory flow ; Forced expiratory volume; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate; salbutamol</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>425</EnrollmentCount><Interventions>ELLIPTA dry powder inhaler; fluticasone furoate; salbutamol; umeclidinium bromide</Interventions><Patients>425</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma</ProtocolTitle><Reference>2016-002843-40; 205832; NCT03012061</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="284379"/><TrialStartDate>JANUARY  , 25, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls>mesalazine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>123</EnrollmentCount><Interventions>budesonide</Interventions><Patients>123</Patients><ProtocolAcronym/><ProtocolTitle>Phase III Study of D-9421-C 9 mg in Patients With Active Crohn's Disease in Japan</ProtocolTitle><Reference>2014-004132-20; D9423C00001; JapicCTI-121765; NCT01514240</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="84227"/><TrialStartDate>FEBRUARY , 29, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Respiratory frequency; Sodium; Systolic blood pressure; Total protein; Urea nitrogen; Urinary specific gravity</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>358</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>358</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 and 110 microg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)</ProtocolTitle><Reference>201492; NCT02424539</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="227683"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Eosinophils; Peak nasal inspiratory flow</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Patients>20</Patients><ProtocolAcronym>NACHO</ProtocolAcronym><ProtocolTitle>Nasal Allergen Challenge-Reproducibility of Biomarkers and Effect of Topical Steroid Treatment</ProtocolTitle><Reference>DC002544/HIREB3820; NACHO; NCT03431961</Reference><Sponsor>Hamilton Health Sciences Corp</Sponsor><Trial id="329091"/><TrialStartDate>MARCH    , 07, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="106967">budesonide (orodispersible tablet, eosinophilic esophagitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>Jorveza</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receives medication without active substance), phase II/III study on the efficacy and tolerability of oral budesonide suspension in comparison with placebo in children and adolescents with eosinophilic esophagitis</ProtocolTitle><Reference>2017-003737-29; BUU-5/EEA; PEDEOS-1</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="374819"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Qvar</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>HS-1277; NCT00238082</Reference><Sponsor>National Jewish Health</Sponsor><Trial id="3697"/><TrialStartDate>NOVEMBER , 30, 1999</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Pemphigus</Condition><Controls>Dermovate; orabase</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Reference>00UAD; NCT03878771</Reference><Sponsor>Beni-Suef University</Sponsor><Trial id="373754"/><TrialStartDate>MARCH    , 13, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>PT-008; PT007</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><EnrollmentCount>600</EnrollmentCount><Interventions>PT-027</Interventions><Patients>600</Patients><ProtocolAcronym>DENALI</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT-027) Used Four Times Daily in Adults and Children 4 Years of Age or Older With Asthma</ProtocolTitle><Reference>2018-003674-27; AV004; DENALI; NCT03847896</Reference><Sponsor>Avillion LLP</Sponsor><Trial id="370792"/><TrialStartDate>APRIL    , 10, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><EnrollmentCount>324</EnrollmentCount><Interventions>PT-003; PT-009; PT-010</Interventions><Patients>324</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Safety and Efficacy of PT-010, PT-003, and PT-009 in Japanese Subjects With COPD Compared With Symbicort Turbohaler</ProtocolTitle><Reference>JapicCTI-184080; NCT03262012; PT010007</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="310434"/><TrialStartDate>AUGUST   , 09, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="101388">dexamethasone (ophthalmic implant, DME), Aerie Pharmaceuticals/ Envisia</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>AR-1105</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)</ProtocolTitle><Reference>AR-1105-CS201; NCT03739593</Reference><Sponsor>Aerie Pharmaceuticals Inc</Sponsor><Trial id="360004"/><TrialStartDate>MARCH    , 13, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel (group 1B); dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel (group 2B)</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>EryDex Pharmacokinetics in Healthy Volunteers</ProtocolTitle><Reference>IED-PK01-2013; NCT01925859</Reference><Sponsor>EryDel SPA</Sponsor><Trial id="151307"/><TrialStartDate>JUNE     , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70712">vamorolone</Drug><EnrollmentCount>86</EnrollmentCount><Interventions>vamorolone</Interventions><Patients>86</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP-15 in Healthy Adult Subjects</ProtocolTitle><Reference>NCT02415439; VBP15-001</Reference><Sponsor>ReveraGen BioPharma Inc</Sponsor><Trial id="226791"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>61</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>61</Patients><ProtocolAcronym/><ProtocolTitle>Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days</ProtocolTitle><Reference>794; NCT01736462</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="99986"/><TrialStartDate>FEBRUARY , 28, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition/><Controls>Pulmicort Flexhaler</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><EnrollmentCount>66</EnrollmentCount><Interventions>PT-027</Interventions><Patients>66</Patients><ProtocolAcronym>ELBRUS</ProtocolAcronym><ProtocolTitle>A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT-027 Compared With Pulmicort Flexhaler</ProtocolTitle><Reference>D6930C00011; ELBRUS; NCT03934333</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="379001"/><TrialStartDate>MAY      , 16, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition/><Controls>Rectabul</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount/><Interventions>budesonide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris Rectal Aerosol Foam</ProtocolTitle><Reference>NCT02800824; PRG-NY-16-007</Reference><Sponsor>Perrigo Co Ltd</Sponsor><Trial id="263269"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>71</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis); levocabastine hydrochloride</Interventions><Patients>71</Patients><ProtocolAcronym/><ProtocolTitle>A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)</ProtocolTitle><Reference>200286; NCT01957202</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157076"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><EnrollmentCount>882</EnrollmentCount><Interventions>fluticasone propionate; salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Interventions><Patients>1661</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma</ProtocolTitle><Reference>2014-000923-25; FSS-AS-30017; NCT02141854</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="189017"/><TrialStartDate>MAY      , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEF25; FEF25-75; FEF50; FEF75; FEV1; FEV1/FVC; FVC/SVC; PEF</Biomarkers><Condition>Asthma</Condition><Controls>Clenil (Chiesi); Flixotide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>QVAR</Interventions><Patients>43</Patients><ProtocolAcronym>OLiVIA</ProtocolAcronym><ProtocolTitle>Effects of QVAR in Smokers With Asthma</ProtocolTitle><Reference>2012-005350-39; 20122011; NCT01741285; OLiVIA</Reference><Sponsor>University Medical Center Groningen</Sponsor><Trial id="100542"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>PST/Laser versus Laser Alone for CSME</ProtocolTitle><Reference>NCT00229918; PST/CSME</Reference><Sponsor>Edward Hines Jr. VA Hospital</Sponsor><Trial id="100166"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Blepharoconjunctivitis</Condition><Controls>AzaSite; dexamethasone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55854">azithromycin + dexamethasone (sustained release, DuraSite), InSite</Drug><EnrollmentCount>417</EnrollmentCount><Interventions>AzaSite Plus</Interventions><Patients>417</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis</ProtocolTitle><Reference>C-07-502-002; NCT00578955</Reference><Sponsor>InSite Vision Inc</Sponsor><Trial id="10106"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Retinal venous occlusion</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount/><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Intravitreal Bevacizumab versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)</ProtocolTitle><Reference>8886; NCT01178697</Reference><Sponsor>Shaheed Beheshti Medical University</Sponsor><Trial id="69043"/><TrialStartDate>JANUARY  , 31, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>896</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>680</Patients><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, two-arm, parallel-group study to compare the efficacy and safety of ciclesonide 320 mg versus ciclesonide 160 mg in patients with severe persistent asthma</ProtocolTitle><Reference>ACE; BY9010/M1-140</Reference><Sponsor>Takeda GmbH</Sponsor><Trial id="76906"/><TrialStartDate>MAY      , 07, 2007</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Proctitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>17</EnrollmentCount><Interventions>Rectabul</Interventions><Patients>17</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis</ProtocolTitle><Reference>BUF-17/RAP; EUDRACT NO.: 2007-002082-13; NCT00828230</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="129552"/><TrialStartDate>SEPTEMBER, 30, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>GSK-2834425; Relovair; Zephyr</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study in Healthy Volunteers to Characterize the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses</ProtocolTitle><Reference>200587; NCT01894386</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="145910"/><TrialStartDate>JULY     , 15, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Scar tissue</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>176</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>176</Patients><ProtocolAcronym>Keloid</ProtocolAcronym><ProtocolTitle>Surgical and Aesthetic Outcome, Quality Of Life, and Cost-Effectiveness of Keloid Treatment</ProtocolTitle><Reference>2012-002675-34; Keloid; NL40235.078.12</Reference><Sponsor/><Trial id="116826"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; Glucose; Heart rate; Potassium; Pulse rate; Systolic blood pressure; Urine cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>503</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>503</Patients><ProtocolAcronym/><ProtocolTitle>Fluticasone Furoate/GW-642444 Inhalation Powder Long-term Safety Study</ProtocolTitle><Reference>106839; HZA106839; NCT01018186</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="62136"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>FEV1; PEF</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>fluticasone propionate; fluticasone propionate; fluticasone propionate + salmeterol xinafoate; salmeterol xinafoate; triamcinolone acetonide</Interventions><Patients>350</Patients><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, triple-dummy, parallel group study to compare the safety and efficacy of fluticasone propionate, triamcinolone acetonide, and fluticasone propionate in combination with salmeterol xinafoate, each delivered via a metered-dose inhaler, in subjects with asthma who remain symptomatic despite receiving inhaler corticosteroids</ProtocolTitle><Reference>FLTA4021</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="115129"/><TrialStartDate>NOVEMBER , 01, 1996</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation</ProtocolTitle><Reference>NCT00406497; SJE2079/2-03-PC</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21563"/><TrialStartDate>APRIL    , 30, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Adhesive capsulitis</Condition><Controls>lidocaine; triamcinolone acetonide</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>58</EnrollmentCount><Interventions>Allogenic Platelet Rich Plasma (PRP)</Interventions><Patients>58</Patients><ProtocolAcronym/><ProtocolTitle>Intra-articular Injection of Allogeneic Platelet Rich Plasma (PRP) for Adhesive Capsulitis</ProtocolTitle><Reference>BRM-11-02; NCT01458691</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="115577"/><TrialStartDate>SEPTEMBER, 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>550</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>550</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 200 microg bid, qd and 400 microg qd in the Morning Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) with Persistent Asthma Symptomatic on Low-Dose ICS Therapy</ProtocolTitle><Reference>2005-001841-40; EudraCT 2005-001841-40; FFA102714</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="117746"/><TrialStartDate>OCTOBER  , 05, 2005</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>Daivobet; Dermoval</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="87535">calcitriol + clobetasol propionate (spray, psoriasis vulgaris), Galderma</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>calcitriol + clobetasol propionate</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Efficacy Evaluation of a Fixed Combination of Calcitriol 3 microg/g With Three Concentrations (100, 250, 500 microg/g) of Clobetasol Propionate as Spray Formulation Using the Modified Dumas-Scholtz Psoriasis Mini Plaque Test Under Non-Occlusive Conditions</ProtocolTitle><Reference>EudraCT 2006-006487-32; RD.03.SPR. 40041</Reference><Sponsor>Galderma SA</Sponsor><Trial id="117900"/><TrialStartDate>FEBRUARY , 27, 2007</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>Seretide Diskus</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>Axahaler; Busal</Interventions><Patients>500</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III, Randomized, Parallel-Group Study to Compare the Therapeutic Efficacy of SMB Budesonide-Salmeterol DPI Capsule 300/25 microg bid Delivered By The Axahaler Versus Seretide Diskus 500/50 microg (Fluticasonepropionate 500 microg/Salmeterol 50 microg) bid Over 12 Weeks and to Evaluate the Safety of SMB Budesonide-Salmeterol 300/25 microg Over an Additional Period of 12 Weeks in Moderate to Severe Persistent Asthmatic Patients</ProtocolTitle><Reference>BUSAL-III-05-1; EudraCT 2006-001514-33</Reference><Sponsor>Laboratoires SMB SA</Sponsor><Trial id="117985"/><TrialStartDate>JUNE     , 05, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate</Biomarkers><Condition>Inflammatory disease</Condition><Controls>prednisolone</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="56124">BI-653048</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>BI-653048</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI-653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects</ProtocolTitle><Reference>1262.9; NCT02224105</Reference><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><Trial id="208883"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-peptide; glucose; insulin</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59618">fosdagrocorat</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>PF-04171327</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>Single-Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism</ProtocolTitle><Reference>A9391006; NCT01199900</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="70377"/><TrialStartDate>AUGUST   , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Graft versus host disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><EnrollmentCount>2</EnrollmentCount><Interventions>orBec</Interventions><Patients>2</Patients><ProtocolAcronym/><ProtocolTitle>Study of orBec as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)</ProtocolTitle><Reference>BDP-GVHD-08; NCT01925950</Reference><Sponsor>Soligenix Inc</Sponsor><Trial id="151308"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls>mesalazine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>311</EnrollmentCount><Interventions>budesonide</Interventions><Patients>311</Patients><ProtocolAcronym/><ProtocolTitle>Oral Budesonide Versus Oral Mesalazine in Active Crohn's Disease (CD)</ProtocolTitle><Reference>2004-001213-34; BUC-52/CDA; NCT00300118</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="16108"/><TrialStartDate>SEPTEMBER, 30, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>58</EnrollmentCount><Interventions>clobetasol</Interventions><Patients>58</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam</ProtocolTitle><Reference>NCT00842153; OEF0701</Reference><Sponsor>Stiefel</Sponsor><Trial id="193445"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Albumin; C-reactive protein; Creatinine; Extracellular fluid; Lean body mass; Natriuretic peptides B; Phase angle; Sodium; Total body mass; Total body water</Biomarkers><Condition>Bullous pemphigoid</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>Clarelux; Impedance analysis</Interventions><Patients>35</Patients><ProtocolAcronym>RECOPB</ProtocolAcronym><ProtocolTitle>Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid</ProtocolTitle><Reference>2014-002804-26; 2014/110/HP; NCT02360202; RECOPB</Reference><Sponsor>Rouen University Hospital</Sponsor><Trial id="221587"/><TrialStartDate>APRIL    , 30, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Dyspnea</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>7</EnrollmentCount><Interventions>Qvar</Interventions><Patients>93</Patients><ProtocolAcronym>ICSADP</ProtocolAcronym><ProtocolTitle>Effectiveness of Inhaled Corticosteroids in Preschool Children With Acute Dyspnea and Wheeze</ProtocolTitle><Reference>2009-009579-36; ICSADP; NCT00962299; NL26689.075.09</Reference><Sponsor>Isala Klinieken</Sponsor><Trial id="192333"/><TrialStartDate>MAY      , 31, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>1116</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>1116</Patients><ProtocolAcronym/><ProtocolTitle>Lung Health Study II</ProtocolTitle><Reference>207; NCT00000569</Reference><Sponsor>National Heart Lung and Blood Institute</Sponsor><Trial id="3630"/><TrialStartDate>SEPTEMBER, 30, 1993</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls>Avamys; Relovair</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Reference>HZA102940; NCT00625196</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="23384"/><TrialStartDate>FEBRUARY , 27, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls>betamethasone sodium phosphate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>140</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>140</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis</ProtocolTitle><Reference>NCT00406887; SJE2079/3-01-PC</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21748"/><TrialStartDate>AUGUST   , 31, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Fovea centralis</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of SJE-2079 for Diabetic Macular Edema</ProtocolTitle><Reference>UMIN000011873</Reference><Sponsor>Senju Pharmaceutical Co Ltd</Sponsor><Trial id="243944"/><TrialStartDate>SEPTEMBER, 26, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Esophageal disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>fluticasone; triamcinolone acetonide</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>Phase I Study of Combination Therapy with Endoscopic Triamcinolone Injection and Fluticasone Swallowing for The Prevention of Esophageal Stricture After Endoscopic Submucosal Dissection</ProtocolTitle><Reference>JPRN-UMIN000010383</Reference><Sponsor>Ishikawa Prefectural Central Hospital</Sponsor><Trial id="137612"/><TrialStartDate>APRIL    , 01, 2013</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Heart rate; QT interval</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi; charcoal block; pressurized metered dose inhaler</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF-5993 pMDI Combination in Healthy Volunteers</ProtocolTitle><Reference>CCD-05993AB2-01; NCT02359292</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="221592"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>1568</Patients><ProtocolAcronym/><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="22103"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Alopecia</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>clobetasol propionate</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia</ProtocolTitle><Reference>NCT01111981; VDC2009O</Reference><Sponsor>Callender Center for Clinical Research</Sponsor><Trial id="66010"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>21</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>21</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Inhaled Ciclesonide in Adult Patients With Asthma</ProtocolTitle><Reference>BY9010/M1-125; NCT00546520</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="22951"/><TrialStartDate>APRIL    , 30, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>528</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>528</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Ciclesonide (CIC) Administered Twice-Daily in Pediatric Patients With Asthma</ProtocolTitle><Reference>EFC6695; EudraCT: 2006-004740-22; NCT00392288; XRP1526</Reference><Sponsor>Takeda Pharmaceuticals International GmbH</Sponsor><Trial id="22410"/><TrialStartDate>SEPTEMBER, 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>C-reactive protein (CRP); Interleukin-6 (IL-6); Monocyte chemoattractant protein-1 (MCP-1)</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Allermist</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Inhaled Steroid Reduces Systemic Inflammation in COPD</ProtocolTitle><Reference>4027; NCT00175565</Reference><Sponsor>University of British Columbia</Sponsor><Trial id="13589"/><TrialStartDate>JANUARY  , 31, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>ALP; ALT; AST; Albumin; Basophils; Bilirubin; Blood pressure; Calcium; Chloride; Cholesterol; Cortisol; Creatinine; Diastolic blood pressure; Eosinophils; FEV1; GGT; Heart rate; Hemoglobin; Inorganic phosphorus; LD; Leukocyte count; Lymphocytes; Monocytes; PFE; Platelets; Potassium; Red blood cells; Sodium; Systolic blood pressure; Total neutrophils; Total protein; Uric acid; Urinary specific gravity; White blood cells; glucose</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>599</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>599</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy</ProtocolTitle><Reference>2007-004442-32; FFA109687; NCT00603382</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="151197"/><TrialStartDate>DECEMBER , 01, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Bone mineral density; Prothrombin time</Biomarkers><Condition>Primary biliary cholangitis</Condition><Controls/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount/><Interventions>Entocort</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis</ProtocolTitle><Reference>07-003586; BUDESONIDE; NCT00587119</Reference><Sponsor>Mayo Clinic Foundation</Sponsor><Trial id="201346"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; eosinophil</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Ciclesonide on Exercise Induced Bronchoconstriction</ProtocolTitle><Reference>BY/M1-121; NCT00525772; OBCIEX</Reference><Sponsor>Hamilton Health Sciences Corp</Sponsor><Trial id="22397"/><TrialStartDate>NOVEMBER , 30, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>ciclesonide; formoterol fumarate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>Ultrahaler; ciclesonide + formoterol</Interventions><Patients>240</Patients><ProtocolAcronym>ADVICE</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 years)</ProtocolTitle><Reference>2004-004708-19; ADVICE; BY9010/M1-506; NCT00314509</Reference><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><Trial id="21993"/><TrialStartDate>JULY     , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume; Peak expiratory flow rate; cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>Alvesco; spacer AeroChamber Plus; spacer AeroChamberMAX</Interventions><Patients>468</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 years)</ProtocolTitle><Reference>2005-002163-84; BY9010/M1-145; NCT00163436</Reference><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><Trial id="22041"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Muscle stiffness</Biomarkers><Condition>Pain</Condition><Controls>Monovisc</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>368</EnrollmentCount><Interventions>CINGAL</Interventions><Patients>368</Patients><ProtocolAcronym/><ProtocolTitle>CINGAL Study for Knee Osteoarthritis</ProtocolTitle><Reference>Cingal 13-01; NCT01891396</Reference><Sponsor>Anika Therapeutics Inc</Sponsor><Trial id="144187"/><TrialStartDate>JUNE     , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Study on Triamcinolone and Bevacizumab Efficacy in Macular Edema Treatment and in Retinic or Chorioretinic Neovessels Treatment</ProtocolTitle><Reference>08059906; EudraCT 2007-003032-37</Reference><Sponsor>IRCCS Policlinico San Matteo</Sponsor><Trial id="141193"/><TrialStartDate>MAY      , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>38</EnrollmentCount><Interventions>MK II inserter; fluocinolone acetonide</Interventions><Patients>38</Patients><ProtocolAcronym/><ProtocolTitle>A Controlled, Multicenter Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye</ProtocolTitle><Reference>NCT02748512; PSV-FAI-006</Reference><Sponsor>EyePoint Pharmaceuticals Inc</Sponsor><Trial id="259049"/><TrialStartDate>FEBRUARY , 29, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Aspartate aminotransferase; C-reactive protein; High-density lipoprotein cholesterol; Lipids; Low-density lipoprotein cholesterol; Total cholesterol; Triglycerides</Biomarkers><Condition>Psoriasis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>Atorvastatin; betamethasone valerate</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis</ProtocolTitle><Reference>NCT02432040; PDS_PGH_2013_002</Reference><Sponsor>Philippine dermatological society</Sponsor><Trial id="228274"/><TrialStartDate>FEBRUARY , 28, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>11</Patients><ProtocolAcronym>RESPOND</ProtocolAcronym><ProtocolTitle>A Pilot Study on the Effect and Safety of Iluvien in Chronic Diabetic Macular Edema Patients</ProtocolTitle><Reference>2014-003491-23; 4C-2014-06; NCT02359526; RESPOND</Reference><Sponsor>Association for Innovation and Biomedical Research on Light and Image</Sponsor><Trial id="221579"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls>triamcinolone acetonide</Controls><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Platelet Rich Plasma</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Platelet Rich Plasma versus Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome</ProtocolTitle><Reference>GTPS PRP VS STEROID; NCT02031367</Reference><Sponsor>Carl R Darnall Army Medical Center</Sponsor><Trial id="166920"/><TrialStartDate>MARCH    , 31, 2014</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Herpes simplex virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><EnrollmentCount>254</EnrollmentCount><Interventions>aciclovir + hydrocortisone (dermatological), Medivir</Interventions><Patients>134</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study Of ME-609 For Treatment Of Herpes Simplex Labialis In Adolescents</ProtocolTitle><Reference>609-07; EudraCT: 2006-002828-42; NCT00375570</Reference><Sponsor>Medivir AB</Sponsor><Trial id="11579"/><TrialStartDate>OCTOBER  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="106967">budesonide (orodispersible tablet, eosinophilic esophagitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>204</EnrollmentCount><Interventions>Jorveza</Interventions><Patients>204</Patients><ProtocolAcronym>EOS-2</ProtocolAcronym><ProtocolTitle>Maintenance of Remission With Budesonide Orodispersible Tablets versus Placebo in Eosinophilic Esophagitis</ProtocolTitle><Reference>2014-001485-99; BUL-2/EER; EOS-2; NCT02493335</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="234441"/><TrialStartDate>JANUARY  , 15, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Acquired immune deficiency syndrome</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>53</EnrollmentCount><Interventions>Qvar; darunavir; ritonavir</Interventions><Patients>53</Patients><ProtocolAcronym/><ProtocolTitle>Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers</ProtocolTitle><Reference>09-CC-0186; 090186; NCT00936793</Reference><Sponsor>National Institutes of Health</Sponsor><Trial id="58697"/><TrialStartDate>JULY     , 06, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-reactive protein; Erythrocyte sedimentation rate; Interleukin-6</Biomarkers><Condition>Polymyalgia rheumatica</Condition><Controls>prednisone IR</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>62</EnrollmentCount><Interventions>prednisone (oral, delayed release), Horizon/SkyePharma/Merck KGaA</Interventions><Patients>62</Patients><ProtocolAcronym/><ProtocolTitle>A Study Assessing the Efficacy and Safety of Lodotra Compared to Prednisone IR in Subjects Suffering From PMR</ProtocolTitle><Reference>2011-002353-57; LOD3501; NCT01821040</Reference><Sponsor>Mundipharma Research Limited</Sponsor><Trial id="118246"/><TrialStartDate>MARCH    , 31, 2013</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><EnrollmentCount>229</EnrollmentCount><Interventions>GSK-961081 + fluticasone propionate (COPD), GlaxoSmithKline; fluticasone propionate; fluticasone propionate; montelukast</Interventions><Patients>38</Patients><ProtocolAcronym>MASCOT</ProtocolAcronym><ProtocolTitle>Management of Asthma in School-Age Children on Therapy</ProtocolTitle><Reference>HTA 05/503/04; ISRCTN03556343; MASCOT; NCT01526161</Reference><Sponsor>The University Hospital Of North Staffordshire NHS Trust</Sponsor><Trial id="84740"/><TrialStartDate>APRIL    , 30, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Adrenocorticotropic hormone; Blood pressure; Body temperature; Dehydroepiandrosterone sulfate; Heart rate; Hydrocortisone; Osteocalcin; Urine cortisol</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>96</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>96</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics After Single- and Multiple-Dosing of AZD-5423 in Japanese Healthy Male Subjects</ProtocolTitle><Reference>D2340C00003; NCT01338350</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="76864"/><TrialStartDate>JUNE     , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV; NO</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>14</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>14</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Intranasal Corticosteroids on Pulmonary Symptoms in Asthmatics With Nasal Congestion</ProtocolTitle><Reference>2009/158; NCT01562093</Reference><Sponsor>St Olavs Hospital</Sponsor><Trial id="85945"/><TrialStartDate>JANUARY  , 31, 2012</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls>salbutamol MDI, IVAX Corp</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>fluticasone + salmeterol (inhaled/Spiromax, asthma), Teva</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages &gt;/= 12 With Persistent Asthma</ProtocolTitle><Reference>ABS-AS-201; NCT01058863</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="116989"/><TrialStartDate>FEBRUARY , 28, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1621</EnrollmentCount><Interventions>Relvar</Interventions><Patients>1620</Patients><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>200820; 2013-004548-44; JapicCTI-142506; NCT02105974</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="180892"/><TrialStartDate>APRIL    , 07, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure</Biomarkers><Condition>Ocular pain</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>241</Patients><ProtocolAcronym/><ProtocolTitle>Second, Phase III Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Reference>NCT02089113; OTX-14-003</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="178013"/><TrialStartDate>APRIL    , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>619</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; placebo + fluticasone furoate + vilanterol; umeclidinium; umeclidinium (125 microg) + fluticasone furoate + vilanterol; umeclidinium (62.5 microg) + fluticasone furoate + vilanterol</Interventions><Patients>1238</Patients><ProtocolAcronym/><ProtocolTitle>Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>200109; NCT01957163</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157082"/><TrialStartDate>OCTOBER  , 01, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Body Mass Index; Diastolic blood pressure; FEV1; Heart rate; PR interval; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Foster</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>1368</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>1368</Patients><ProtocolAcronym>Trilogy</ProtocolAcronym><ProtocolTitle>Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster in COPD</ProtocolTitle><Reference>2013-001057-27; CCD-1207-PR-0091; NCT01917331; Trilogy</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="149179"/><TrialStartDate>MARCH    , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>CLS-1003; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Interventions><Patients>20</Patients><ProtocolAcronym>HULK</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema</ProtocolTitle><Reference>CLS1004-101; HULK; NCT02944240; NCT02949024</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="277937"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Adrenal gland hypofunction</Condition><Controls>Cortef</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><EnrollmentCount>51</EnrollmentCount><Interventions>Infacort</Interventions><Patients>51</Patients><ProtocolAcronym/><ProtocolTitle>A Study of Infacort Versus Cortef in Healthy Adult Male and Female Subjects</ProtocolTitle><Reference>INFACORT 007; NCT03311932</Reference><Sponsor>Diurnal Ltd</Sponsor><Trial id="316172"/><TrialStartDate>APRIL    , 16, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>EGP-437</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</ProtocolTitle><Reference>EGP-437-001; NCT00694135</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="18517"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount/><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Intravitreal Bevacizumab Versus Bevacizumab Combined With Triamcinolone for Neovascular AMD</ProtocolTitle><Reference>8533; NCT00370370</Reference><Sponsor>Shaheed Beheshti Medical University</Sponsor><Trial id="5282"/><TrialStartDate>NOVEMBER , 30, 2005</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>betamethasone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><EnrollmentCount>231</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Patients>281</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and safety of Institut Biochimique SA (IBSA) 0.1% Betamethasone Valerate (BMV) Medicated Plaster Versus Reference Marketed Product for the Treatment of Chronic Plaque Psoriasis</ProtocolTitle><Reference>04EU/BMT06; EudraCT: 2005-003050-96; ISRCTN68864186</Reference><Sponsor/><Trial id="153953"/><TrialStartDate>APRIL    , 11, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume in 1 sec (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="71455">SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Interventions><Patients>64</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC-1316</ProtocolTitle><Reference>NCT02041221; SPARC_LTD_ CLR_13_16</Reference><Sponsor>Sun Pharmaceutical Advanced Research Co Ltd</Sponsor><Trial id="168932"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>GTPase KRas</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>123</EnrollmentCount><Interventions>clobetasol; regorafenib</Interventions><Patients>123</Patients><ProtocolAcronym>ReDOS</ProtocolAcronym><ProtocolTitle>Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer</ProtocolTitle><Reference>NCI-2015-00011; NCT02368886; P30CA015083; RU021407I; ReDOS</Reference><Sponsor>Academic and Community Cancer Research United</Sponsor><Trial id="222641"/><TrialStartDate>MARCH    , 27, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Relovair; Spiriva</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1479</EnrollmentCount><Interventions>CHF-5993</Interventions><Patients>1479</Patients><ProtocolAcronym>Tristar</ProtocolAcronym><ProtocolTitle>Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>2014-001487-35; CCD-05993AA1-07; NCT02467452; Tristar</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="231716"/><TrialStartDate>MAY      , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>17-alpha-hydroxyprogesterone; Adrenocorticotropic hormone; Body Mass Index; C-terminal telopeptide of collagen type I; Corticosterone; Cortodoxone; Glucose; Hydrocortisone; Insulin; Muscle strength; Osteocalcin; Procollagen Type I N-terminal peptide; Six-minute walk distance; Testosterone</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="70712">vamorolone</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>vamorolone</Interventions><Patients>48</Patients><ProtocolAcronym>VISION-DMD</ProtocolAcronym><ProtocolTitle>An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Reference>1R44NS095423-01; 1U34AR068616-01; 2016-004263-38; NCT02760277; VBP15-003; VISION-DMD</Reference><Sponsor>ReveraGen BioPharma Inc</Sponsor><Trial id="260111"/><TrialStartDate>AUGUST   , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Colitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>57</EnrollmentCount><Interventions>Salofalk Granu-Stix; budesonide</Interventions><Patients>57</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis</ProtocolTitle><Reference>2008-005994-36; BUG-1/LMC; NCT01209208</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="70722"/><TrialStartDate>MAY      , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>170</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>170</Patients><ProtocolAcronym/><ProtocolTitle>Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema</ProtocolTitle><Reference>NCT00441662; Wills Eye Sub-Tenon Kenalog</Reference><Sponsor>Wills Eye Institute</Sponsor><Trial id="95811"/><TrialStartDate>NOVEMBER , 30, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>ACR 20; ACR 50; ACR 70; C-reactive protein</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>dipyridamole; prednisolone; prednisone</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><EnrollmentCount>294</EnrollmentCount><Interventions>prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Interventions><Patients>294</Patients><ProtocolAcronym>Synergy</ProtocolAcronym><ProtocolTitle>A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis</ProtocolTitle><Reference>NCT01369745; Synergy; Z102-008</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="78033"/><TrialStartDate>JUNE     , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>529</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>529</Patients><ProtocolAcronym/><ProtocolTitle>Long-term, Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Microg in Allergic Rhinitis</ProtocolTitle><Reference>BDP-AR-303; NCT00988247</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="88339"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>338</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="197089"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>338</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="197089"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>338</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="197089"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Seretide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>528</EnrollmentCount><Interventions>Relvar</Interventions><Patients>528</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the 24 h Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100 microg Fluticasone Furoate [FF]/25 microg Vilanterol [VI]) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50 microg Salmeterol/500 microg Fluticasone Propionate [FP])</ProtocolTitle><Reference>113107; NCT01342913</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="76887"/><TrialStartDate>FEBRUARY , 01, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>363</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>363</Patients><ProtocolAcronym/><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Reference>793; NCT01591655</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="87162"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure (IOP); Visual acuity</Biomarkers><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>Medidur</Interventions><Patients>6</Patients><ProtocolAcronym>MAP</ProtocolAcronym><ProtocolTitle>The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot</ProtocolTitle><Reference>MAP; NA 00012714; NCT00605423</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="33513"/><TrialStartDate>JANUARY  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Patients>20</Patients><ProtocolAcronym>FAVOR</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina</ProtocolTitle><Reference>C-01-08-006; FAVOR; NCT00770770</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="30143"/><TrialStartDate>MAY      , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1; PEF; Urinary cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate; fluticasone propionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>587</EnrollmentCount><Interventions>fluticasone furoate + vilanterol</Interventions><Patients>586</Patients><ProtocolAcronym/><ProtocolTitle>Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW-642444) in Adult and Adolescent Asthmatics</ProtocolTitle><Reference>106829; EudraCT: 2010-019594-14; HZA106829; JapicCTI-101197; NCT01134042</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="66853"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Diastolic blood pressure; Heart rate; QRS complex; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Patients>49</Patients><ProtocolAcronym>TRIPLE10</ProtocolAcronym><ProtocolTitle>A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF-5993 pMDI in Subjects With Renal Impairment</ProtocolTitle><Reference>2013-002140-91; CCD-05993AA1-10; NCT02040597; TRIPLE10</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="168962"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Cardiovascular inflammation</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos</Interventions><Patients>30</Patients><ProtocolAcronym>SILENCE</ProtocolAcronym><ProtocolTitle>Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease</ProtocolTitle><Reference>2011-002686-37; 2011-002686-37 AMC; NCT01601106; NL37190.018.11; NTR2936; SILENCE</Reference><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><Trial id="87549"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers/><Condition>Contact dermatitis</Condition><Controls>vehicle ointment (paraffin oil/soft white paraffin)</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>Clarelux; Durhalieve; Protopic; glycerol</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of glycerol, two topical steroids, and a topical immune modulator against skin irritation</ProtocolTitle><Reference>2008-001678-34; NCT00779792; WA+TR_1</Reference><Sponsor>Odense University Hospital</Sponsor><Trial id="31700"/><TrialStartDate>SEPTEMBER, 30, 2008</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Dermatitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>GK-664-S</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>A Open-Label, Phase III, Multicenter, Parallel Group Study to Evaluate Efficacy and Safety Study of GK-664-S in Subjects With Moderate-to-Severe Scalp Eczema Dermatitis Except for Seborrheic Dermatitis</ProtocolTitle><Reference>JapicCTI-184247</Reference><Sponsor>Maruho Co Ltd</Sponsor><Trial id="366908"/><TrialStartDate>DECEMBER , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls>inhaled corticosteroids (ICS) therapy; long acting bronchodilator therapy; triple maintenance therapy</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>2802</EnrollmentCount><Interventions>Relovair</Interventions><Patients>2802</Patients><ProtocolAcronym>Salford Lung Study 1</ProtocolAcronym><ProtocolTitle>A Randomized Effectiveness Study Comparing Fluticasone Furoate (FF, GW-685698)/Vilanterol (VI, GW-642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>115151; 2011-002452-13; HZC115151; NCT01551758; Salford Lung Study 1</Reference><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><Trial id="85621"/><TrialStartDate>MARCH    , 13, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Musculoskeletal pain</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>122</EnrollmentCount><Interventions>lidocaine; triamcinolone acetonide</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder</ProtocolTitle><Reference>IT-avdelingen; Interne tjenester; NCT00840229; REK; Rikshospitalet HF; S-08546</Reference><Sponsor>Rikshospitalet University Hospital</Sponsor><Trial id="44888"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure; Macula retinae; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount/><Interventions>Iluvien</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Fluocinolone Acetonide Insert (Iluvien) for Diabetic Macular Edema (FAD) Study</ProtocolTitle><Reference>IRB00082826; NCT02902744</Reference><Sponsor>Johns Hopkins University</Sponsor><Trial id="271751"/><TrialStartDate>MARCH    , 01, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Hydrocortisone</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>hydrocortisone</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Plenadren</Interventions><Patients>30</Patients><ProtocolAcronym>PlenadrEMA</ProtocolAcronym><ProtocolTitle>Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism</ProtocolTitle><Reference>2014-002039-32; H-1-2014-073; NCT02282150; PLEN-EMA-HYPO; PlenadrEMA; PlenadrEMA/1.1/2014</Reference><Sponsor>H:S Rigshospitalet, Rigshospitalet, Denmark</Sponsor><Trial id="214973"/><TrialStartDate>OCTOBER  , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Secreted frizzled-related protein 1; sFRP1</Biomarkers><Condition>Ulcerative colitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Uceris</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>The Use of Corticosteroids (Budenofalk) as a Chemopreventative Agent in Ulcerative Colitis Associated Neoplasia</ProtocolTitle><Reference>EudraCT 2009-015077-12; rrk3681</Reference><Sponsor>University Hospital Birmingham NHS Foundation Trust</Sponsor><Trial id="140176"/><TrialStartDate>NOVEMBER , 23, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Blood platelets; Calcium; Diastolic blood pressure; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Neutrophils; PR interval; Potassium; QRS complex; QT interval; Skin; Sodium; Systolic blood pressure</Biomarkers><Condition>Atopic dermatitis</Condition><Controls>fluticasone</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="70428">870086 (topical, atopic dermatitis), GlaxoSmithKline</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>870086 (topical, atopic dermatitis), GlaxoSmithKline</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Test the Effect of Two Different Doses of Topical GW-870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo</ProtocolTitle><Reference>113434; 2010-022280-35; NCT01299610</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="74969"/><TrialStartDate>DECEMBER , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Adhesive capsulitis</Condition><Controls>bupivacaine, AstraZeneca</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>46</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide (sustained-release, pain), Flexion</Interventions><Patients>46</Patients><ProtocolAcronym/><ProtocolTitle>Effectiveness of triamcinolone in suprascapular nerve block for adhesive capsulitis</ProtocolTitle><Reference>AJIRB-MED-CT4-17-414; KCT0002926</Reference><Sponsor>Ajou University Hospital</Sponsor><Trial id="343336"/><TrialStartDate>JUNE     , 29, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>7+</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Blood pressure; Calcium; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Forced expiratory volume; Glucose; Heart rate; Hematocrit; Hemoglobin; Immunoglobulin E; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Sodium; Systolic blood pressure; Total protein; Urea nitrogen</Biomarkers><Condition>Asthma</Condition><Controls>Albuterol + salbutamol; DISKUS DPI; ELLIPTA DPI; Foxair; Metered-dose inhaler; Relvar Ellipta</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>2544</EnrollmentCount><Interventions>Albuterol + salbutamol; DISKUS DPI; ELLIPTA DPI; Foxair; GSK-2834425; Metered-dose inhaler</Interventions><Patients>2544</Patients><ProtocolAcronym>CAPTAIN</ProtocolAcronym><ProtocolTitle>A Phase III, Parallel-Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate + Umeclidinium Bromide + Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma</ProtocolTitle><Reference>2016-001304-37; 205715; CAPTAIN; JapicCTI-173792; NCT02924688</Reference><Sponsor>GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline SA/Spain, GlaxoSmithKline plc, Innoviva Inc</Sponsor><Trial id="274454"/><TrialStartDate>OCTOBER  , 13, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Reference>116524; NCT01725685</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="97979"/><TrialStartDate>NOVEMBER , 08, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Betesil</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A single-center, prospective, randomized, double-blind, intra-patient (left-to-right) placebo-controlled, pilot study to assess the efficacy and safety of a betamethasone valerate 0.1% medicated plaster in the treatment of finger nail psoriasis</ProtocolTitle><Reference>14I-BMT01; 2014-000291-25</Reference><Sponsor>Institut Biochimique SA</Sponsor><Trial id="329808"/><TrialStartDate>SEPTEMBER, 10, 2014</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular disease</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="65121">beclomethasone dipropionate (intravitreal injection), Allergan</Drug><EnrollmentCount>121</EnrollmentCount><Interventions>AGN-208397</Interventions><Patients>121</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of AGN-208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</ProtocolTitle><Reference>208397-001; NCT01027650</Reference><Sponsor>Allergan Inc</Sponsor><Trial id="62499"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic conjunctivitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56186">ciclosporin + prednisolone (allergic conjunctivitis), CombinatoRx/Fovea</Drug><EnrollmentCount>155</EnrollmentCount><Interventions>FOV-1101-00; Pred Forte; Pred Mild</Interventions><Patients>155</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Efficacy of Coadministration of FOV-1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation</ProtocolTitle><Reference>08-003-27; NCT00833495</Reference><Sponsor>Fovea Pharmaceuticals SA</Sponsor><Trial id="54107"/><TrialStartDate>JANUARY  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>MaQaid</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Treatment of macular edema following BRVO with STTA</ProtocolTitle><Reference>UMIN000031215</Reference><Sponsor>Aichi Medical University, Kamiiida daiichi General Hospital</Sponsor><Trial id="330917"/><TrialStartDate>FEBRUARY , 28, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Osteoarthritis</Condition><Controls>Kenalog-40</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Study to Compare Exposure of TA Following Administration of Either FX-006 or TAcs in Patients With Bilateral Knee OA</ProtocolTitle><Reference>FX-006-2017-012; NCT03378076</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="323314"/><TrialStartDate>DECEMBER , 06, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls>mometasone (nasal/ dermatological)</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>125</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>125</Patients><ProtocolAcronym/><ProtocolTitle>Long Term Safety Of GW-685698X Via Nasal Biopsy</ProtocolTitle><Reference>FFR104503; NCT00224523</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="12096"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>154</EnrollmentCount><Interventions>dexamethasone (sustained release, intratympanic injection, ear disorders), Otonomy</Interventions><Patients>154</Patients><ProtocolAcronym/><ProtocolTitle>OTO-104 for the Treatment of Meniere's Disease</ProtocolTitle><Reference>104-201102; NCT01412177</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="79896"/><TrialStartDate>NOVEMBER , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV / FVC ratio; Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>30</Patients><ProtocolAcronym>STORM</ProtocolAcronym><ProtocolTitle>Lung Deposition of TRIMBOW pMDI in Healthy Volunteers, Asthmatic and COPD Patients</ProtocolTitle><Reference>2017-005030-29; CLI-05993AA1-20; NCT03795350; STORM</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="365704"/><TrialStartDate>JANUARY  , 14, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls>Flixonase</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>260</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Patients>260</Patients><ProtocolAcronym>NASANIF</ProtocolAcronym><ProtocolTitle>A Study to Assess Efficacy and Safety of Nasacort Nasal Spray in Comparison With Flixonase Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>NASANIF; NCT03317015; TRICAL07830; U1111-1178-4882</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="316886"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Adrenocorticotropic hormone; Bone mineral density</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>budesonide</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)</ProtocolTitle><Reference>NCT03245840; SHP621-303</Reference><Sponsor>Shire plc</Sponsor><Trial id="308369"/><TrialStartDate>OCTOBER  , 05, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Eosinophils</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><EnrollmentCount>420</EnrollmentCount><Interventions>budesonide</Interventions><Patients>420</Patients><ProtocolAcronym/><ProtocolTitle>A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histological Response and Determine if Reduction in Dysphagia is Achieved</ProtocolTitle><Reference>NCT02605837; SHP621-301; SHP621-301 induction study</Reference><Sponsor>Shire plc</Sponsor><Trial id="246014"/><TrialStartDate>OCTOBER  , 01, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Tryptase</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen</ProtocolTitle><Reference>16367B (OC 3); NCT00791973</Reference><Sponsor>University of Chicago</Sponsor><Trial id="36009"/><TrialStartDate>NOVEMBER , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>blood pressure; heart rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD-5423 When Administered in Different Ways</ProtocolTitle><Reference>D2340C00012; Eudract 2012-002307-17; NCT01635985</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="96548"/><TrialStartDate>AUGUST   , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>15+</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Bretaris Genuair; Duaklir Genuair; Incruse; Laventair; Onbrez Breezhaler; Serevent; Spiolto Respimat; Spiriva Respimat; Striverdi Respimat; Tovanor Breezhaler; Ultibro Breezhaler; formoterol; usual care for comorbidity</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1032</EnrollmentCount><Interventions>Alabaster; Aliflus Diskus; Fobuler; Revinty Ellipta; usual care for comorbidity</Interventions><Patients>1032</Patients><ProtocolAcronym>ICS-Life</ProtocolAcronym><ProtocolTitle>Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>AIFA-ICSLIFE-001; ICS-Life; NCT03662711</Reference><Sponsor>University of Ferrara</Sponsor><Trial id="352724"/><TrialStartDate>NOVEMBER , 11, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Estimated glomerular filtration rate; Synovial membrane</Biomarkers><Condition>Osteoarthritis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>FX-006</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Effect of FX-006 on Synovial Inflammation in Patients With osteoarthritis (OA) of the Knee</ProtocolTitle><Reference>FX006-2017-014; NCT03529942</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="340019"/><TrialStartDate>APRIL    , 24, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Glucose; Hydrocortisone; Leukocyte count</Biomarkers><Condition>Sciatica</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="106609">dexamethasone sodium phosphate (epidural steroid injectable gel, sciatia), Scilex Holding</Drug><EnrollmentCount>19</EnrollmentCount><Interventions>SP-102</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>A Research Study to Characterize the Pharmacodynamics and Safety of Repeat-dose SP-102</ProtocolTitle><Reference>NCT03613662; SP-102-03</Reference><Sponsor>Semnur Pharmaceuticals Inc</Sponsor><Trial id="348693"/><TrialStartDate>JULY     , 13, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>PT-007</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><EnrollmentCount>3100</EnrollmentCount><Interventions>PT-027</Interventions><Patients>3100</Patients><ProtocolAcronym>MANDALA</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT-027) in Adults and Children 4 Years of Age or Older With Asthma</ProtocolTitle><Reference>2018-003673-10; AV003; MANDALA; NCT03769090</Reference><Sponsor>Avillion LLP</Sponsor><Trial id="365206"/><TrialStartDate>DECEMBER , 27, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls>Qvar; montelukast</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount/><Interventions>ZENHALE; albuterol; prednisolone</Interventions><Patients/><ProtocolAcronym>MF/F Pediatric Asthma HPA Axis Study</ProtocolAcronym><ProtocolTitle>Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5 to 11 Years Old With Persistent Asthma</ProtocolTitle><Reference>2009-010108-27; MF/F Pediatric Asthma HPA Axis Study; NCT01615874; P05574; PN158</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="88259"/><TrialStartDate>OCTOBER  , 26, 2012</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>2,3-Diphosphoglycerate; Adenosine Triphosphate; Body temperature; Diastolic blood pressure; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Lactic Acid; Potassium; Systolic blood pressure</Biomarkers><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Recovery and Survival of EryDex in Non-patient Volunteers</ProtocolTitle><Reference>ERY51CR-01-2014; NCT02380924</Reference><Sponsor>EryDel SPA</Sponsor><Trial id="223659"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>4</EnrollmentCount><Interventions>Entocord</Interventions><Patients>4</Patients><ProtocolAcronym/><ProtocolTitle>Study to Detect Oral Administration of Budesonide in Women</ProtocolTitle><Reference>2017-004839-37; IMIMFTCL/DACORSIN/3; NCT03537326</Reference><Sponsor>Parc de Salut Mar</Sponsor><Trial id="340871"/><TrialStartDate>MAY      , 22, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>142</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>142</Patients><ProtocolAcronym/><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery</ProtocolTitle><Reference>664; NCT01298752</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="74849"/><TrialStartDate>FEBRUARY , 28, 2011</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure; Visual acuity</Biomarkers><Condition>Cataract</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>EyeGate II drug delivery system; dexamethasone</Interventions><Patients>79</Patients><ProtocolAcronym/><ProtocolTitle>Open-Label, Multicenter, Phase Ib/IIa Clinical Trial Designed To Evaluate The Safety And Efficacy Of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution In Patients Having Undergone Cataract Surgery With Implantation Of A Posterior Chamber Intraocular Lens (IOL)</ProtocolTitle><Reference>EGP-437-008; NCT02571556</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="242633"/><TrialStartDate>NOVEMBER , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood cell count; Bone mineral density; Calcium; Collagen type I trimeric cross-linked peptide; Epicardial adipose tissue; Erythrocyte sedimentation rate; Fibrinogen; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Immunoglobulins; Low-density lipoprotein cholesterol; Osteocalcin; Parathyroid hormone; Phosphate; Total cholesterol; Triglycerides; Vitamin D</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>cortisone acetate; hydrocortisone</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>89</EnrollmentCount><Interventions>Plenadren</Interventions><Patients>89</Patients><ProtocolAcronym>DREAM</ProtocolAcronym><ProtocolTitle>Dual Release Hydrocortisone Versus Conventional Glucocorticoid Replacement Therapy in Hypocortisolism</ProtocolTitle><Reference>DREAM; HYPOSURRENALISM_1; NCT02277587</Reference><Sponsor>Universita degli Studi di Roma La Sapienza</Sponsor><Trial id="214912"/><TrialStartDate>MARCH    , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Lower back pain</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population</ProtocolTitle><Reference>319-2010; NCT01382771</Reference><Sponsor>University of Florida</Sponsor><Trial id="103767"/><TrialStartDate>OCTOBER  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>Flutiform; Relvar Ellipta; Symbicort Turbohaler</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>Rapid effect of Flutiform on pulmonary function compared with Relvar and Symbicort</ProtocolTitle><Reference>UMIN000029379</Reference><Sponsor>Tohno Chuo Clinic</Sponsor><Trial id="314707"/><TrialStartDate>OCTOBER  , 02, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Visual acuity</Biomarkers><Condition>Allergic conjunctivitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>73</EnrollmentCount><Interventions>OTX-DP</Interventions><Patients>73</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis</ProtocolTitle><Reference>NCT02445326; OTX-14-007</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="229470"/><TrialStartDate>APRIL    , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Shoulder motion</Biomarkers><Condition>Tendon disease</Condition><Controls>Azmacort</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount/><Interventions>ketorolac</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Subacromial Injection With Corticosteroid Versus Nonsteroidal Anti-inflammatory Drugs (NSAID) in Shoulder Impingement Syndrome</ProtocolTitle><Reference>IMPINGEMENT; NCT01449448</Reference><Sponsor>Madigan Army Medical Center</Sponsor><Trial id="147302"/><TrialStartDate>SEPTEMBER, 30, 2000</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Cataract</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Triamcinolone Assisted Anterior Vitrectomy</ProtocolTitle><Reference>NCT01051648; TRIAM1</Reference><Sponsor>Cairo University</Sponsor><Trial id="116449"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV 25 to 75; FEV1; FVC; blood pressure; cortisol; creatinine; heart rate; nitric oxide; peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>budesonide (Captisol-enabled inhalation solution/eFlow, asthma), Verus Pharmaceuticals</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="93782">budesonide (Captisol-enabled inhalation solution/eFlow, asthma), Verus Pharmaceuticals</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-Label, Active-Controlled, Two-Period Crossover Study to Evaluate Relative Efficacy and Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebulizer and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebulizer in Children with Mild-to-Moderate Persistent Asthma</ProtocolTitle><Reference>EudraCT 2006-003801-21; VPI-102-04</Reference><Sponsor>Verus Pharmaceuticals Inc</Sponsor><Trial id="116845"/><TrialStartDate>NOVEMBER , 14, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, repeat-dose, multicenter study to compare the safety and pharmacokinetics of Nasacort in pediatric patients with that of adult patients with perennial allergic rhinitis</ProtocolTitle><Reference>XRG 5029C/1000</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="89198"/><TrialStartDate>APRIL    , 30, 2003</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Rheumatoid arthritis</Condition><Controls>prednisolone</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59618">fosdagrocorat</Drug><EnrollmentCount>78</EnrollmentCount><Interventions>PF-04171327</Interventions><Patients>78</Patients><ProtocolAcronym/><ProtocolTitle>A Phase I, Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers</ProtocolTitle><Reference>A9391002; NCT00812825</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="56932"/><TrialStartDate>JANUARY  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>6-beta hydroxycortisol; Cortisol</Biomarkers><Condition>Allergic rhinitis</Condition><Controls>prednisone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>112</Patients><ProtocolAcronym/><ProtocolTitle>A Study of GW-685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults</ProtocolTitle><Reference>FFR20002; NCT00116818</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11789"/><TrialStartDate>JANUARY  , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount>11</EnrollmentCount><Interventions>laser; triamcinolone acetonide</Interventions><Patients>11</Patients><ProtocolAcronym>IVTA</ProtocolAcronym><ProtocolTitle>Triamcinolone versus Laser for Diabetic Macular Edema</ProtocolTitle><Reference>2746; IVTA; IVTA - DME; NCT00229931</Reference><Sponsor>University of Oklahoma</Sponsor><Trial id="180232"/><TrialStartDate>NOVEMBER , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount/><Interventions>BTR-15</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Phase III, unblinded, continued long-term administration study of BTR-15 targeting pediatric asthma patients</ProtocolTitle><Reference>JapicCTI-090806</Reference><Sponsor>Teijin Pharma Ltd</Sponsor><Trial id="122481"/><TrialStartDate>JULY     , 23, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Birth weight; FOXP3; IL-10; TGF-alpha</Biomarkers><Condition>Sleep apnea</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome</ProtocolTitle><Reference>15868B; 15868B; NCT00603044</Reference><Sponsor>University of Chicago</Sponsor><Trial id="23198"/><TrialStartDate>JANUARY  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; FeNO</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>91</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>91</Patients><ProtocolAcronym>YSCO</ProtocolAcronym><ProtocolTitle>The Protective Effect of a Nasal Corticosteroid (Avamys) On Exercise Induced Airway Obstruction in Cold Air in Children</ProtocolTitle><Reference>EudraCT: 2009-010563-17; FF1; ISRCTN90761040; NL26953.044.09; YSCO</Reference><Sponsor>Stichting Pediatrisch Onderzoek Enschede</Sponsor><Trial id="118794"/><TrialStartDate>MARCH    , 05, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Lateral epicondylitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Cryotherapy; casting; indomethacin; triamcinolone acetonide</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis</ProtocolTitle><Reference>NCT00554476; RCT-246910-06</Reference><Sponsor>Islamic Azad University of Tehran-Medical Sciences</Sponsor><Trial id="168727"/><TrialStartDate>JANUARY  , 31, 2003</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>365</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>365</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray in Chinese Adult and Adolescents with Seasonal Allergies</ProtocolTitle><Reference>2015-004889-28; FFR113342</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="283339"/><TrialStartDate>DECEMBER , 21, 2016</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>87</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>87</Patients><ProtocolAcronym/><ProtocolTitle>Intravitreal Injection of Triamcinolone Acetonide in Retinitis</ProtocolTitle><Reference>IRCT201104266293N1</Reference><Sponsor>Tehran University of Medical Sciences</Sponsor><Trial id="122471"/><TrialStartDate>SEPTEMBER, 23, 2007</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>beclomethasone dipropionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount/><Interventions>BTR-15</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, comparative, dose-confirmation study of BTR-15 to target pediatric asthma patients</ProtocolTitle><Reference>JapicCTI-090805</Reference><Sponsor>Teijin Pharma Ltd</Sponsor><Trial id="122480"/><TrialStartDate>JULY     , 23, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>22</EnrollmentCount><Interventions>Zuprata</Interventions><Patients>22</Patients><ProtocolAcronym>DOGWOOD</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis</ProtocolTitle><Reference>CLS1001-201; DOGWOOD; NCT02255032</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="212568"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Liver disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>deflazacort</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>A Single-Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics</ProtocolTitle><Reference>MP-104-CL-023; NCT02286609</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="215409"/><TrialStartDate>DECEMBER , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>240</Patients><ProtocolAcronym>POPCICLE</ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide Inhaled Once-Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 years) (BY9010/CA-101)</ProtocolTitle><Reference>BY9010/CA-101; EudraCT: 2007-003736-34; NCT00163293; POPCICLE; U1111-1189-7814</Reference><Sponsor>Takeda GmbH</Sponsor><Trial id="22004"/><TrialStartDate>JANUARY  , 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body height; CD11a; CD11b; Forced expiratory volume in one second (FEV1); Forced vital capacity (FVC); Intercellular adhesion molecule-1; Interleukin 8; Lean body mass; Lung; MoPhabs A17; MoPhabs A27; Soluble intercellular adhesion molecule 1 (sICAM1); Total body mass; Tumor necrosis factor; sE-Selectin; umour necrotising factor alpha (TNFa)</Biomarkers><Condition>Cystic fibrosis</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Cystic Fibrosis; a Hereditary Inflammatory Process</ProtocolTitle><Reference>ISRCTN03484127; NTR91</Reference><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><Trial id="124286"/><TrialStartDate>JANUARY  , 01, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Patients>25</Patients><ProtocolAcronym>HAS-EU-2010</ProtocolAcronym><ProtocolTitle>A Retrospective Trial of Suprachoroidal Drug Therapy for Advanced Exudative Age-Related Macular Degeneration</ProtocolTitle><Reference>011/1231; DRKS00000609; HAS-EU-2010</Reference><Sponsor>Iscience Corp</Sponsor><Trial id="127743"/><TrialStartDate>APRIL    , 12, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Eosinophils; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>10355</EnrollmentCount><Interventions>Relovair; Trelegy Ellipta; Zephyr</Interventions><Patients>10355</Patients><ProtocolAcronym>IMPACT</ProtocolAcronym><ProtocolTitle>A Study Comparing the Efficacy, Safety and Tolerability of Fixed-Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>1.137.774; 100603; 116855; 2013-003075-35; 38506514.7.1001.0070; 883.250; ANZstudy; CTT116855; HKUCTR-1885; IMPACT; JapicCTI-142653; NCT02164513; RBR-4sxpff; U1111-1160-5241; UW 14-364</Reference><Sponsor>GlaxoSmithKline BR, GlaxoSmithKline plc</Sponsor><Trial id="196961"/><TrialStartDate>JUNE     , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Calprotectin</Biomarkers><Condition>Ulcerative colitis</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>budesonide</Interventions><Patients>61</Patients><ProtocolAcronym>TOPICAL-1</ProtocolAcronym><ProtocolTitle>Budesonide 9 mg Capsules in Active UC</ProtocolTitle><Reference>2014-005635-14; BUX-3/UCA; NCT02550418; TOPICAL-1</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="241407"/><TrialStartDate>OCTOBER  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls>Rinderon</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis</ProtocolTitle><Reference>NCT00405496; SJE2079/2-02-PC</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21747"/><TrialStartDate>MARCH    , 31, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Adhesive capsulitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>53</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>53</Patients><ProtocolAcronym/><ProtocolTitle>To determine whether ultrasound-guided intraarticular injection with high dose corticosteroid in patients with adhesive capsulitis is better than low dose or placebo in improving pain and function</ProtocolTitle><Reference>AJIRB-MED-CT4-10-072; KCT0000103</Reference><Sponsor>Ajou University Hospital</Sponsor><Trial id="128627"/><TrialStartDate>AUGUST   , 31, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function</ProtocolTitle><Reference>FFA10013; NCT00419237</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="22672"/><TrialStartDate>JANUARY  , 13, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Eosinophils; FEV1; Forced Vital Capacity; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>1432</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Patients>657</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Ciclesonide Versus Fixed Combination of Fluticasone Propionate/Salmeterol Versus Placebo in Patients With Mild Persistent Asthma (12 to 75 years)</ProtocolTitle><Reference>BY9010/M1-132; NCT00163358</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="22090"/><TrialStartDate>SEPTEMBER, 30, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>38</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>38</Patients><ProtocolAcronym/><ProtocolTitle>Study of GW-685698X In Patients With Seasonal Allergic Rhinitis</ProtocolTitle><Reference>FFR100652; NCT00363740</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="13132"/><TrialStartDate>FEBRUARY , 28, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume in 1 s (FEV1); Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>612</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>609</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW-642444) in Adult and Adolescent Asthmatics</ProtocolTitle><Reference>106827; 2010-019590-15; HZA106827; NCT01165138; P/119/2011</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="68324"/><TrialStartDate>AUGUST   , 20, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>E-selectin; ICAM-1; cortisol; creatinine</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>Qvar; fluticasone; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; prednisolone</Interventions><Patients>17</Patients><ProtocolAcronym>PAW01</ProtocolAcronym><ProtocolTitle>Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma</ProtocolTitle><Reference>Eudract no: 2008-001811-40; NCT00829257; PAW01; PAW01</Reference><Sponsor>University of Dundee</Sponsor><Trial id="42844"/><TrialStartDate>JANUARY  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>450</Patients><ProtocolAcronym/><ProtocolTitle>Effects of Ciclesonide MDI 50 mg/Day and 200 mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma</ProtocolTitle><Reference>LTS6159; NCT00270348; XRP1526B - 343</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="22281"/><TrialStartDate>DECEMBER , 31, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Serum cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>27</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>27</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Pharmacodynamics of GW-685698 in Pediatric Asthmatic Patients</ProtocolTitle><Reference>102942; HZA102942; NCT01332292</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="76319"/><TrialStartDate>MAY      , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>576</EnrollmentCount><Interventions>GW685698X; GW685698X 110 microg; GW685698X 55 microg</Interventions><Patients>554</Patients><ProtocolAcronym/><ProtocolTitle>Seasonal Allergic Rhinitis In Pediatric Subjects</ProtocolTitle><Reference>FFR100010; NCT00107757</Reference><Sponsor>GlaxoSmithKline Inc</Sponsor><Trial id="13567"/><TrialStartDate>MARCH    , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Fovea centralis; Retina; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls>Eylea</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>CLS-1003</Interventions><Patients>460</Patients><ProtocolAcronym>SAPPHIRE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With intravitreal Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Reference>2016-004648-12; 2017-CT0411; CLS1003-301; CLS1003-301 Amendment 1; CTRI/2017/11/010451; NCT02980874; PHRR170812-001654; SAPPHIRE</Reference><Sponsor>Clearside Biomedical Inc, Syneos Health Inc</Sponsor><Trial id="281144"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Wet age related macular degeneration</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Photodynamic therapy; triamcinolone acetonide; verteporfin</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>A Non-Randomized, Single-Center, Open-Label, Case Series Study of Intravitreal Triamcinolone Acetate Injections (IVTA) Used as Adjunctive to Verteporfin Photodynamic Therapy (PDT) in the Treatment Predominantly Classic CNV Lesions Associated With Age-Related Macular Degeneration (AMD)</ProtocolTitle><Reference>EudraCT 2005-005290-30; TCA-05-01</Reference><Sponsor>Semmelweis University</Sponsor><Trial id="142748"/><TrialStartDate>OCTOBER  , 18, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers>Body surface area</Biomarkers><Condition>Atopic dermatitis</Condition><Controls>Azmacort; clobetasone butyrate; fluocinolone acetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>367</EnrollmentCount><Interventions>Azmacort; clobetasone butyrate; dupilumab; fluocinolone acetonide</Interventions><Patients>367</Patients><ProtocolAcronym/><ProtocolTitle>Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants &gt;/= 6 to &lt; 12 Years With Severe Atopic Dermatitis (AD)</ProtocolTitle><Reference>2016-004997-16; IND Number-107969; NCT03345914; P/069/2017; P/219/2016; R668-AD-1652</Reference><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><Trial id="319940"/><TrialStartDate>NOVEMBER , 17, 2017</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults</ProtocolTitle><Reference>BDB-AS-101; NCT02030457</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="166763"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>Relvar; fluticasone</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once-Daily Versus Fluticasone Propionate (FP) Twice-Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)</ProtocolTitle><Reference>2017-001516-11; 201832; NCT02730351</Reference><Sponsor>GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline plc</Sponsor><Trial id="257624"/><TrialStartDate>MAY      , 01, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Esophagus tumor</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>The Evaluation of Prophylactic Effect of Intralesional Steroid Injection to Prevent Esophageal Stricture After ESD (Endoscopic Submucosal Dissection) of Superficial Esophageal Cancers</ProtocolTitle><Reference>JPRN-UMIN000005649</Reference><Sponsor>Kobe University</Sponsor><Trial id="149189"/><TrialStartDate>SEPTEMBER, 16, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Cortisol; FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>1031</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Patients>1030</Patients><ProtocolAcronym/><ProtocolTitle>A 6-Month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>112206; HZC112206; JapicCTI-101096; NCT01053988</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="63573"/><TrialStartDate>OCTOBER  , 05, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>Advair; fluticasone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1526</EnrollmentCount><Interventions>Ellipta</Interventions><Patients>1526</Patients><ProtocolAcronym/><ProtocolTitle>An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 microg Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 microg Inhalation Powder, and Fluticasone Propionate 250 microg Inhalation Powder in Adults and Adolescents With Persistent Asthma</ProtocolTitle><Reference>1209850; 201378; 2014-002253-19; 40739015.4.1001.5336; 86/2015; 942328; NCT02301975; RBR-4f9tcc; U1111-1172-1687</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="216821"/><TrialStartDate>MARCH    , 01, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>342</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Patients>342</Patients><ProtocolAcronym>BASALT</ProtocolAcronym><ProtocolTitle>Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term</ProtocolTitle><Reference>494; BASALT; NCT00495157; U10 HL074073; U10 HL074204; U10 HL074206; U10 HL074208; U10 HL074212; U10 HL074218; U10 HL074225; U10 HL074227; U10 HL074231</Reference><Sponsor>National Heart Lung and Blood Institute</Sponsor><Trial id="22479"/><TrialStartDate>JUNE     , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Choroid; Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls>aflibercept</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>46</EnrollmentCount><Interventions>CLS-TA; aflibercept</Interventions><Patients>46</Patients><ProtocolAcronym>TANZANITE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Reference>CLS1003-201; NCT02303184; TANZANITE</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="216985"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Bronchial wall; Lung; Specific airway resistance; Specific airway volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>CHF-5993</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Functional Respiratory Imaging Study (FRI)</ProtocolTitle><Reference>2017-000438-79; CCD-05993AA1-16; NCT03268226</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="311029"/><TrialStartDate>NOVEMBER , 20, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Adrenocorticotropic hormone; Blood pressure; Body temperature; Dehydroepiandrosterone sulfate; Heart rate; Hydrocortisone; Osteocalcin; Urine cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>96</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>96</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics After Single- and Multiple-Dosing of AZD-5423 in Japanese Healthy Male Subjects</ProtocolTitle><Reference>D2340C00003; NCT01338350</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="76864"/><TrialStartDate>JUNE     , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Macrophages</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>beclomethasone dipropionate, CFC-free), Teva</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Inhaled Steroids on Gene Expression in the Lungs-2</ProtocolTitle><Reference>0809009975; NCT00826748</Reference><Sponsor>Weill Medical College of Cornell University</Sponsor><Trial id="42589"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Glucose</Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide injectable suspension (Kenalog)</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>33</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>33</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Effects of FX-006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes</ProtocolTitle><Reference>FX006-2015-010; NCT02762370</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="260068"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>111</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; bupivacaine, AstraZeneca; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>111</Patients><ProtocolAcronym/><ProtocolTitle>The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized, Double-blind, Placebo-controlled Trial</ProtocolTitle><Reference>4-2012-0147; NCT01961752</Reference><Sponsor>Yonsei University</Sponsor><Trial id="157615"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Body height; Forced expiratory volume; Heart rate; Total body mass; cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 years)</ProtocolTitle><Reference>2005-001386-34; BY9010/M1-208; NCT00163371</Reference><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><Trial id="22089"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Fractional concentration of exhaled nitric oxide; Nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>budesonide/formoterol; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Relvar on ACOS</ProtocolTitle><Reference>UMIN000014191</Reference><Sponsor>Toyama City Hospital</Sponsor><Trial id="196622"/><TrialStartDate>JUNE     , 14, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Fractional concentration of exhaled nitric oxide; Nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>budesonide/formoterol; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Relvar on ACOS</ProtocolTitle><Reference>UMIN000014191</Reference><Sponsor>Toyama City Hospital</Sponsor><Trial id="196622"/><TrialStartDate>JUNE     , 14, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Fovea centralis; Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>160</EnrollmentCount><Interventions>Zuprata</Interventions><Patients>160</Patients><ProtocolAcronym>PEACHTREE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis</ProtocolTitle><Reference>CLS1001-301; CLS1001-301 Version 3.2; CTRI/2016/09/007269; NCT02595398; PEACHTREE</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="244835"/><TrialStartDate>NOVEMBER , 17, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Contact dermatitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Patients>170</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Reference>NCT01011621; PRE/P/08-1</Reference><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><Trial id="180987"/><TrialStartDate>FEBRUARY , 28, 2010</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers>Bronchial epithelial cells; Eosinophils; Epithelial cells; Exhaled breath pH; Exhaled nitric oxide; FEF; FEV1; FVC; Histone deacetylase; Lymphocytes; Macrophages; Neutrophils</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>79</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; beclometasone (inhaled, CFC-free), Teva; beclometasone (inhaled, CFC-free), Teva + theophylline; rosiglitazone; theophylline; theophylline</Interventions><Patients>91</Patients><ProtocolAcronym/><ProtocolTitle>Rosiglitazone Versus Theophylline in Asthmatic Smokers</ProtocolTitle><Reference>2004-004247-22 EUDRACT; NCT00119496; RES104033</Reference><Sponsor>University of Glasgow</Sponsor><Trial id="21855"/><TrialStartDate>JULY     , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Cataract</Condition><Controls>Pred Forte</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>tobramycin + prednisolone acetate (ophthalmic), ISTA</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>Study of T-Pred compared to Pred-Forte</ProtocolTitle><Reference>CL-PKT-0312081-P; NCT00699803</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="31880"/><TrialStartDate>MAY      , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount/><Interventions>WP-0508ST</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>WP-0508ST (uveitis) Phase III trial</ProtocolTitle><Reference>JapicCTI-142695</Reference><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><Trial id="215369"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>ACR 20; Erythrocyte sedimentation rate; Hydrocortisone; Interleukin-6; Joint stiffness; Joint swelling; Painful joint count</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>immediate-release prednisone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>288</EnrollmentCount><Interventions>prednisone</Interventions><Patients>288</Patients><ProtocolAcronym>CAPRA-1</ProtocolAcronym><ProtocolTitle>Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis</ProtocolTitle><Reference>CAPRA-1; EMR 62215-003; NCT00146640</Reference><Sponsor>Merck KGaA</Sponsor><Trial id="2351"/><TrialStartDate>AUGUST   , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Hydrocortisone; T-cell surface glycoprotein CD4</Biomarkers><Condition>Ataxia telangiectasia</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><EnrollmentCount>22</EnrollmentCount><Interventions>EryDex</Interventions><Patients>22</Patients><ProtocolAcronym/><ProtocolTitle>Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients</ProtocolTitle><Reference>2010-022315-19; IEDAT 01; NCT01255358</Reference><Sponsor>EryDel SPA</Sponsor><Trial id="75227"/><TrialStartDate>FEBRUARY , 28, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Fovea centralis; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls>Lucentis</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>Avastin; Lucentis; triamcinolone acetonide</Interventions><Patients>460</Patients><ProtocolAcronym>TOPAZ</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO</ProtocolTitle><Reference>2017-002089-37; CLS1003-302; CTRI/2018/05/014044; NCT03203447; TOPAZ</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="303712"/><TrialStartDate>MARCH    , 05, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Throat disease</Condition><Controls>chlorhexidine gluconate</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>triamcinolone acetonide; triamcinolone acetonide + chlorhexidine gluconate</Interventions><Patients>143</Patients><ProtocolAcronym/><ProtocolTitle>Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat</ProtocolTitle><Reference>NCT00908817; ST</Reference><Sponsor>Soonchunhyang University Hospital</Sponsor><Trial id="56389"/><TrialStartDate>MAY      , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>238</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>238</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents</ProtocolTitle><Reference>114496; FFA114496; NCT01431950</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="80716"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>338</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="197089"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cortisol; FEV1; hsCRP</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>budesonide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>353</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>353</Patients><ProtocolAcronym>AZD5423 COPD study</ProtocolAcronym><ProtocolTitle>Multicenter Study to Assess the Efficacy and Safety of AZD-5423 in COPD Patients on a Background Therapy of Formoterol</ProtocolTitle><Reference>2011-005389-39; AZD5423 COPD study; D2340C00011; NCT01555099</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="85693"/><TrialStartDate>APRIL    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>242</EnrollmentCount><Interventions>CINGAL</Interventions><Patients>242</Patients><ProtocolAcronym/><ProtocolTitle>Repeat Injection of Cingal for Osteoarthritis of the Knee</ProtocolTitle><Reference>Cingal 13-02; NCT02381652</Reference><Sponsor>Anika Therapeutics Inc</Sponsor><Trial id="223638"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>715</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>713</Patients><ProtocolAcronym/><ProtocolTitle>Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6 to 11 Years) With Seasonal Allergies</ProtocolTitle><Reference>BDP-AR-305; NCT01307319</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="75462"/><TrialStartDate>MARCH    , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular pain</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>363</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>363</Patients><ProtocolAcronym/><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Reference>793; NCT01591655</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="87162"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>budesonide + formoterol fumarate, AstraZeneca</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>fluticasone + salmeterol (inhaled/Spiromax, asthma), Teva</Interventions><Patients>400</Patients><ProtocolAcronym>ELIOT</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) Spiromax as Compared to Symbicort Turbohaler as Treatment for Adult Patients With Asthma</ProtocolTitle><Reference>2013-004630-14; BFS-AS-40035; ELIOT; NCT02062463</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="206087"/><TrialStartDate>JUNE     , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>129</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>129</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert</ProtocolTitle><Reference>2013-001810-14; NCT01694186; PSV-FAI-001</Reference><Sponsor>EyePoint Pharmaceuticals Inc</Sponsor><Trial id="92797"/><TrialStartDate>JUNE     , 30, 2013</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>64</Patients><ProtocolAcronym>MACS</ProtocolAcronym><ProtocolTitle>Ciclesonide for the Treatment of Airway Hyperresponsiveness</ProtocolTitle><Reference>BY9010/CH-101; MACS; NCT00826969; U1111-1137-3949</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="42845"/><TrialStartDate>SEPTEMBER, 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Atherosclerosis</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos</Interventions><Patients>30</Patients><ProtocolAcronym>SILENCE</ProtocolAcronym><ProtocolTitle>Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease</ProtocolTitle><Reference>2011-002686-37; 2011-002686-37 AMC; NCT01601106; NL37190.018.11; NTR2936; SILENCE</Reference><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><Trial id="87549"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Heart rate; Heart rate; Serum cortisol; Serum potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>Relovair</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW-642444-M Combination in Healthy Subjects and in Subjects With Severe Impairment</ProtocolTitle><Reference>113970; NCT01266980</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="73501"/><TrialStartDate>NOVEMBER , 18, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis</ProtocolTitle><Reference>2008-4; NCT00997620</Reference><Sponsor>Western Sky Medical Research</Sponsor><Trial id="61214"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>365</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>365</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects with Allergic Rhinitis</ProtocolTitle><Reference>113342; NCT01231464</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="71819"/><TrialStartDate>SEPTEMBER, 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>160</EnrollmentCount><Interventions>Diskus; Ellipta; Spiriva HandiHaler; Turbuhaler</Interventions><Patients>160</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Study Assessing Critical Errors, Training/Teaching Time, And Preference Attributes Of The Ellipta Dry Powder Inhaler, In Comparison To Combinations Of Dry Powder Inhalers Used To Provide Triple Therapy, In Patients With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>206215; NCT02982187</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="281232"/><TrialStartDate>DECEMBER , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>ELLIPTA dry powder inhaler; fluticasone furoate; salbutamol</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount/><Interventions>ELLIPTA dry powder inhaler; fluticasone furoate; salbutamol; vilanterol</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>The Efficacy of Fluticasone Furoate/Vilanterol Versus Fluticasone Furoate on Asthma</ProtocolTitle><Reference>206962; NCT03363191</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="321810"/><TrialStartDate>MARCH    , 07, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>ACTH; Blood cortisol; Urinary cortisol</Biomarkers><Condition>Tendinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>methylprednisolone (Pfizer); triamcinolone acetonide</Interventions><Patients>44</Patients><ProtocolAcronym>TPESP2011-12</ProtocolAcronym><ProtocolTitle>Evaluation of Efficacy and Hypothalamus-Pituitary-Adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection</ProtocolTitle><Reference>2012-000866-40; NCT01652495; TPESP2011-12; TPESP2011-12</Reference><Sponsor>Istituti Ortopedici Rizzoli</Sponsor><Trial id="89690"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Hearing loss</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>OTO-104</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss</ProtocolTitle><Reference>104-201607; NCT02997189</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="282838"/><TrialStartDate>NOVEMBER , 30, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Blood glucose; Diastolic blood pressure; Heart rate; Heart rate; Serum potassium; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>fluticasone furoate; umeclidinium; vilanterol</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of Fluticasone Furoate, Umeclidinium and Vilanterol in Healthy Subjects</ProtocolTitle><Reference>116415; 873; CTT116415; IND IDE Number 114; NCT01691547</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="92256"/><TrialStartDate>DECEMBER , 17, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1; Peak Expiratory Flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>421</EnrollmentCount><Interventions>fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Patients>421</Patients><ProtocolAcronym>ILA115938</ProtocolAcronym><ProtocolTitle>Evaluate the Safety, Efficacy and Dose Response of GSK-573719 in Combination With Fluticasone Furoate in Subjects With Asthma</ProtocolTitle><Reference>115938; ILA115938; ILA115938; NCT01573624</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="86335"/><TrialStartDate>APRIL    , 03, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers>FEV1; PEF (peak expiratory flow); Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1040</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate (100/25 microg); fluticasone furoate + vilanterol trifenatate (200/25 microg); vilanterol trifenatate</Interventions><Patients>1039</Patients><ProtocolAcronym/><ProtocolTitle>An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microg (mcg), FF/VI 100/25 Microg (mcg), and FF 100 Microg (mcg) in Adults and Adolescents With Persistent Asthma</ProtocolTitle><Reference>116863; 2012-002797-32; HZA116863; NCT01686633</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="91744"/><TrialStartDate>SEPTEMBER, 20, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Interleukin-6</Biomarkers><Condition>Polymyalgia rheumatica</Condition><Controls>prednisone (immediate release)</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>8</EnrollmentCount><Interventions>Rayos</Interventions><Patients>8</Patients><ProtocolAcronym/><ProtocolTitle>Delayed-Release Prednisone in PMR</ProtocolTitle><Reference>HZNP-PRE-IIS02; NCT02702778</Reference><Sponsor>Dinora, Inc</Sponsor><Trial id="255348"/><TrialStartDate>FEBRUARY , 29, 2016</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>B-lymphocyte antigen CD20</Biomarkers><Condition>Diffuse large B-cell lymphoma</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="81677">valproic acid + prednisone (oral, diffuse large B-cell lymphoma), Valcuria/Respiratorius</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>VAL-001, Valcuria; cyclophosphamide; doxorubicin; prednisone; rituximab; vincristine</Interventions><Patients>32</Patients><ProtocolAcronym>VALFRID</ProtocolAcronym><ProtocolTitle>Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma</ProtocolTitle><Reference>NCT01622439; VALFRID; Version1.1</Reference><Sponsor>Skåne University Hospital</Sponsor><Trial id="97190"/><TrialStartDate>JUNE     , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Allergic conjunctivitis</Condition><Controls>Ora-CAC model</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>86</EnrollmentCount><Interventions>OTX-DP; Ora-CAC model</Interventions><Patients>86</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis</ProtocolTitle><Reference>NCT02988882; OTX-15-002</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="281747"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>MaQaid</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Treatment of macular edema following BRVO with STTA</ProtocolTitle><Reference>UMIN000031215</Reference><Sponsor>Aichi Medical University, Kamiiida daiichi General Hospital</Sponsor><Trial id="330917"/><TrialStartDate>FEBRUARY , 28, 2018</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Cortisol; Glucose; Heart rate; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study</ProtocolTitle><Reference>112777; NCT01453023</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="81600"/><TrialStartDate>OCTOBER  , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anterior chamber</Biomarkers><Condition>Cataract</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>101</EnrollmentCount><Interventions>EyeGate; dexamethasone</Interventions><Patients>101</Patients><ProtocolAcronym/><ProtocolTitle>Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery</ProtocolTitle><Reference>EGP-437-009; NCT03180255</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="301426"/><TrialStartDate>JULY     , 26, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Glucose; Heart rate; Heart rate; PR interval; Potassium; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>CHF-1535</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>191</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>191</Patients><ProtocolAcronym>CARSAF</ProtocolAcronym><ProtocolTitle>Phase II Study to Evaluate the Cardiac Safety of two Doses of CHF-5993 Both Combined With CHF-1535 Twice-Daily Versus CHF-1535 Twice-Daily in Patients With Moderate to Severe COPD</ProtocolTitle><Reference>2011-004759-37; CARSAF; CCD-1107-PR-0067; NCT01584505</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="86885"/><TrialStartDate>APRIL    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>40</Patients><ProtocolAcronym>REACT</ProtocolAcronym><ProtocolTitle>Evaluation of Iluvien for the treatment of DME</ProtocolTitle><Reference>2016-001680-37; REACT; REACT</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="330740"/><TrialStartDate>OCTOBER  , 22, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls>Eylea</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><EnrollmentCount>71</EnrollmentCount><Interventions>Eylea; triamcinolone acetonide</Interventions><Patients>71</Patients><ProtocolAcronym>TYBEE</ProtocolAcronym><ProtocolTitle>Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema</ProtocolTitle><Reference>CLS1004-201; NCT03126786; TYBEE</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="295885"/><TrialStartDate>JULY     , 11, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Creatinine; Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>CHF-5993</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese versus Caucasians</ProtocolTitle><Reference>CLI-05993AB4-01; NCT03859414</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="371937"/><TrialStartDate>MARCH    , 18, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>C-C motif chemokine 2; C-X-C motif chemokine 10; Intercellular adhesion molecule-1; Interleukin-1 beta; Interleukin-6; Interleukin-8; Pigment epithelium-derived factor; Placenta growth factor; Platelet-derived growth factor; Vascular endothelial growth factors</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>12</Patients><ProtocolAcronym>Iluvit</ProtocolAcronym><ProtocolTitle>Investigation of the influence of the corticosteroid agent Iluvien on inflammation and growth factors in the eye of patients suffering from diabetic-related retina damage with swelling of the center of the retina</ProtocolTitle><Reference>2016-004488-38; 347/17; DRKS00014915; ILV-001; Iluvit</Reference><Sponsor>Johann Wolfgang Goethe-Universitat Frankfurt am Main</Sponsor><Trial id="337288"/><TrialStartDate>DECEMBER , 28, 2017</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Stevens Johnson syndrome</Condition><Controls>Dermovate; orabase</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Reference>00UAD; NCT03878771</Reference><Sponsor>Beni-Suef University</Sponsor><Trial id="373754"/><TrialStartDate>MARCH    , 13, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>PT-008; PT007</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><EnrollmentCount>600</EnrollmentCount><Interventions>PT-027</Interventions><Patients>600</Patients><ProtocolAcronym>DENALI</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT-027) Used Four Times Daily in Adults and Children 4 Years of Age or Older With Asthma</ProtocolTitle><Reference>2018-003674-27; AV004; DENALI; NCT03847896</Reference><Sponsor>Avillion LLP</Sponsor><Trial id="370792"/><TrialStartDate>APRIL    , 10, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ulcerative colitis</Condition><Controls>Budesonide MMX</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>777</EnrollmentCount><Interventions>budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Interventions><Patients>777</Patients><ProtocolAcronym>TOPICAL-2</ProtocolAcronym><ProtocolTitle>Novel budesonide capsules versus budesonide tables in patients with ulcerative colitis refractory to standard treatment with mesalazine</ProtocolTitle><Reference>2017-004576-57; BUX-4/UCA; TOPICAL-2</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="379131"/><TrialStartDate>APRIL    , 26, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>Flovent Diskus; Pulmicort Flexhaler; Qvar</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Flovent Diskus versus Qvar versus Pulmicort Flexhaler on Short Term Growth</ProtocolTitle><Reference>NCT01520688; RC#5255</Reference><Sponsor>West Penn Allegheny Health System Inc</Sponsor><Trial id="84529"/><TrialStartDate>FEBRUARY , 29, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Charcoal; Seretide Diskus; Seretide Diskus; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Reference>3106007; EudraCT 2012-00378-41; NCT01766843</Reference><Sponsor>Orion Corp</Sponsor><Trial id="104633"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Ear pressure</Biomarkers><Condition>Otitis media</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>91</EnrollmentCount><Interventions>Azmacort</Interventions><Patients>91</Patients><ProtocolAcronym/><ProtocolTitle>Short-Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays</ProtocolTitle><Reference>103-04; IST4008; NCT00279916; XRG5029C/4008</Reference><Sponsor>Mayo Clinic Foundation</Sponsor><Trial id="11760"/><TrialStartDate>SEPTEMBER, 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Cortisol; Creatinine; Forced expiratory volume in 1 second (FEV1); Forced expriatory flow; Forced vital capacity (FVC); Heart rate; Histamine provocative; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>Qvar; propranolol</Interventions><Patients>16</Patients><ProtocolAcronym>ANDA1</ProtocolAcronym><ProtocolTitle>Beta Blocker Therapy in Mild to Moderate Asthmatics</ProtocolTitle><Reference>2011-002512-89; 2011RC16; ANDA1; NCT01544634</Reference><Sponsor>University of Dundee</Sponsor><Trial id="173490"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>GSK-2834425; Relovair; Zephyr</Interventions><Patients>44</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study in Healthy Volunteers to Characterize the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses</ProtocolTitle><Reference>200587; NCT01894386</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="145910"/><TrialStartDate>JULY     , 15, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>Ventolin</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91606">budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Synbitide HFA MDI</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy Study of Synbitide HFA MDI in Asthma Patients</ProtocolTitle><Reference>INTB012; INTB012; NCT02162784</Reference><Sponsor>Intech Biopharm Ltd</Sponsor><Trial id="196587"/><TrialStartDate>FEBRUARY , 28, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>651</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>651</Patients><ProtocolAcronym/><ProtocolTitle>A phase IV, open-label study to assess the safety and efficacy of Nasacort in patients with seasonal and perennial allergic rhinitis</ProtocolTitle><Reference>XRG5029C/4005</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="89194"/><TrialStartDate>MARCH    , 22, 2002</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>fluticasone</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47921">799943</Drug><EnrollmentCount>650</EnrollmentCount><Interventions>GW-799943X</Interventions><Patients>650</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 500 microg of GW-799943X Administered qd in the Morning, 500 microg of GW-799943X Administered qd in the Evening, and 1000 microg GW-799943X Administered qd in the Morning Compared With Placebo and Fluticasone Propionate 250 microg bid, All Delivered by Rotadisk/Diskhaler for 28 Days in Subjects With Persistent Bronchial Asthma Symptomatic on Low-Dose ICS</ProtocolTitle><Reference>EudraCT 2004-005058-30; ODS100207</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="117524"/><TrialStartDate>JUNE     , 29, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>adrenaline; lidocaine; triamcinolone acetonide</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>adrenaline; hylan G-F 20; lidocaine</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee</ProtocolTitle><Reference>NCT01874574; ORTHOTU-01</Reference><Sponsor>Thammasat University</Sponsor><Trial id="139011"/><TrialStartDate>JANUARY  , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>Karison® Creme; mometasone furoate; nortriptyline HCl</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="56234">mometasone + nortriptyline (topical cream, psoriasis), CombinatoRx</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>CRx-191</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Phase I study of topical CRx-191 in normal healthy volunteers</ProtocolTitle><Reference>CRx-191-002; EudraCT Number: 2006-005903-33; NCT00544687</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="23649"/><TrialStartDate>SEPTEMBER, 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>IOP</Biomarkers><Condition>Glaucoma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Glaucoma drainage device; triamcinolone acetonide</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>Glaucoma Drainage Device With and Without Adjunctive Intra-Bleb Injection of Triamcinolone Acetonide: A Randomized Controlled Trial</ProtocolTitle><Reference>CUHK_CCT00049; ChiCTR-TRC-09000744</Reference><Sponsor>Hong Kong Eye Hospital</Sponsor><Trial id="125878"/><TrialStartDate>MARCH    , 24, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>22</EnrollmentCount><Interventions>Zuprata</Interventions><Patients>22</Patients><ProtocolAcronym>DOGWOOD</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis</ProtocolTitle><Reference>CLS1001-201; DOGWOOD; NCT02255032</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="212568"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>fluticasone propionate; triamcinolone acetonide</Interventions><Patients>475</Patients><ProtocolAcronym/><ProtocolTitle>A Phase IV, Double-blind, Double-dummy, Randomized, Placebo-controlled, Parallel-group, Comparison of Fluticasone Propionate Aqueous Nasal Spray and Triamcinolone Acetonide Aqueous Nasal Spray in Subjects With Seasonal Allergic Rhinitis</ProtocolTitle><Reference>FLTA4008</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157120"/><TrialStartDate>SEPTEMBER, 30, 1997</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Glaucoma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>mitomycin; triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Phaco-Trabeculectomy With Intra-Bleb Injection of Triamcinolone Acetonide Versus Phaco-Trabeculectomy With Mitomycin C in Patients With Co-Existing Cataract and Glaucoma – a Randomized, Controlled Trial</ProtocolTitle><Reference>CUHK_CCT00045; ChiCTR-TRC-09000644</Reference><Sponsor>Hong Kong Eye Hospital</Sponsor><Trial id="124137"/><TrialStartDate>MAY      , 11, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Cataract</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>mitomycin; triamcinolone acetonide</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Phaco-Trabeculectomy With Intra-Bleb Injection of Triamcinolone Acetonide Versus Phaco-Trabeculectomy With Mitomycin C in Patients With Co-Existing Cataract and Glaucoma – a Randomized, Controlled Trial</ProtocolTitle><Reference>CUHK_CCT00045; ChiCTR-TRC-09000644</Reference><Sponsor>Hong Kong Eye Hospital</Sponsor><Trial id="124137"/><TrialStartDate>MAY      , 11, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Eosinophils; FEV / FVC ratio; Forced Vital Capacity; Forced expiratory volume; Nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Respiratory disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>360</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>360</Patients><ProtocolAcronym/><ProtocolTitle>The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms (NSRS)</ProtocolTitle><Reference>NCT02294279; OR01013</Reference><Sponsor>Research in Real-Life Ltd</Sponsor><Trial id="216230"/><TrialStartDate>MAY      , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>It is a Study of Two Modes of Treatment; Which Are Called Laser Photocoagulation Alone And With Drug Triamcinolone, in The Patients Which Are Suffering From Eye Disease Caused by Diabetes Mellitus</ProtocolTitle><Reference>CTRI/2012/08/002878</Reference><Sponsor>Government Medical College, Bhavnagar, Sir Takhtsinhji General Hospital</Sponsor><Trial id="127814"/><TrialStartDate>AUGUST   , 31, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cortisol; Fasting glucose; Osteocalcin</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW-870086-X In Healthy Volunteers</ProtocolTitle><Reference>NCT00549497; SIG110405</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="22368"/><TrialStartDate>SEPTEMBER, 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>Qnaze</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Allergic Rhinitis Changes the Sinus Microbiome</ProtocolTitle><Reference>IRB 12-1812; NCT01852513</Reference><Sponsor>University of Chicago</Sponsor><Trial id="130194"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; Forced Vital Capacity; cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>ciclesonide; fluticasone propionate</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 years)</ProtocolTitle><Reference>BY9010/M1-129; NCT00163332</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="22010"/><TrialStartDate>MARCH    , 31, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Muscle strength</Biomarkers><Condition>Lateral epicondylitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>132</EnrollmentCount><Interventions>lidocaine (endometriosis), Isifer; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>165</Patients><ProtocolAcronym>PINTe</ProtocolAcronym><ProtocolTitle>Optimizating corticosteroid injection for lateral epicondylalgia with the addition of physiotherapy: A randomized control trial with placebo comparison</ProtocolTitle><Reference>2007001703; ACTRN12609000051246; ANZCTR82438; PINTe</Reference><Sponsor>Griffith University, National Health and Medical Research Council, University of Queensland</Sponsor><Trial id="128680"/><TrialStartDate>AUGUST   , 01, 2008</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls>Pred Forte</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate in the Treatment of Uveitis</ProtocolTitle><Reference>NCT00501579; ST-601A-001</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21754"/><TrialStartDate>JULY     , 13, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Respiratory disorder</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>1568</Patients><ProtocolAcronym/><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="22103"/><TrialStartDate>JANUARY  , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>Lodotra</Interventions><Patients>5</Patients><ProtocolAcronym>MONA</ProtocolAcronym><ProtocolTitle>A New Modified-Release Tablet Formulation of Prednisone (Lodotra) in Patients With Nocturnal Asthma</ProtocolTitle><Reference>EudraCT-Number: 2007-007316-29; MONA; NCT00686335; NP01-201</Reference><Sponsor>Horizon Pharma GmbH</Sponsor><Trial id="22273"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>Kenalog-40</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>Proof of Concept Study Comparing FX-006 to Kenalog-40 in Patients With Post-Traumatic Osteoarthritis of the Knee</ProtocolTitle><Reference>FX006-2014-007; NCT02468583</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="231796"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Rheumatoid arthritis</Condition><Controls>prednisolone</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>58</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>58</Patients><ProtocolAcronym/><ProtocolTitle>Is a Single Dose Intramuscular (IM) Triamcinolone Acetonide Injection More Effective in Treating Symptomatic Flare in Established Rheumatoid Arthritis Than Equivalent Dose Of Oral Prednisolone?</ProtocolTitle><Reference>EudraCT 2007-006729-28</Reference><Sponsor>Trafford Healthcare NHS Trust</Sponsor><Trial id="133394"/><TrialStartDate>JANUARY  , 25, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount/><Interventions>WP-0508ST</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>WP-0508ST phase II/III trial</ProtocolTitle><Reference>JapicCTI-132139</Reference><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><Trial id="139399"/><TrialStartDate>MAY      , 30, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>A Study Of GW-685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics</ProtocolTitle><Reference>FFR100012; NCT00116883</Reference><Sponsor>GlaxoSmithKline Inc</Sponsor><Trial id="13948"/><TrialStartDate>FEBRUARY , 28, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Vitiligo</Condition><Controls/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>Lattice laser; Narrow Band Ultra Violet B (NB-UVB) phototherapy; betamethasone; betamethasone; triamcinolone acetonide</Interventions><Patients>289</Patients><ProtocolAcronym/><ProtocolTitle>Dot matrix laser + Betamethason Copound Injection / Triamcinolone Acetonide + NB-UVB versus dipropionate betamethasone cream + NB-UVB for the treatment of the acral type (including the subcarinal parts) of vitiligo: the efficacy and safety of the multicenter, open, randomized, controlled clinical trial</ProtocolTitle><Reference>ChiCTR-TRC-12002593</Reference><Sponsor>Science and Technology Education Department of the Ministry of Health, The First Hospital Of China Medical University</Sponsor><Trial id="102612"/><TrialStartDate>SEPTEMBER, 01, 2014</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Randomised Controlled Trial of Intravitreal Triamcinolone in Patients With Diabetic Macular Edema Refractory to Laser Treatment</ProtocolTitle><Reference>EudraCT 2005-000397-45; OY060301</Reference><Sponsor>The Queen's Medical Center</Sponsor><Trial id="141188"/><TrialStartDate>JUNE     , 02, 2005</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="71455">SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Drug><EnrollmentCount>222</EnrollmentCount><Interventions>SUN-0597</Interventions><Patients>222</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of SPARC-1310 in Seasonal Allergic Rhinitis</ProtocolTitle><Reference>CLR_13_10; NCT01940146; SPARC LTD CLR_13_10</Reference><Sponsor>Sun Pharmaceutical Advanced Research Co Ltd</Sponsor><Trial id="154380"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>1260</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>1260</Patients><ProtocolAcronym>SCORE</ProtocolAcronym><ProtocolTitle>Steroid Injections versus Standard Treatment For Macular Edema Due To Retinal Blood Vessel Blockage</ProtocolTitle><Reference>05-EI-0101; 050101; NCT00106132; SCORE</Reference><Sponsor>National Eye Institute</Sponsor><Trial id="95382"/><TrialStartDate>MARCH    , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Fovea centralis; Intraocular pressure; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>A Non-Randomized, Open-Label, Single-Center, Phase IV Study of the Effect and Safety of Iluvien in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy</ProtocolTitle><Reference>M-01-13-002; NCT02472366</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="232076"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Atopic dermatitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46177">mapracorat</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>ZK-245186</Interventions><Patients>64</Patients><ProtocolAcronym/><ProtocolTitle>Dose-escalation of Different Concentrations of ZK-245186 in Atopic Dermatitis</ProtocolTitle><Reference>1402942; 14501; NCT00944632</Reference><Sponsor>Bayer AG, Intendis GmbH</Sponsor><Trial id="59066"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; FEV1; Heart rate; Peak expiratory flow rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>542</EnrollmentCount><Interventions>beclometasone dipropionate + formoterol (inhaled, Modulite), Chiesi</Interventions><Patients>542</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of CHF-1535 200/6 microg in Not Adequately Controlled Asthmatic Patients</ProtocolTitle><Reference>2010-020602-14; CCD-1005-PR-0040; NCT01577082</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="86498"/><TrialStartDate>APRIL    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort; budesonide; formoterol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><EnrollmentCount>3316</EnrollmentCount><Interventions>PT-009</Interventions><Patients>2389</Patients><ProtocolAcronym>TELOS</ProtocolAcronym><ProtocolTitle>Study to Assess Efficacy and Safety of PT-009 Compared to PT-005, PT-008 and Symbicort Turbuhaler on Lung Function Over 24 Weeks in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Reference>2016-000154-34; D7820C00001; NCT02766608; PT009002; TELOS</Reference><Sponsor>AstraZeneca AB, Pearl Therapeutics Inc</Sponsor><Trial id="260435"/><TrialStartDate>MAY      , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>352</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>352</Patients><ProtocolAcronym/><ProtocolTitle>Study Of Adults And Adolescents With Vasomotor Rhinitis</ProtocolTitle><Reference>2004-004743-22; FFR30006; NCT00117325</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="198181"/><TrialStartDate>JULY     , 11, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Crohns disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>55</EnrollmentCount><Interventions>Entocort</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Maintenance Study of Entocort for Children With Crohn's Disease</ProtocolTitle><Reference>2011-003742-40; D9422C00002; NCT01453946</Reference><Sponsor>Perrigo Co plc</Sponsor><Trial id="81640"/><TrialStartDate>DECEMBER , 31, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate; forced expiratory volume 1 s; peak expiratory flow</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>628</EnrollmentCount><Interventions>Qvar; albuterol/salbutamol</Interventions><Patients>628</Patients><ProtocolAcronym/><ProtocolTitle>A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4 to 11 Years Old With Persistent Asthma</ProtocolTitle><Reference>2013-004632-30; BDB-AS-302; NCT02040766</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="168945"/><TrialStartDate>DECEMBER , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Fovea centralis; Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>108</EnrollmentCount><Interventions>Durezol; Durezol; Nevanac; prednisolone acetate (Pred Forte)</Interventions><Patients>108</Patients><ProtocolAcronym>MEND</ProtocolAcronym><ProtocolTitle>Macular Edema Nepafenac Versus Difluprednate Uveitis Trial</ProtocolTitle><Reference>18-24978; CMEND; MEND; MEND; NCT01939691</Reference><Sponsor>University of California San Francisco</Sponsor><Trial id="154306"/><TrialStartDate>SEPTEMBER, 12, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Airway resistance; Forced expiratory volume; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>budesonide + formoterol fumarate, AstraZeneca; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; procaterol</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide/formoterol maintenance reliever therapy versus fluticasone furoate /vilanterol fixed-dose treatment of asthma on airway inflammation with adult asthma</ProtocolTitle><Reference>UMIN000017042</Reference><Sponsor>Hiroshima Clinic</Sponsor><Trial id="226148"/><TrialStartDate>JUNE     , 01, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic conjunctivitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><EnrollmentCount>251</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Patients>251</Patients><ProtocolAcronym/><ProtocolTitle>Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis</ProtocolTitle><Reference>685; NCT01289431</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="74436"/><TrialStartDate>FEBRUARY , 28, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Choroid; Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls>aflibercept</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>46</EnrollmentCount><Interventions>CLS-TA; aflibercept</Interventions><Patients>46</Patients><ProtocolAcronym>TANZANITE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Reference>CLS1003-201; NCT02303184; TANZANITE</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="216985"/><TrialStartDate>JANUARY  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory volume; Hydrocortisone; Peak expiratory flow rate; peak expiratory flow</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>ciclesonide; fluticasone</Interventions><Patients>503</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 years)</ProtocolTitle><Reference>2004-001681-40; BY9010/IT-101; BY9010/IT-101 incl. amendment 1; NCT00163319</Reference><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><Trial id="22006"/><TrialStartDate>NOVEMBER , 30, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alkaline phosphatase; Blood pressure; Body temperature; Estradiol; Follicle-stimulating hormone; Glucose; Heart rate; Hydrocortisone; Luteinizing Hormone; Lymphocytes; PR interval; Prostate-specific antigen; QRS complex; QT interval; Sex hormone-binding globulin; Testosterone</Biomarkers><Condition>Metastatic prostate cancer</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77410">dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>Oncocort</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Study investigating intravenously administrated Oncocort in patients with metastatic prostate cancer</ProtocolTitle><Reference>2016-003121-42; CHDR1635</Reference><Sponsor>Enceladus Pharmaceuticals</Sponsor><Trial id="291118"/><TrialStartDate>NOVEMBER , 28, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery</ProtocolTitle><Reference>2995/2007; NCT00801450</Reference><Sponsor>University of Sao Paulo</Sponsor><Trial id="165535"/><TrialStartDate>SEPTEMBER, 30, 2007</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Acute sinusitis</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>741</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate (bid); fluticasone furoate (qd)</Interventions><Patients>737</Patients><ProtocolAcronym/><ProtocolTitle>Dose-Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis</ProtocolTitle><Reference>113203; NCT01018030</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="62140"/><TrialStartDate>JANUARY  , 06, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>fluticasone + salmeterol (inhaled/Spiromax, asthma), Teva</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>Dose-Ranging Study of the Salmeterol Component of Fluticasone/Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects</ProtocolTitle><Reference>FSS-AS-201; NCT01772368</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="105408"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Fovea centralis; IOP; Retina; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>11</EnrollmentCount><Interventions>Zuprata</Interventions><Patients>8</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis</ProtocolTitle><Reference>CLS1001-101; NCT01789320</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="109683"/><TrialStartDate>FEBRUARY , 28, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>408</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; vitamin D3</Interventions><Patients>408</Patients><ProtocolAcronym>VIDA</ProtocolAcronym><ProtocolTitle>Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma</ProtocolTitle><Reference>1U10HL098115; ASTHMANET 001; NCT01248065; VIDA</Reference><Sponsor>Milton S. Hershey Medical Center</Sponsor><Trial id="188785"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body surface area</Biomarkers><Condition>Psoriasis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><EnrollmentCount>217</EnrollmentCount><Interventions>Bryhali</Interventions><Patients>217</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis</ProtocolTitle><Reference>NCT02514577; V01-122A-301</Reference><Sponsor>Bausch Health Companies Inc</Sponsor><Trial id="239785"/><TrialStartDate>NOVEMBER , 20, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; Urinary cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>648</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>698</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma</ProtocolTitle><Reference>2006-005228-18; FFA106783; NCT00398645</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="22312"/><TrialStartDate>NOVEMBER , 15, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Heart rate; O2 saturation; Oxygen saturation</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Entocort EC</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>9</EnrollmentCount><Interventions>Symbicort</Interventions><Patients>9</Patients><ProtocolAcronym/><ProtocolTitle>Effects of Symbicort on the Ventilatory Kinematics</ProtocolTitle><Reference>AAAI1932; NCT01712854</Reference><Sponsor>Columbia University</Sponsor><Trial id="95866"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Growth disorder</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>ELLIPTA; fluticasone furoate; salbutamol</Interventions><Patients>58</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Inhaled Fluticasone Furoate on Short-term Growth in Pediatric Subjects With Asthma</ProtocolTitle><Reference>107112; NCT02502734</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="235316"/><TrialStartDate>SEPTEMBER, 07, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Skin</Biomarkers><Condition>Psoriasis</Condition><Controls>Betesil</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>LEO-90100</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>A Psoriasis Plaque Test Trial With LEO-90100 Compared to Betesil in Patients With Psoriasis Vulgaris</ProtocolTitle><Reference>2015-001798-41; LP0053-1227; NCT02518048</Reference><Sponsor>LEO Pharma A/S</Sponsor><Trial id="236834"/><TrialStartDate>AUGUST   , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Retinal venous occlusion</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount/><Interventions>WP-0508ST</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>WP-0508ST (RVO) Phase III trial</ProtocolTitle><Reference>JapicCTI-142694</Reference><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><Trial id="215368"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount/><Interventions>WP-0508ST</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>WP-0508ST (uveitis) Phase III trial</ProtocolTitle><Reference>JapicCTI-142695</Reference><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><Trial id="215369"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood sugar; Intraocular pressure (IOP); Macular thickness; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>19</EnrollmentCount><Interventions>dexamethasone + cyclodextrin; triamcinolone acetonide</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>Topical Dexamethasone Aqueous Solution for Macular Edema</ProtocolTitle><Reference>JPRN-UMIN000001790</Reference><Sponsor>Shimane University</Sponsor><Trial id="152050"/><TrialStartDate>MARCH    , 01, 2009</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-reactive protein (CRP); Serum amyloid A (SAA); Serum urate</Biomarkers><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>230</EnrollmentCount><Interventions>canakinumab</Interventions><Patients>228</Patients><ProtocolAcronym>BETA-RELIEVED</ProtocolAcronym><ProtocolTitle>Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study</ProtocolTitle><Reference>2009-015018-23; 2009-017503-29; 2010-019559-23; ACZ885H2356; BETA-RELIEVED; CACZ885H2356; CACZ885H2356E1; CACZ885H2356E2; NCT01029652; NCT01071213; NCT01160016</Reference><Sponsor>Novartis AG</Sponsor><Trial id="62581"/><TrialStartDate>DECEMBER , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Adhesive capsulitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>108</EnrollmentCount><Interventions>lidocaine; lidocaine; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>108</Patients><ProtocolAcronym/><ProtocolTitle>An RCT in Treatment of Adhesive Capsulitis Arthrographic Joint Distention With Local Anesthetic Alone</ProtocolTitle><Reference>NCT02001740; SURG-246-12</Reference><Sponsor>Queen's University</Sponsor><Trial id="163100"/><TrialStartDate>DECEMBER , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; Forced expiratory volume; Heart rate; Hydrocortisone; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>190</EnrollmentCount><Interventions>Arnuity; fluticasone</Interventions><Patients>190</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of GW-685698X an Inhaled Corticosteroid Once-Daily and Twice-Daily for the Treatment of Asthma</ProtocolTitle><Reference>112202; NCT00766090</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="30011"/><TrialStartDate>OCTOBER  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>ProAir</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>713</EnrollmentCount><Interventions>Breath-Actuated Inhaler (BAI); Metered Dose Inhaler (MDI); ProAir; Qvar</Interventions><Patients>850</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma</ProtocolTitle><Reference>2015-002510-80; BDB-AS-30039; NCT02513160</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="236335"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Tendon disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><EnrollmentCount>108</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Patients>108</Patients><ProtocolAcronym/><ProtocolTitle>Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Short-Term Efficacy and Safety of Two Different Treatment Regimens of Betamethasone Valerate 2.25 Mg Medicated Plaster in Patients With Chronic Tendinopathies of the Upper and Lower Limbs</ProtocolTitle><Reference>12I-BMT08; EUCTR2012-005030-11-IT; EudraCT 2012-005030-11</Reference><Sponsor>Institut Biochimique SA</Sponsor><Trial id="151394"/><TrialStartDate>FEBRUARY , 11, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Adrenocorticotropic Hormone; C-terminal telopeptide of collagen type I; CRP; Collagen type I trimeric cross-linked peptide; Eosinophils; Glucose; Hemoglobin A, glycosylated; Hydrocortisone; Lymphocytes; N-terminal type I collagen telopeptide/Creatinine ratio; Neutrophils; Osteocalcin; P1NP; Parathyroid hormone; UNTx/Ucr; adiponectin</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59618">fosdagrocorat</Drug><EnrollmentCount>323</EnrollmentCount><Interventions>fosdagrocorat</Interventions><Patients>323</Patients><ProtocolAcronym/><ProtocolTitle>Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis</ProtocolTitle><Reference>2010-023782-22; A9391010; CTRI/2012/07/002810; NCT01393639; NMRR-11-813-9929</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="79213"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>558</EnrollmentCount><Interventions>GW-685698</Interventions><Patients>558</Patients><ProtocolAcronym/><ProtocolTitle>Perennial Allergic Rhinitis Study In Pediatric Subjects</ProtocolTitle><Reference>2004-004745-18; FFR30008; NCT00108914</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11727"/><TrialStartDate>FEBRUARY , 28, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Cataract</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><EnrollmentCount>135</EnrollmentCount><Interventions>Pred Forte; T-Pred</Interventions><Patients>135</Patients><ProtocolAcronym/><ProtocolTitle>Study of T-PRED(TM) Compared to Pred Forte(R) II</ProtocolTitle><Reference>CL-PKT-0415083-P; NCT00854061</Reference><Sponsor>Bausch &amp; Lomb Inc</Sponsor><Trial id="47631"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Dermatitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>125</EnrollmentCount><Interventions>clobetasol propionate foam, Connetics</Interventions><Patients>125</Patients><ProtocolAcronym/><ProtocolTitle>Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) versus Vehicle Foam in the Treatment of Chronic Hand Dermatitis</ProtocolTitle><Reference>115054; NCT01323673</Reference><Sponsor>Stiefel</Sponsor><Trial id="75815"/><TrialStartDate>NOVEMBER , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>beclometasone dipropionate + formoterol fumarate (inhaled, Modulite), Chiesi; budesonide + formoterol fumarate, AstraZeneca; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>231</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca; ciclesonide (metered dose inhaler), Nycomed; fluticasone propionate</Interventions><Patients>231</Patients><ProtocolAcronym>WISDOM</ProtocolAcronym><ProtocolTitle>Pragmatic randomized controlled trial for stepping down of asthma controller treatment in patients controlled</ProtocolTitle><Reference>2016-0838; KCT0002103; WISDOM</Reference><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><Trial id="275290"/><TrialStartDate>SEPTEMBER, 26, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Glycated hemoglobin; Hydrocortisone</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>hydrocortisone</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>64</EnrollmentCount><Interventions>dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Interventions><Patients>64</Patients><ProtocolAcronym>DC 06/02</ProtocolAcronym><ProtocolTitle>Once-Daily Oral Modified-Release Hydrocortisone in Patients With Adrenal Insufficiency</ProtocolTitle><Reference>104-07; DC 06/02; EudraCT: 2006-0007084-89; NCT00915343</Reference><Sponsor>Shire plc</Sponsor><Trial id="57668"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>OTX-DP</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Reference>NCT01666210; OTX-12-002</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="90260"/><TrialStartDate>OCTOBER  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Reference>NCT01550471; RC#5401</Reference><Sponsor>West Penn Allegheny Health System Inc</Sponsor><Trial id="86234"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Reference>200284; NCT01962467</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157921"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rectosigmoiditis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>281</EnrollmentCount><Interventions>Rectabul</Interventions><Patients>281</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Reference>BUCF3002; NCT01008423</Reference><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><Trial id="61738"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ulcerative proctitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>281</EnrollmentCount><Interventions>Rectabul</Interventions><Patients>281</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Reference>BUCF3002; NCT01008423</Reference><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><Trial id="61738"/><TrialStartDate>NOVEMBER , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ulcerative colitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount/><Interventions>Rectabul</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Phase II study of AJG-511 in patients with active ulcerative colitis</ProtocolTitle><Reference>JapicCTI-132294</Reference><Sponsor>EA Pharma Co Ltd</Sponsor><Trial id="157022"/><TrialStartDate>OCTOBER  , 03, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59618">fosdagrocorat</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>PF-04171327; midazolam</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>A Midazolam Drug Interaction Study With PF-04171327</ProtocolTitle><Reference>A9391007; NCT00987038</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="60720"/><TrialStartDate>SEPTEMBER, 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>250</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; mephamesone; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>250</Patients><ProtocolAcronym>InfStu</ProtocolAcronym><ProtocolTitle>The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration</ProtocolTitle><Reference>EKSG 13/061; InfStu; NCT01945554</Reference><Sponsor>Kantonsspital St Gallen</Sponsor><Trial id="155140"/><TrialStartDate>JULY     , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anterior chamber; Intraocular pressure; Leukocyte count</Biomarkers><Condition>Ocular pain</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><EnrollmentCount>438</EnrollmentCount><Interventions>OTX-DP</Interventions><Patients>438</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Reference>NCT02736175; OTX-15-003</Reference><Sponsor>Ocular Therapeutix Inc</Sponsor><Trial id="258056"/><TrialStartDate>OCTOBER  , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>GW-685698X</Interventions><Patients>350</Patients><ProtocolAcronym/><ProtocolTitle>Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis</ProtocolTitle><Reference>2004-004744-43; FFR30007; NCT00118703</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11077"/><TrialStartDate>JULY     , 01, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Multiple sclerosis</Condition><Controls>Solu-Medrol</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>15</EnrollmentCount><Interventions>Nanocort</Interventions><Patients>15</Patients><ProtocolAcronym/><ProtocolTitle>Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)</ProtocolTitle><Reference>2009-013884-21; GLPG0303-CL-204; NCT01039103</Reference><Sponsor>Enceladus Pharmaceuticals, Galapagos NV</Sponsor><Trial id="63043"/><TrialStartDate>DECEMBER , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Choroidal neovascularization</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="60951">triamcinolone acetonide (controlled release/intravitreal injection/Verisome, diabetic macular edema), EyePoint</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>IBI-20089; Lucentis</Interventions><Patients>10</Patients><ProtocolAcronym>20089/Combo</ProtocolAcronym><ProtocolTitle>IBI-20089 + Lucentis Combined Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)</ProtocolTitle><Reference>20089/Combo; 2009-1067; NCT01175395</Reference><Sponsor>University of Illinois</Sponsor><Trial id="68844"/><TrialStartDate>SEPTEMBER, 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body Mass Index; Body temperature; Diastolic blood pressure; Forced expiratory volume; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>520</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>520</Patients><ProtocolAcronym>CONTRAST</ProtocolAcronym><ProtocolTitle>Effect of High-Dose Ciclesonide on Asthma Control</ProtocolTitle><Reference>2011-000683-99; CL-9709-301-RD; CONTRAST; NCT01455194; U1111-1133-6333</Reference><Sponsor>Takeda Development Centre Europe Ltd</Sponsor><Trial id="81694"/><TrialStartDate>NOVEMBER , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>34</EnrollmentCount><Interventions>Advair; Qvar; Serevent Diskus</Interventions><Patients>34</Patients><ProtocolAcronym/><ProtocolTitle>Non-Invasive Measures of Distal Lung Disease in Asthmatics</ProtocolTitle><Reference>IXR-403-4-196; NCT00250341</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="22364"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>Kenalog</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>55</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>30</Patients><ProtocolAcronym>SHIP</ProtocolAcronym><ProtocolTitle>Study to Compare Exposure of TA Following Administration of FX-006 or TAcs in Patients With OA of the Shoulder or Hip</ProtocolTitle><Reference>FX006-2017-013; NCT03382262; SHIP</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="323551"/><TrialStartDate>DECEMBER , 18, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Eosinophils; Forced Vital Capacity; Forced expiratory volume; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>30</Patients><ProtocolAcronym>SPIRA</ProtocolAcronym><ProtocolTitle>Small Particle Steroids in Refractory Asthma</ProtocolTitle><Reference>09115; 2010-018249-78; 9890; MREC N: 10/H0408/19; NCT01171365; SPIRA</Reference><Sponsor>University of Nottingham</Sponsor><Trial id="192547"/><TrialStartDate>JANUARY  , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure; Lens; Optic cup; Optic disc</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>550</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>550</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-Round) Allergic Rhinitis</ProtocolTitle><Reference>2015-004891-31; FFR110537; NCT00682643</Reference><Sponsor>GlaxoSmithKline Inc</Sponsor><Trial id="22920"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>17</EnrollmentCount><Interventions>Medidur FA</Interventions><Patients>17</Patients><ProtocolAcronym/><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy</ProtocolTitle><Reference>C-01-08-004; NCT00695318</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="32426"/><TrialStartDate>DECEMBER , 01, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Arterial stiffness; Blood pressure; Pulse rate; Pulse wave velocity</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Spiriva HandiHaler</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>260</EnrollmentCount><Interventions>Relovair</Interventions><Patients>260</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Compare the Impact of Fulticasone Furoate/Vilanterol versus Tiotropium on Arterial Stiffness in COPD</ProtocolTitle><Reference>115247; 2010-024435-16; NCT01395888</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="79358"/><TrialStartDate>JUNE     , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-reactive protein (CRP); Serum amyloid A protein (SAA)</Biomarkers><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>canakinumab</Interventions><Patients>200</Patients><ProtocolAcronym>H2255</ProtocolAcronym><ProtocolTitle>Targeted Dose Finding of Canakinumab (ACZ-885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients</ProtocolTitle><Reference>CACZ885H2255; EudraCT 2008-004666-61; H2255; H2255; NCT00798369</Reference><Sponsor>Novartis AG</Sponsor><Trial id="37260"/><TrialStartDate>NOVEMBER , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Blood pressure; Forced expiratory volume; Heart rate; PR interval; QRS complex; QT interval; R-R interval</Biomarkers><Condition>Asthma</Condition><Controls>moxifloxacin</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>85</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>85</Patients><ProtocolAcronym/><ProtocolTitle>Corrected QT (QTc) Study With Flucticasone Furoate and GW-642444</ProtocolTitle><Reference>102936; NCT01209026</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="70692"/><TrialStartDate>JUNE     , 23, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>36</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>36</Patients><ProtocolAcronym/><ProtocolTitle>A Four-way Crossover, Single- and Repeat-Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)</ProtocolTitle><Reference>115441; NCT01669070</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="90428"/><TrialStartDate>AUGUST   , 15, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of FX-006 in Patients With Hip Osteoarthritis</ProtocolTitle><Reference>FX006-2018-015; NCT03793010</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="365500"/><TrialStartDate>DECEMBER , 12, 2018</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Globulins; Glucose; Hematocrit; Hemoglobin; Ketones; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; PR interval; Phosphate; Potassium; QRS complex; QT interval; Respiratory frequency; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea; Uric acid; Urinary specific gravity; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>batefenterol succinate; batefenterol succinate + fluticasone furoate; fluticasone furoate; fluticasone furoate + vilanterol trifenatate; fluticasone furoate + vilanterol trifenatate</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>GSK-961081 Alone and With Fluticasone Furoate (FF), Phase I (PhI), Single-Dose Regimen (SD), Repeat-Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)</ProtocolTitle><Reference>201958; NCT02666287</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="251911"/><TrialStartDate>JANUARY  , 27, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Globulins; Glucose; Hematocrit; Hemoglobin; Ketones; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; PR interval; Phosphate; Potassium; QRS complex; QT interval; Respiratory frequency; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea; Uric acid; Urinary specific gravity; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>batefenterol succinate; batefenterol succinate + fluticasone furoate; fluticasone furoate; fluticasone furoate + vilanterol trifenatate; fluticasone furoate + vilanterol trifenatate</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>GSK-961081 Alone and With Fluticasone Furoate (FF), Phase I (PhI), Single-Dose Regimen (SD), Repeat-Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)</ProtocolTitle><Reference>201958; NCT02666287</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="251911"/><TrialStartDate>JANUARY  , 27, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Addisons disease</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>Plenadren</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Optimizing Steroid Replacement in Patients With Adrenal Insufficiency</ProtocolTitle><Reference>2016/09/05; NCT03282487</Reference><Sponsor>Adelaide and Meath Hospital, Tallaght Regional Hospital</Sponsor><Trial id="312737"/><TrialStartDate>SEPTEMBER, 05, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Cortisol; Creatinine; Eosinophil; Eosinophil cationic protein; Eosinophilic cationic protein; Mannitol PD15; Nitric Oxide; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>Qvar</Interventions><Patients>26</Patients><ProtocolAcronym>ANDA3</ProtocolAcronym><ProtocolTitle>Targeted Small Airways Therapy in Persistent Asthma</ProtocolTitle><Reference>13/ES/0064; 2012-003923-39; 2012RC16; ANDA3; NCT01894048</Reference><Sponsor>Tayside Medical Science Center, University of Dundee</Sponsor><Trial id="145796"/><TrialStartDate>OCTOBER  , 28, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="103922">mometasone furoate (sustained release transmucosal formulation, chronic sinusitis), Lyra Therapeutics</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>mometasone</Interventions><Patients>20</Patients><ProtocolAcronym/><ProtocolTitle>480 Biomedical Sinus Drug Depot</ProtocolTitle><Reference>480MFSDD2016-001; NCT02942186; NCT02967731</Reference><Sponsor>Lyra Therapeutics</Sponsor><Trial id="280158"/><TrialStartDate>JUNE     , 06, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Eosinophils; Peak nasal inspiratory flow</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Patients>20</Patients><ProtocolAcronym>NACHO</ProtocolAcronym><ProtocolTitle>Nasal Allergen Challenge-Reproducibility of Biomarkers and Effect of Topical Steroid Treatment</ProtocolTitle><Reference>DC002544/HIREB3820; NACHO; NCT03431961</Reference><Sponsor>Hamilton Health Sciences Corp</Sponsor><Trial id="329091"/><TrialStartDate>MARCH    , 07, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Creatinine; Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>32</EnrollmentCount><Interventions>CHF-5993</Interventions><Patients>32</Patients><ProtocolAcronym/><ProtocolTitle>PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese versus Caucasians</ProtocolTitle><Reference>CLI-05993AB4-01; NCT03859414</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="371937"/><TrialStartDate>MARCH    , 18, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>438</EnrollmentCount><Interventions>Relvar; salbutamol</Interventions><Patients>438</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects</ProtocolTitle><Reference>2017-002266-45; 207040; NCT03380429</Reference><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><Trial id="323386"/><TrialStartDate>JANUARY  , 31, 2018</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Juvenile rheumatoid arthritis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>260</EnrollmentCount><Interventions>CINGAL; etanercept; methotrexate; methylprednisolone acetate</Interventions><Patients>260</Patients><ProtocolAcronym>STARS</ProtocolAcronym><ProtocolTitle>Step-up and Step-down Therapeutic Strategies in Childhood Arthritis</ProtocolTitle><Reference>2018-001931-27; NCT03728478; STARS</Reference><Sponsor>The Gaslini Institute</Sponsor><Trial id="358840"/><TrialStartDate>MARCH    , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Maximal oxygen uptake</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>Relvar Ellipta</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate</ProtocolTitle><Reference>NCT03739294; WADAVIL2018</Reference><Sponsor>Bispebjerg Hospital</Sponsor><Trial id="359853"/><TrialStartDate>FEBRUARY , 08, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Sciatica</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="106609">dexamethasone sodium phosphate (epidural steroid injectable gel, sciatia), Scilex Holding</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>SP-102</Interventions><Patients>400</Patients><ProtocolAcronym>CLEAR</ProtocolAcronym><ProtocolTitle>Corticosteroid Lumbar Epidural Analgesia for Radiculopathy</ProtocolTitle><Reference>CLEAR; NCT03372161; SP-102-02</Reference><Sponsor>Semnur Pharmaceuticals Inc</Sponsor><Trial id="322493"/><TrialStartDate>DECEMBER , 08, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Bone mineral density; C-reactive protein; Heart rate; Hemoglobin A, glycosylated; PR interval; Q-wave; QRS complex; QT interval; R-wave; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-wave</Biomarkers><Condition>Ataxia telangiectasia</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>EryDex</Interventions><Patients>50</Patients><ProtocolAcronym>OLE-IEDAT</ProtocolAcronym><ProtocolTitle>Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study</ProtocolTitle><Reference>2018-000338-36; CTRI/2019/02/017732; IEDAT-03-2018; NCT03563053; OLE-IEDAT; US IND 115929</Reference><Sponsor>CliniRx Tangent Research India Pvt Ltd, EryDel SPA</Sponsor><Trial id="344005"/><TrialStartDate>JUNE     , 12, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>35</EnrollmentCount><Interventions>LEO-90100; betamethasone dipropionate; calcipotriol + betamethasone dipropionate, LEO; clobetasol propionate foam, Connetics; fluocinolone acetonide (Synalar)</Interventions><Patients>35</Patients><ProtocolAcronym/><ProtocolTitle>A Vasoconstriction Study With LEO-90100</ProtocolTitle><Reference>LP0053-69; NCT01946386</Reference><Sponsor>LEO Pharma A/S</Sponsor><Trial id="155226"/><TrialStartDate>SEPTEMBER, 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Qnaze; beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol</ProtocolTitle><Reference>BDP-AR-101; NCT01537692</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="85132"/><TrialStartDate>MARCH    , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>19</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca; triamcinolone acetonide</Interventions><Patients>19</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-controlled, Cross-over Study Comparing the Clinical Pharmacokinetics, Pharmacodynamics and Tolerability of Triamcinolone Acetonide Versus Budesonide in Healthy Volunteers</ProtocolTitle><Reference>CMS-3104</Reference><Sponsor>Aventis Pharmaceuticals Inc</Sponsor><Trial id="106503"/><TrialStartDate>MAY      , 31, 2000</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>72</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>72</Patients><ProtocolAcronym/><ProtocolTitle>AZD-5423 Single Ascending Dose Study</ProtocolTitle><Reference>D2340C00001; NCT00963183</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="59980"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-Label, Two-Way, Cross-over Study to Assess the Absolute Bioavailability of GW-685698X Administered Intranasally in Healthy Male and Female Subjects</ProtocolTitle><Reference>FFR10010</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="153600"/><TrialStartDate>MAY      , 16, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="56124">BI-653048</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>glucocorticoid mimetics (inflammation), Boehringer Ingelheim</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability and Pharmacokinetics of BI-653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers</ProtocolTitle><Reference>1262.1; NCT02217644</Reference><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><Trial id="208311"/><TrialStartDate>NOVEMBER , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>C-reactive protein; Erythrocyte</Biomarkers><Condition>Crohns disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><EnrollmentCount>51</EnrollmentCount><Interventions>EryDex</Interventions><Patients>51</Patients><ProtocolAcronym>Crodex</ProtocolAcronym><ProtocolTitle>Intra-Erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-Dependent Crohn's Disease</ProtocolTitle><Reference>2008-007329-38; Crodex; Crodex01; NCT01277289</Reference><Sponsor>EryDel SPA</Sponsor><Trial id="75025"/><TrialStartDate>APRIL    , 30, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; Hydrocortisone; PEF</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>343</Patients><ProtocolAcronym/><ProtocolTitle>Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents</ProtocolTitle><Reference>112059; 2010-020144-34; FFA112059; NCT01159912</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="68093"/><TrialStartDate>JUNE     , 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>153</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>153</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis</ProtocolTitle><Reference>CTRI/2014/12/005337; NCT02746991; PSV-FAI-005</Reference><Sponsor>EyePoint Pharmaceuticals Inc</Sponsor><Trial id="258836"/><TrialStartDate>JUNE     , 30, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>fluticasone furoate; fluticasone propionate</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, multicenter study was conducted to evaluate the efficacy and safety of powder for inhalation of fluticasone furoate and powder for inhalation of fluticasone propionate in the treatment of asthma in adults and adolescents who are receiving treatment with inhaled corticosteroids</ProtocolTitle><Reference>FFA115285</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="169280"/><TrialStartDate>OCTOBER  , 18, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>34</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>34</Patients><ProtocolAcronym>SMART</ProtocolAcronym><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, crossover, single-center study to assess the efficacy and efficacy of Nasacort in patients with perennial allergic rhinitis</ProtocolTitle><Reference>SMART; XRG5029C/4004</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="88927"/><TrialStartDate>JULY     , 25, 2002</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>40</EnrollmentCount><Interventions>Flutiform; Relvar</Interventions><Patients>40</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of clinical efficacy between FFC and VFC</ProtocolTitle><Reference>UMIN000031039</Reference><Sponsor>Kyorin Pharmaceutical Co Ltd</Sponsor><Trial id="326992"/><TrialStartDate>JANUARY  , 29, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Body surface area</Biomarkers><Condition>Psoriasis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>63</EnrollmentCount><Interventions>Sorilux; Sorilux; clobetasol propionate foam, Connetics</Interventions><Patients>63</Patients><ProtocolAcronym/><ProtocolTitle>Olux-E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis</ProtocolTitle><Reference>NCT01745133; OLX0112</Reference><Sponsor>Derm Research, PLLC</Sponsor><Trial id="101105"/><TrialStartDate>JANUARY  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>637</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone</Interventions><Patients>474</Patients><ProtocolAcronym/><ProtocolTitle>A 12-week, randomized, open-label, parallel-group study to evaluate the safety and efficacy of ciclesonide versus fluticasone propionate in patients with moderate persistent asthma</ProtocolTitle><Reference>BY9010/M1-133</Reference><Sponsor>Takeda GmbH</Sponsor><Trial id="76915"/><TrialStartDate>DECEMBER , 31, 2003</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Alanine Aminotransferase; Albumin; Alkaline Phosphatase; Aspartate Aminotransferase; Creatinine; Glucose; Hematocrit; Hemoglobin; Platelets; Potassium; Red blood cells; Sodium; Total Bilirubin; Total Protein; Urea Nitrogen; White blood cells</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>Avamys</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>A Phase IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS Aqueous Nasal Spray 110 microg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis</ProtocolTitle><Reference>112185; AVY-REG00108VN; NCT01270958</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="73628"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>GW-685698X; fluticasone propionate</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, multicenter, double-blind, placebo-controlled, balanced incomplete block, multiple-dose, three-period crossover study to determine  the effect of 3 days repeat dosing of GW-685698X and fluticasone propionate (1000 microg) on exhaled nitric oxide in patients with mild to moderate asthma</ProtocolTitle><Reference>FFA10028</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="87541"/><TrialStartDate>MARCH    , 24, 2003</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="55108">triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Drug><EnrollmentCount>2</EnrollmentCount><Interventions>triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Interventions><Patients>2</Patients><ProtocolAcronym/><ProtocolTitle>A Study of MK-0140 in Diabetic Patients With Macular Edema</ProtocolTitle><Reference>0140-001; 2008_521; MK0140-001; NCT00692614</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="16677"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Proctitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount>114</EnrollmentCount><Interventions>Rectabul</Interventions><Patients>114</Patients><ProtocolAcronym/><ProtocolTitle>The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Reference>BFPS3073; NCT01349673</Reference><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><Trial id="77185"/><TrialStartDate>JUNE     , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>FEV1; FeNO</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>91</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>91</Patients><ProtocolAcronym>YSCO</ProtocolAcronym><ProtocolTitle>The Protective Effect of a Nasal Corticosteroid (Avamys) On Exercise Induced Airway Obstruction in Cold Air in Children</ProtocolTitle><Reference>EudraCT: 2009-010563-17; FF1; ISRCTN90761040; NL26953.044.09; YSCO</Reference><Sponsor>Stichting Pediatrisch Onderzoek Enschede</Sponsor><Trial id="118794"/><TrialStartDate>MARCH    , 05, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Retinal thickness</Biomarkers><Condition>Macular edema</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Clinical study about ophthalmic local administrations of triamcinolone acetonide for macular edema and/or retinal periphlebitis</ProtocolTitle><Reference>JPRN-UMIN000005778</Reference><Sponsor>Yamagata University</Sponsor><Trial id="121608"/><TrialStartDate>JULY     , 01, 2006</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>130</EnrollmentCount><Interventions>Budenofalk; Entocort; Flagyl; Medrol; azathioprine; folic acid; infliximab; methotrexate; prednisolone</Interventions><Patients>130</Patients><ProtocolAcronym/><ProtocolTitle>The Ideal Management of Crohn's Disease: Top-Down Versus Step-Up Strategies - A Prospective, Controlled Trial in the Benelux</ProtocolTitle><Reference>ISRCTN61510219; NTR379</Reference><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><Trial id="120593"/><TrialStartDate>MAY      , 01, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique; calcipotriol + betamethasone dipropionate, LEO</Interventions><Patients>300</Patients><ProtocolAcronym/><ProtocolTitle>Comparison of Efficacy and Safety of Betesil Medicated Plaster Versus Daivobet/Dovobet Ointment in the Treatment of Chronic Plaque Psoriasis</ProtocolTitle><Reference>09EU_BMT12; EudraCT: 2009-016969-28; ISRCTN34974208</Reference><Sponsor>Institut Biochimique SA</Sponsor><Trial id="120685"/><TrialStartDate>APRIL    , 01, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>304</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>304</Patients><ProtocolAcronym/><ProtocolTitle>Study In Adults And Adolescents With Seasonal Allergic Rhinitis</ProtocolTitle><Reference>FFR30003; NCT00115622</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="12091"/><TrialStartDate>DECEMBER , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Central macular thickness; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>bevacizumab; grid laser photocoagulation; triamcinolone acetonide</Interventions><Patients>105</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Macular Laser Photocoagulation With or Without Intravitreal Injection of Bevacizumab (Avastin) or Triamcinolone Acetonide for Diffuse Diabetic Macular Edema</ProtocolTitle><Reference>IRCT201205029617N1</Reference><Sponsor>Ahvaz Jundishapur University of Medical Sciences</Sponsor><Trial id="125066"/><TrialStartDate>MAY      , 10, 2011</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>380</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>380</Patients><ProtocolAcronym/><ProtocolTitle>Study In Adolescent and Adult Subjects 12 Years of Age and Older With Seasonal Allergic Rhinitis To Assess Onset of Action</ProtocolTitle><Reference>FFR101816; NCT00118729</Reference><Sponsor>GlaxoSmithKline Inc</Sponsor><Trial id="12406"/><TrialStartDate>APRIL    , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>61</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>61</Patients><ProtocolAcronym/><ProtocolTitle>Study FFR116365, an Open-label Study of GW-685698X in Pediatric Subjects With Perennial Allergic Rhinitis</ProtocolTitle><Reference>116365; FFR116365; JapicCTI-121890; NCT01622231</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="88495"/><TrialStartDate>JUNE     , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Sarcoidosis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount>7</EnrollmentCount><Interventions>methotrexate; methylprednisolone; prednisone; prednisone; triamcinolone acetonide</Interventions><Patients>7</Patients><ProtocolAcronym>UVEXATE</ProtocolAcronym><ProtocolTitle>Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis</ProtocolTitle><Reference>NCT00918554; P070140; UVEXATE</Reference><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><Trial id="169537"/><TrialStartDate>SEPTEMBER, 30, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Adrenocorticotropic Hormone; Fasting blood glucose; Hypothalamic-pituitary-adrenal (HPA) axis hormone; Lymphocyte; Osteocalcin</Biomarkers><Condition>Multiple sclerosis</Condition><Controls>methylprednisolone</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64904">methylprednisolone (PEGylated liposomal, neuroinflammation), EnhanX Biopharm</Drug><EnrollmentCount>47</EnrollmentCount><Interventions>2B3-201</Interventions><Patients>42</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis (MS) Patients</ProtocolTitle><Reference>2013-004077-28; 2B3-201-CR-001; NCT02048358</Reference><Sponsor>2-BBB Medicines BV</Sponsor><Trial id="170415"/><TrialStartDate>NOVEMBER , 30, 2013</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Arm circumference</Biomarkers><Condition>Anesthesia</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>66</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide</Interventions><Patients>66</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Effectiveness of Corticosteroid Preparation in Sympathetic Ganglion Block on Lymphedema</ProtocolTitle><Reference>2010-0206; KCT0000300</Reference><Sponsor>Seoul National University Hospital</Sponsor><Trial id="127593"/><TrialStartDate>APRIL    , 30, 2010</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55108">triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Drug><EnrollmentCount>31</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>31</Patients><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema</ProtocolTitle><Reference>NCT00915837; SRDX- 001; STRIDE</Reference><Sponsor>SurModics Inc</Sponsor><Trial id="57663"/><TrialStartDate>JUNE     , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount/><Interventions>Relovair</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, multicenter, parallel group comparative study of fluticasone furoate inhalation powder and fluticasone furoate / GW642444 formulations that target persistent asthma adolescent patients</ProtocolTitle><Reference>108 627; JapicCTI-101294</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="131588"/><TrialStartDate>OCTOBER  , 05, 2010</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Herpes simplex virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><EnrollmentCount>417</EnrollmentCount><Interventions>ME-609</Interventions><Patients>380</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis</ProtocolTitle><Reference>98-609-013; NCT00736437</Reference><Sponsor>Medivir AB</Sponsor><Trial id="23303"/><TrialStartDate>AUGUST   , 31, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>Carbomix granules; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><EnrollmentCount>129</EnrollmentCount><Interventions>Carbomix granules; fluticasone propionate + salmeterol xinafoate; fluticasone propionate + salmeterol xinafoate</Interventions><Patients>129</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus</ProtocolTitle><Reference>3106009; NCT02162485</Reference><Sponsor>Orion Corp</Sponsor><Trial id="196211"/><TrialStartDate>JUNE     , 30, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide</Interventions><Patients>129</Patients><ProtocolAcronym/><ProtocolTitle>Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema</ProtocolTitle><Reference>8411; NCT00370669</Reference><Sponsor>Shaheed Beheshti Medical University</Sponsor><Trial id="4334"/><TrialStartDate>NOVEMBER , 30, 2005</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>17-alpha-hydroxyprogesterone; Adrenocorticotropic hormone; Blood pressure; Body Mass Index; Body temperature; Bone formation rate; C-terminal telopeptide of collagen type I; Corticosterone; Cortodoxone; Dystrophin; Glucose; Heart rate; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Hydrocortisone; Insulin; Low-density lipoprotein cholesterol; Muscle strength; Osteocalcin; Procollagen Type I N-terminal peptide; Respiratory frequency; Six-minute walk distance; Testosterone; Total body mass; Total cholesterol; Triglycerides</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>deflazacort; glucocorticoid therapy; prednisone</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="70712">vamorolone</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>vamorolone</Interventions><Patients>48</Patients><ProtocolAcronym>VISION-DMD</ProtocolAcronym><ProtocolTitle>A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Reference>1R44NS095423-01; 1U34AR068616-01; 2016-004263-38; NCT02760264; VBP15-002; VBP15-003; VISION-DMD</Reference><Sponsor>ReveraGen BioPharma Inc</Sponsor><Trial id="260105"/><TrialStartDate>JUNE     , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diarrhea</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>16</EnrollmentCount><Interventions>Entocort EC</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis</ProtocolTitle><Reference>1132-03; IRUSBUEN0002; NCT00217022; UL1RR024150</Reference><Sponsor>Mayo Clinic Foundation</Sponsor><Trial id="199220"/><TrialStartDate>JUNE     , 30, 2003</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Patients>16</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 years)</ProtocolTitle><Reference>BY9010/M1-131; NCT00163345</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="22011"/><TrialStartDate>SEPTEMBER, 30, 2003</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Obstructive sleep apnea</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>44</EnrollmentCount><Interventions>Thermosmart; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>44</Patients><ProtocolAcronym>Thermosmart</ProtocolAcronym><ProtocolTitle>Effect of Heated Humidity With Thermosmart Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure</ProtocolTitle><Reference>F &amp; P 07-004; NCT00665977; Thermosmart</Reference><Sponsor>Clayton Sleep Insititute</Sponsor><Trial id="175536"/><TrialStartDate>SEPTEMBER, 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>12</EnrollmentCount><Interventions>ciclesonide</Interventions><Patients>12</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Traditional Paper Symptom Diary Versus the VOCEL Mobile Diary</ProtocolTitle><Reference>CICLE-L-01335; NCT00367263</Reference><Sponsor>Allergy and Asthma Medical Group and Research Center</Sponsor><Trial id="22407"/><TrialStartDate>OCTOBER  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Knee stiffness</Biomarkers><Condition>Pain</Condition><Controls>Kenalog-40</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>Proof of Concept Study Comparing FX-006 to Kenalog-40 in Patients With Post-Traumatic Osteoarthritis of the Knee</ProtocolTitle><Reference>FX006-2014-007; NCT02468583</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="231796"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>106</EnrollmentCount><Interventions>Qvar; ciclesonide</Interventions><Patients>106</Patients><ProtocolAcronym/><ProtocolTitle>Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>BY9010/M1-408; NCT00659048</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="13328"/><TrialStartDate>DECEMBER , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>17-alpha-hydroxyprogesterone; Androgens; Androstenedione; Testosterone</Biomarkers><Condition>Congenital adrenal hyperplasia</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>Infacort</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>Extension Study for Patients Entered Into Study Infacort 003</ProtocolTitle><Reference>2015-000458-40; INFACORT 004; NCT02733367</Reference><Sponsor>Diurnal Ltd</Sponsor><Trial id="257842"/><TrialStartDate>MARCH    , 04, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Diastolic blood pressure; Forced expiratory volume; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>620</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; placebo + fluticasone furoate + vilanterol; umeclidinium; umeclidinium (125 microg) + fluticasone furoate + vilanterol; umeclidinium (62.5 microg) + fluticasone furoate + vilanterol</Interventions><Patients>1238</Patients><ProtocolAcronym/><ProtocolTitle>Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD): Study 2</ProtocolTitle><Reference>077; 200110; 2013-002239-44; 479; 855; IND IDE 104; NCT02119286</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="183041"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>52</EnrollmentCount><Interventions>beclometasone; beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>52</Patients><ProtocolAcronym/><ProtocolTitle>A Single-Center, Open-Label, Randomized, Two-Way Cross Over Study to Determine the Effects on the Short-Term Lower Leg Growth Rate Between Qvar 100 microg BD Delivered via a Metered Dose Inhaler (MDI) (TEVA UK Ltd) With a Reference Beclometasone Formulation via a Reference MDI in Children With Mild to Moderate Asthma</ProtocolTitle><Reference>EudraCT 2007-007455-14; QV-001/2007-Pae</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="151641"/><TrialStartDate>APRIL    , 08, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Fundus of eye; Intraocular pressure; Macula retinae</Biomarkers><Condition>Macular edema</Condition><Controls>dexamethasone (sustained release ophthalmic), Allergan/Sanwa</Controls><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Open-Label, Multicenter, Phase Ib/IIa Clinical Trial Designed To Evaluate The Safety And Efficacy Of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution In Patients With Macular Edema</ProtocolTitle><Reference>EGP-437-007; NCT02485249</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="233505"/><TrialStartDate>JULY     , 31, 2015</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body height; Cortisol/Creatinine ratio; Hydrocortisone</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>299</EnrollmentCount><Interventions>loratadine; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Patients>299</Patients><ProtocolAcronym/><ProtocolTitle>Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Reference>2014-004645-27; NCT00449072; XRG5029C_3503</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="13825"/><TrialStartDate>MARCH    , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62431">budesonide + azelastine (intranasal Captisol-enabled, allergic rhinitis), Sedor Pharmaceuticals</Drug><EnrollmentCount>65</EnrollmentCount><Interventions>CDX-313; Pulmicort</Interventions><Patients>65</Patients><ProtocolAcronym/><ProtocolTitle>Compare Captisol-Enabled Budesonide Nasal Solution and Rhinocort Aqua in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis</ProtocolTitle><Reference>CDX947CT001; NCT00938613; P2DS06001</Reference><Sponsor>Ligand Pharmaceuticals Inc</Sponsor><Trial id="59051"/><TrialStartDate>FEBRUARY , 28, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>prednisolone</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><EnrollmentCount>279</EnrollmentCount><Interventions>CRx-102</Interventions><Patients>279</Patients><ProtocolAcronym>COMET-1</ProtocolAcronym><ProtocolTitle>CRx-102 Osteoarthritis Multicenter Evaluation Trial</ProtocolTitle><Reference>COMET-1; CRx-102-006; NCT00521989</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="22235"/><TrialStartDate>AUGUST   , 31, 2007</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>ciclesonide; formoterol fumarate</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48419">ciclesonide + formoterol (inhaled, asthma), Altana/sanofi-aventis</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>Ultrahaler; ciclesonide + formoterol</Interventions><Patients>240</Patients><ProtocolAcronym>ADVICE</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 years)</ProtocolTitle><Reference>2004-004708-19; ADVICE; BY9010/M1-506; NCT00314509</Reference><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><Trial id="21993"/><TrialStartDate>JULY     , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Fovea centralis; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls>Eylea</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><EnrollmentCount>460</EnrollmentCount><Interventions>CLS-1003</Interventions><Patients>460</Patients><ProtocolAcronym>SAPPHIRE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With intravitreal Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Reference>2016-004648-12; 2017-CT0411; CLS1003-301; CLS1003-301 Amendment 1; CTRI/2017/11/010451; NCT02980874; PHRR170812-001654; SAPPHIRE</Reference><Sponsor>Clearside Biomedical Inc, Syneos Health Inc</Sponsor><Trial id="281144"/><TrialStartDate>JANUARY  , 31, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Cortisol; Heart rate; Pulse rate</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>736</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Patients>736</Patients><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 microg for 52 Weeks in Adult and Adolescent Subjects With Perennial Allergic Rhinitis</ProtocolTitle><Reference>EudraCT 2004-000091-14; FFR102123</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="140891"/><TrialStartDate>SEPTEMBER, 17, 2004</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>Iluvien</Interventions><Patients>120</Patients><ProtocolAcronym>FAME</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study</ProtocolTitle><Reference>C-01-11-008; FAME; NCT01304706</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="75048"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Glucose; PR interval; Peak expiratory flow rate; QRS complex; QT interval</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>870</EnrollmentCount><Interventions>ELLIPTA dry powder inhaler; Ellipta</Interventions><Patients>870</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma</ProtocolTitle><Reference>107116; 2016-004086-87; CTR20181312; HZA107116; JapicCTI-183937; NCT03248128</Reference><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><Trial id="308779"/><TrialStartDate>OCTOBER  , 20, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rheumatoid arthritis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><EnrollmentCount>147</EnrollmentCount><Interventions>prednisone (oral, delayed release), Horizon/Mundipharma</Interventions><Patients>147</Patients><ProtocolAcronym>K-IMPROvE</ProtocolAcronym><ProtocolTitle>Efficacy of Lodotra (Prednisone) in Reduction of Morning Stiffness Duration</ProtocolTitle><Reference>K-IMPROvE; LOD13-KR-401; NCT02072200</Reference><Sponsor>Mundipharma Korea Ltd</Sponsor><Trial id="175309"/><TrialStartDate>SEPTEMBER, 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Ocular inflammation</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><EnrollmentCount>6</EnrollmentCount><Interventions>IBI-10090</Interventions><Patients>6</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery</ProtocolTitle><Reference>C09-01; NCT01048593</Reference><Sponsor>Icon Bioscience Inc</Sponsor><Trial id="63370"/><TrialStartDate>JANUARY  , 31, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Graft versus host disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><EnrollmentCount>130</EnrollmentCount><Interventions>orBec; orBec; prednisone</Interventions><Patients>129</Patients><ProtocolAcronym/><ProtocolTitle>Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD</ProtocolTitle><Reference>ENT 00-02; NCT00233896</Reference><Sponsor>Enteron Pharmaceuticals Inc</Sponsor><Trial id="26921"/><TrialStartDate>JULY     , 31, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>21</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Patients>21</Patients><ProtocolAcronym/><ProtocolTitle>The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children</ProtocolTitle><Reference>NCT01006655; qvar-adenosineCTIL</Reference><Sponsor>Rambam Health Care Campus</Sponsor><Trial id="61615"/><TrialStartDate>MARCH    , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><EnrollmentCount>956</EnrollmentCount><Interventions>Iluvien; standard of care laser photocoagulation</Interventions><Patients>956</Patients><ProtocolAcronym>FAME</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Implant Compared to Sham Injection in Patients with Diabetic Macular Edema</ProtocolTitle><Reference>C-01-05-001; FAME; NCT00344968</Reference><Sponsor>Alimera Sciences Inc</Sponsor><Trial id="4321"/><TrialStartDate>SEPTEMBER, 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>C-reactive protein</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>DMARD therapy</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><EnrollmentCount>59</EnrollmentCount><Interventions>CRx-102; DMARD therapy</Interventions><Patients>59</Patients><ProtocolAcronym/><ProtocolTitle>A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA</ProtocolTitle><Reference>CRx-102-002; NCT00747214</Reference><Sponsor>Zalicus Inc</Sponsor><Trial id="25682"/><TrialStartDate>NOVEMBER , 30, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ulcerative colitis</Condition><Controls>Entocort EC</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>514</EnrollmentCount><Interventions>Budesonide-MMX</Interventions><Patients>511</Patients><ProtocolAcronym>CORE II</ProtocolAcronym><ProtocolTitle>Randomized, placebo-controlled trial of budesonide-MMX 6 and 9 mg in patients with ulcerative colitis</ProtocolTitle><Reference>CB-01-02/02; CORE II; NCT00679380</Reference><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><Trial id="18729"/><TrialStartDate>JUNE     , 30, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Otitis externa</Condition><Controls>Ciprodex</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64095">dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics</Drug><EnrollmentCount>70</EnrollmentCount><Interventions>FST-201</Interventions><Patients>70</Patients><ProtocolAcronym/><ProtocolTitle>FST-201 in the Treatment of Acute Otitis Externa</ProtocolTitle><Reference>FST201-AOE-AS; NCT00961675</Reference><Sponsor>Shire plc</Sponsor><Trial id="59715"/><TrialStartDate>AUGUST   , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Seasonal allergic rhinitis</Condition><Controls>fluticasone furoate (nasal, allergic rhinitis), GSK</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>962</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>962</Patients><ProtocolAcronym/><ProtocolTitle>A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis</ProtocolTitle><Reference>71047201; LEK PROJECT NUMBER: 2010-02; NCT01279057</Reference><Sponsor>Sandoz Inc</Sponsor><Trial id="176014"/><TrialStartDate>DECEMBER , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body temperature; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA Presentation</ProtocolTitle><Reference>200939; NCT02218723</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="208426"/><TrialStartDate>OCTOBER  , 28, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount/><Interventions>Patanase; Veramyst</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo</ProtocolTitle><Reference>10-270-0006; NCT01076439</Reference><Sponsor>ORA Inc</Sponsor><Trial id="64469"/><TrialStartDate>FEBRUARY , 24, 2010</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>Kenalog-40</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><EnrollmentCount>50</EnrollmentCount><Interventions>Zilretta</Interventions><Patients>50</Patients><ProtocolAcronym/><ProtocolTitle>Study to Characterize the Local Duration of Exposure From FX-006 in Patients With Osteoarthritis of the Knee</ProtocolTitle><Reference>FX006-2013-005; NCT02003365</Reference><Sponsor>Flexion Therapeutics Inc</Sponsor><Trial id="163029"/><TrialStartDate>NOVEMBER , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Ear disease</Condition><Controls>Ciprodex</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64095">dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics</Drug><EnrollmentCount>5</EnrollmentCount><Interventions>FST-201</Interventions><Patients>5</Patients><ProtocolAcronym/><ProtocolTitle>FST-201 In The Treatment of Acute Otitis Externa</ProtocolTitle><Reference>FST201-AOE-02; NCT00945802</Reference><Sponsor>Shire plc</Sponsor><Trial id="59121"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>CHF-1535</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>1153</EnrollmentCount><Interventions>CHF-5993</Interventions><Patients>1153</Patients><ProtocolAcronym>TRIMARAN</ProtocolAcronym><ProtocolTitle>Triple in Asthma With Uncontrolled Patient on Medium Strength of ICS + LABA</ProtocolTitle><Reference>2015-000716-18; CCD-05993AB1-03; NCT02676076; TRIMARAN</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="252805"/><TrialStartDate>FEBRUARY , 17, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Bronchospasm</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount/><Interventions>Relovair</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise</ProtocolTitle><Reference>106847; NCT01435902</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="80962"/><TrialStartDate>JANUARY  , 31, 2012</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Crohns disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>75</EnrollmentCount><Interventions>Entocort</Interventions><Patients>75</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of D-9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease</ProtocolTitle><Reference>D9421C00002; JapicCTI-080566; NCT00573469</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="18570"/><TrialStartDate>OCTOBER  , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Interventions><Patients>150</Patients><ProtocolAcronym/><ProtocolTitle>Study to Assess the Efficacy and Safety of Budesonide (PT-008) in Adult Subjects With Mild to Moderate Persistent Asthmaa</ProtocolTitle><Reference>NCT02105012; PT008001</Reference><Sponsor>Pearl Therapeutics Inc</Sponsor><Trial id="180805"/><TrialStartDate>APRIL    , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Peak nasal inspiratory flow; Peak nasal inspiratory flow</Biomarkers><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>315</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>315</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-Round) Allergic Rhinitis</ProtocolTitle><Reference>2007-006562-15; FFU111439; NCT00609674</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="13885"/><TrialStartDate>JANUARY  , 31, 2008</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Forced expiratory volume (FEV1); Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>28</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Patients>28</Patients><ProtocolAcronym/><ProtocolTitle>To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 microg Once-Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma</ProtocolTitle><Reference>117156; NCT01808339</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="115209"/><TrialStartDate>MARCH    , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>Advair; Symbicort</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>423</EnrollmentCount><Interventions>Relovair</Interventions><Patients>423</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma</ProtocolTitle><Reference>116492; NCT02446418</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="229982"/><TrialStartDate>JULY     , 09, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Fovea centralis; Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>160</EnrollmentCount><Interventions>Zuprata</Interventions><Patients>160</Patients><ProtocolAcronym>PEACHTREE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis</ProtocolTitle><Reference>CLS1001-301; CLS1001-301 Version 3.2; CTRI/2016/09/007269; NCT02595398; PEACHTREE</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="244835"/><TrialStartDate>NOVEMBER , 17, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Atopic dermatitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Patients>170</Patients><ProtocolAcronym/><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Reference>NCT01011621; PRE/P/08-1</Reference><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><Trial id="180987"/><TrialStartDate>FEBRUARY , 28, 2010</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Intraocular Pressure</Biomarkers><Condition>Glaucoma</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>dexamethasone; phacoemulsification; trabeculectomy; triamcinolone acetonide</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, parallel, control study to assess the safety and efficacy of intracameral triamcinolone acetonide in combination with phacoemulsification and trabeculectomy in glaucoma patients</ProtocolTitle><Reference>ChiCTR-TRC-12002313</Reference><Sponsor>Beijing Shijitan Hospital</Sponsor><Trial id="96132"/><TrialStartDate>JANUARY  , 01, 2012</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Meniere disease</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><EnrollmentCount>128</EnrollmentCount><Interventions>dexamethasone</Interventions><Patients>128</Patients><ProtocolAcronym/><ProtocolTitle>A One Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom</ProtocolTitle><Reference>104-201403; 2014-001337-86; NCT02265393</Reference><Sponsor>Otonomy Inc</Sponsor><Trial id="213744"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>C-reactive protein; Serum amyloid A protein</Biomarkers><Condition>Gout</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>226</EnrollmentCount><Interventions>canakinumab; triamcinolone acetonide</Interventions><Patients>226</Patients><ProtocolAcronym>Beta-RELIEVED-II</ProtocolAcronym><ProtocolTitle>Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a One Year Open-label Extension Study</ProtocolTitle><Reference>2009-017802-35; 2010-018913-32; 2010-020060-38; Beta-RELIEVED-II; CACZ885H2357; CACZ885H2357E1; CACZ885H2357E2; H2357; NCT01080131; NCT01137344; NCT01194921</Reference><Sponsor>Novartis AG, Novartis Pharma Services AG</Sponsor><Trial id="202551"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Forced expiratory volume; Forced expiratory volume or FEV1; Hydrocortisone; Peak expiratory flow rate; Peak expiratory flow rate (PEFR)</Biomarkers><Condition>Asthma</Condition><Controls>Aerobec Autohaler; Flixotide</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>FlutiForm</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Pediatric Subjects Aged 5 to &lt; 12 Years</ProtocolTitle><Reference>2013-004719-32; FLT2504; NCT02063139</Reference><Sponsor>Mundipharma Research Limited</Sponsor><Trial id="173450"/><TrialStartDate>FEBRUARY , 28, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Macular edema</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><EnrollmentCount/><Interventions>WP-0508ST</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>WP-0508ST (RVO) Phase III trial</ProtocolTitle><Reference>JapicCTI-142694</Reference><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><Trial id="215368"/><TrialStartDate>OCTOBER  , 31, 2014</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Methacholine</Biomarkers><Condition>Asthma</Condition><Controls>salbutamol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>288</EnrollmentCount><Interventions>Combined beclomethasone dipropionate group; Daily beclomethasone dipropionate group; Qvar</Interventions><Patients>288</Patients><ProtocolAcronym>TREXA</ProtocolAcronym><ProtocolTitle>Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma</ProtocolTitle><Reference>445; 5U10HL064287; 5U10HL064288; 5U10HL064295; 5U10HL064305; 5U10HL064307; 5U10HL064313; NCT00394329; TREXA</Reference><Sponsor>National Heart Lung and Blood Institute</Sponsor><Trial id="22487"/><TrialStartDate>NOVEMBER , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CRP; Total body mass</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="59618">fosdagrocorat</Drug><EnrollmentCount>86</EnrollmentCount><Interventions>PF-04171327</Interventions><Patients>86</Patients><ProtocolAcronym/><ProtocolTitle>A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis</ProtocolTitle><Reference>2009-013223-37; A9391005; NCT00938587</Reference><Sponsor>Pfizer Inc</Sponsor><Trial id="58785"/><TrialStartDate>OCTOBER  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Duchenne dystrophy</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>deflazacort</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy</ProtocolTitle><Reference>MP-104-CL-005; NCT02251600</Reference><Sponsor>PTC Therapeutics Inc</Sponsor><Trial id="211918"/><TrialStartDate>DECEMBER , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>48</EnrollmentCount><Interventions>mometasone (nasal); triamcinolone acetonide</Interventions><Patients>48</Patients><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, single-dose, crossover pilot study to assess the safety and efficacy of Nasacort and Nasonex in patients with allergic rhinitis</ProtocolTitle><Reference>XRG5029C_4006</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="89192"/><TrialStartDate>SEPTEMBER, 09, 2002</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Macular disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>EyeGate II drug delivery system; dexamethasone</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy</ProtocolTitle><Reference>EGP-437-010; NCT02644694</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="250160"/><TrialStartDate>MARCH    , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Eosinophils; Forced expiratory volume in 1 s</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>1635</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>1635</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate Annual Rate of Exacerbations and Safety of Three Dosage Strengths of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>102970; 2009-013064-40; HZC102970; NCT01017952</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="62127"/><TrialStartDate>SEPTEMBER, 25, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Reference>NCT01550471; RC#5401</Reference><Sponsor>West Penn Allegheny Health System Inc</Sponsor><Trial id="86234"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Patients>25</Patients><ProtocolAcronym/><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Reference>NCT01550471; RC#5401</Reference><Sponsor>West Penn Allegheny Health System Inc</Sponsor><Trial id="86234"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Perennial allergic rhinitis</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Reference>200284; NCT01962467</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="157921"/><TrialStartDate>OCTOBER  , 31, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Inflammatory disease</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><EnrollmentCount>120</EnrollmentCount><Interventions>difluprednate</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery</ProtocolTitle><Reference>NCT00616070; ST-601-003</Reference><Sponsor>Sirion Therapeutics Inc</Sponsor><Trial id="21689"/><TrialStartDate>DECEMBER , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Hydrocortisone</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="106967">budesonide (orodispersible tablet, eosinophilic esophagitis), Dr Falk Pharma/Salix</Drug><EnrollmentCount>88</EnrollmentCount><Interventions>Jorveza</Interventions><Patients>88</Patients><ProtocolAcronym>EOS-1</ProtocolAcronym><ProtocolTitle>Budesonide Orodispersible Tablet versus Placebo in Active Eosinophilic Esophagitis</ProtocolTitle><Reference>2014-001484-12; BUL-1/EEA; EOS-1; EOS-1; NCT02434029</Reference><Sponsor>Dr Falk Pharma GmbH</Sponsor><Trial id="228513"/><TrialStartDate>NOVEMBER , 11, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><EnrollmentCount>37</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Patients>37</Patients><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effect of Repeat Doses of GW-870086-X in Mild to Moderate Asthmatics</ProtocolTitle><Reference>112851; NCT00945932</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="59095"/><TrialStartDate>JULY     , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Intraocular pressure</Biomarkers><Condition>Age related macular degeneration</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="60951">triamcinolone acetonide (controlled release/intravitreal injection/Verisome, diabetic macular edema), EyePoint</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>IBI-20089; Lucentis</Interventions><Patients>10</Patients><ProtocolAcronym>20089/Combo</ProtocolAcronym><ProtocolTitle>IBI-20089 + Lucentis Combined Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)</ProtocolTitle><Reference>20089/Combo; 2009-1067; NCT01175395</Reference><Sponsor>University of Illinois</Sponsor><Trial id="68844"/><TrialStartDate>SEPTEMBER, 30, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Diastolic blood pressure; Heart rate; QRS complex; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>42</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Patients>49</Patients><ProtocolAcronym>TRIPLE10</ProtocolAcronym><ProtocolTitle>A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF-5993 pMDI in Subjects With Renal Impairment</ProtocolTitle><Reference>2013-002140-91; CCD-05993AA1-10; NCT02040597; TRIPLE10</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="168962"/><TrialStartDate>JANUARY  , 31, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>26</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Patients>26</Patients><ProtocolAcronym/><ProtocolTitle>A study to see if it is safe to give a new asthma controller drug and a new asthma reliever drug together (called fluticasone furoate/vilanterol) to 5 to 11 year old children with asthma</ProtocolTitle><Reference>2012-000754-55; HZA112777</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="211035"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls>budesonide</Controls><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="29656">TPI-1020</Drug><EnrollmentCount>27</EnrollmentCount><Interventions>TPI-1020</Interventions><Patients>27</Patients><ProtocolAcronym/><ProtocolTitle>Inhaled TPI-1020 versus inhaled budesonide in smokers with mild reversible asthma</ProtocolTitle><Reference>NCT00327808; TPI 1020-202</Reference><Sponsor>Pharmaxis Ltd</Sponsor><Trial id="22059"/><TrialStartDate>MAY      , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Creatinine; Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Hydrocortisone; PR interval; Peak expiratory flow rate; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>619</EnrollmentCount><Interventions>CHF-781</Interventions><Patients>619</Patients><ProtocolAcronym>BEAM</ProtocolAcronym><ProtocolTitle>An 8-week, Dose Ranging Study of CHF-718 pMDI in Asthmatic Subjects</ProtocolTitle><Reference>BEAM; CCD-05993AA3-01; NCT03084718</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="295866"/><TrialStartDate>JULY     , 28, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Seborrheic dermatitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><EnrollmentCount>80</EnrollmentCount><Interventions>GK-664-S</Interventions><Patients>80</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate Efficacy and Safety of GK-664-S in Subjects With Moderate-to-Severe Scalp Seborrheic Dermatitis</ProtocolTitle><Reference>JapicCTI-184246</Reference><Sponsor>Maruho Co Ltd</Sponsor><Trial id="366907"/><TrialStartDate>DECEMBER , 01, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body Mass Index; Body height; Diastolic blood pressure; Eyelid; Glucose; Heart rate; Hemoglobin A, glycosylated; Insulin; Intraocular pressure; Respiratory frequency; Systolic blood pressure; Total body mass; Visual acuity; Waist to Hip Ratio</Biomarkers><Condition>Thyroid associated ophthalmopathy</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><EnrollmentCount>20</EnrollmentCount><Interventions>Nanocort</Interventions><Patients>20</Patients><ProtocolAcronym>GO Nanocort</ProtocolAcronym><ProtocolTitle>A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of grave's orbitopathy with reduced systemic steroid exposure</ProtocolTitle><Reference>GO Nanocort; NL61298.078.17 OZR-2016-34; NTR6579</Reference><Sponsor>Oogziekenhuis Rotterdam</Sponsor><Trial id="307691"/><TrialStartDate>SEPTEMBER, 01, 2017</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Allergic rhinitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="71455">SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Drug><EnrollmentCount>159</EnrollmentCount><Interventions>SPARC-1203</Interventions><Patients>159</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of SPARC-1203 in Allergic Rhinitis</ProtocolTitle><Reference>2012-001613-16; CLR_12_03; NCT01614691; SPARC_Ltd._CLR_12_03</Reference><Sponsor>Sun Pharmaceutical Advanced Research Co Ltd</Sponsor><Trial id="88219"/><TrialStartDate>JUNE     , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Aspartate aminotransferase; Body Mass Index; Creatine kinase; Forced Vital Capacity; Lactate dehydrogenase; Muscle strength; Total body mass</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>prednisone</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><EnrollmentCount>196</EnrollmentCount><Interventions>Emflaza; prednisone</Interventions><Patients>196</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III, Randomized, Double-blind, Placebo-controlled and Active-comparator Study to Evaluate the Safety and Efficacy of Deflazacort and Prednisone in Male Patients With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Reference>MP-104-NM-001</Reference><Sponsor>Marathon Pharmaceuticals LLC</Sponsor><Trial id="262577"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Myalgia</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>122</EnrollmentCount><Interventions>lidocaine; triamcinolone acetonide</Interventions><Patients>120</Patients><ProtocolAcronym/><ProtocolTitle>Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder</ProtocolTitle><Reference>IT-avdelingen; Interne tjenester; NCT00840229; REK; Rikshospitalet HF; S-08546</Reference><Sponsor>Rikshospitalet University Hospital</Sponsor><Trial id="44888"/><TrialStartDate>FEBRUARY , 28, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Body Mass Index; Forced expiratory volume in 1 s (FEV1); Pulse wave velocity; Troponin I, cardiac muscle</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>16568</EnrollmentCount><Interventions>Relovair; fluticasone furoate; vilanterol</Interventions><Patients>16568</Patients><ProtocolAcronym>SUMMIT</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>113782; 2010-021638-72; CCRN 593 (COPD); CTRI/2012/04/002563; HZC113782; HZC113782 14824; IND IDE 077855; NCT01313676; NMRR-13-59-14824; PHRR131025-000134; SUMMIT; UKCRN 10474</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="75513"/><TrialStartDate>JANUARY  , 25, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Body Mass Index; Forced expiratory volume in 1 s (FEV1); Pulse wave velocity; Troponin I, cardiac muscle</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><EnrollmentCount>16568</EnrollmentCount><Interventions>Relovair; fluticasone furoate; vilanterol</Interventions><Patients>16568</Patients><ProtocolAcronym>SUMMIT</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Reference>113782; 2010-021638-72; CCRN 593 (COPD); CTRI/2012/04/002563; HZC113782; HZC113782 14824; IND IDE 077855; NCT01313676; NMRR-13-59-14824; PHRR131025-000134; SUMMIT; UKCRN 10474</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="75513"/><TrialStartDate>JANUARY  , 25, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body height; Eosinophils; Total body mass</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><EnrollmentCount>93</EnrollmentCount><Interventions>budesonide</Interventions><Patients>119</Patients><ProtocolAcronym/><ProtocolTitle>OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension</ProtocolTitle><Reference>MPI-101-06; NCT01642212</Reference><Sponsor>Shire plc</Sponsor><Trial id="89242"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Psoriasis</Condition><Controls>Olux</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="18168">clobetasol propionate foam, Connetics</Drug><EnrollmentCount>78</EnrollmentCount><Interventions>Clobex</Interventions><Patients>78</Patients><ProtocolAcronym/><ProtocolTitle>A Comparison Between Clobetasol Propionate 0.05% (Clobex) Spray and Clobetasol Propionate 0.05% (Olux) Foam</ProtocolTitle><Reference>NCT00436540; US10013</Reference><Sponsor>Galderma Laboratories LP</Sponsor><Trial id="171257"/><TrialStartDate>MARCH    , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>243</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + GW-642444</Interventions><Patients>243</Patients><ProtocolAcronym/><ProtocolTitle>A Long-term Safety Study of Fluticasone Furoate (FF)/GW-642444 and FF in Japanese Subjects With Asthma</ProtocolTitle><Reference>113989; JapicCTI-101343; NCT01244984</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="72445"/><TrialStartDate>JULY     , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>351</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>351</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma</ProtocolTitle><Reference>115285; NCT01436110</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="80895"/><TrialStartDate>SEPTEMBER, 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>FEV1; Hydrocortisone; PEF</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>597</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Patients>593</Patients><ProtocolAcronym/><ProtocolTitle>A Dose-ranging Study of Fluticasone Furoate (FF)</ProtocolTitle><Reference>106855; 2011-003338-15; HZA106855; JapicCTI-121885; NCT01563029</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="85984"/><TrialStartDate>MARCH    , 28, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Reference>116524; NCT01725685</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="97979"/><TrialStartDate>NOVEMBER , 08, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Body temperature; Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Forced expiratory volume; Heart rate; Hydrocortisone; Peak expiratory flow rate; Respiratory frequency; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><EnrollmentCount>56</EnrollmentCount><Interventions>budesonide; fluticasone; fluticasone furoate</Interventions><Patients>56</Patients><ProtocolAcronym/><ProtocolTitle>Phase IIa, AMP Challenge, Dose-Escalation Study to Assess the Dose-Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects</ProtocolTitle><Reference>2016-003002-14; 203162; NCT02991859</Reference><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><Trial id="282142"/><TrialStartDate>FEBRUARY , 09, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Osteoarthritis</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="103224">CINGAL</Drug><EnrollmentCount>526</EnrollmentCount><Interventions>CINGAL</Interventions><Patients>526</Patients><ProtocolAcronym/><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-up</ProtocolTitle><Reference>2017-003205-18; CINGAL 17-02; NCT03390036</Reference><Sponsor>Anika Therapeutics Inc</Sponsor><Trial id="324751"/><TrialStartDate>DECEMBER , 07, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Retinal venous occlusion</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="65121">beclomethasone dipropionate (intravitreal injection), Allergan</Drug><EnrollmentCount>121</EnrollmentCount><Interventions>AGN-208397</Interventions><Patients>121</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of AGN-208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</ProtocolTitle><Reference>208397-001; NCT01027650</Reference><Sponsor>Allergan Inc</Sponsor><Trial id="62499"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Adrenal gland hypofunction</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>Plenadren</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Optimizing Steroid Replacement in Patients With Adrenal Insufficiency</ProtocolTitle><Reference>2016/09/05; NCT03282487</Reference><Sponsor>Adelaide and Meath Hospital, Tallaght Regional Hospital</Sponsor><Trial id="312737"/><TrialStartDate>SEPTEMBER, 05, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anterior chamber</Biomarkers><Condition>Pain</Condition><Controls/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><EnrollmentCount>101</EnrollmentCount><Interventions>EyeGate; dexamethasone</Interventions><Patients>101</Patients><ProtocolAcronym/><ProtocolTitle>Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery</ProtocolTitle><Reference>EGP-437-009; NCT03180255</Reference><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><Trial id="301426"/><TrialStartDate>JULY     , 26, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Uveitis</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><EnrollmentCount>38</EnrollmentCount><Interventions>Zuprata</Interventions><Patients>38</Patients><ProtocolAcronym>AZALEA</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis</ProtocolTitle><Reference>AZALEA; CLS1001-302; NCT03097315</Reference><Sponsor>Clearside Biomedical Inc</Sponsor><Trial id="292964"/><TrialStartDate>APRIL    , 01, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort Turbuhaler</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>990</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>990</Patients><ProtocolAcronym>TRIVERSYTI</ProtocolAcronym><ProtocolTitle>Active-Controlled Trial of CHF-5993 Pressurized Metered-dose Inhaler (pMDI) Versus Symbicort Turbuhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Reference>CCD-5993AA1-14; CHINA; NCT03197818; SOUTH KOREA; TAIWAN; TRIVERSYTI</Reference><Sponsor>Chiesi Farmaceutici SpA</Sponsor><Trial id="303203"/><TrialStartDate>DECEMBER , 13, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Lung malformation</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>Inhaled Extra-Fine Hydrofluoalkane-Beclomethasone (Qvar) in Premature Infants With Bronchopulmonary Dysplasia (BPD)</ProtocolTitle><Reference>0110-10; NCT01373008</Reference><Sponsor>B'nai Zion Medical Center</Sponsor><Trial id="78295"/><TrialStartDate>JUNE     , 30, 2011</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>1204</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Patients>1204</Patients><ProtocolAcronym/><ProtocolTitle>A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 microg and QVAR 40 microg, Inhalation Aerosol</ProtocolTitle><Reference>AI-BDP-001; NCT03562949</Reference><Sponsor>Amneal Ireland Limited</Sponsor><Trial id="343764"/><TrialStartDate>OCTOBER  , 31, 2018</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Diarrhea</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><EnrollmentCount>9</EnrollmentCount><Interventions>Entocort</Interventions><Patients>9</Patients><ProtocolAcronym/><ProtocolTitle>Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients</ProtocolTitle><Reference>IIT-BUDESONIDE-MPA; NCT02991768; STUDY00140436</Reference><Sponsor>University of Kansas Medical Center</Sponsor><Trial id="282139"/><TrialStartDate>JANUARY  , 27, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Airway resistance; Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume; Inspiratory capacity; Lung; Specific airway conductance </Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Fostair</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>Trimbow</Interventions><Patients>24</Patients><ProtocolAcronym>TRIFLOW</ProtocolAcronym><ProtocolTitle>A Study Comparing the Effects of Trimbow to Fostair in COPD</ProtocolTitle><Reference>2018-003113-17; MEU 17/361; NCT03842904; TRIFLOW</Reference><Sponsor>Medicines Evaluation Unit</Sponsor><Trial id="370288"/><TrialStartDate>DECEMBER , 13, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Duchenne dystrophy</Condition><Controls/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="70712">vamorolone</Drug><EnrollmentCount/><Interventions>vamorolone</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy</ProtocolTitle><Reference>NCT03863119; VBP15-EAP</Reference><Sponsor>ReveraGen BioPharma Inc</Sponsor><Trial id="372311"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Rhinitis</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>77</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>48</Patients><ProtocolAcronym>RhiCNANI</ProtocolAcronym><ProtocolTitle>Efficacy and safety study of Nasacort in chronic non-allergic and non-infectious rhinitis in adults</ProtocolTitle><Reference>EudraCT #: 2006-000059-16; NCT00344942; RhiCNANI; TRICA_L_00872</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="13146"/><TrialStartDate>APRIL    , 24, 2006</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><EnrollmentCount>1550</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Patients>1550</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Study The Effects of Beclomethasone Dipropionate Metered Dose Inhaler in Patients With Asthma</ProtocolTitle><Reference>CR176-17; CTRI/2019/02/017719</Reference><Sponsor>AXIS Clinicals Limited, Aurobindo Pharma Research Center II</Sponsor><Trial id="371803"/><TrialStartDate>FEBRUARY , 28, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>blood pressure; heart rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64294">AZD-5423</Drug><EnrollmentCount>18</EnrollmentCount><Interventions>AZD-5423</Interventions><Patients>18</Patients><ProtocolAcronym/><ProtocolTitle>A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD-5423 When Administered in Different Ways</ProtocolTitle><Reference>D2340C00012; Eudract 2012-002307-17; NCT01635985</Reference><Sponsor>AstraZeneca plc</Sponsor><Trial id="96548"/><TrialStartDate>AUGUST   , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Lower back pain</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="113006">reformulated dexamethasone acetate (epidural/sustained release, low back pain), SpineThera</Drug><EnrollmentCount>180</EnrollmentCount><Interventions>SX-600</Interventions><Patients>180</Patients><ProtocolAcronym>SALIENT</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of SX-600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain</ProtocolTitle><Reference>CLIN-0012-STA19-01; NCT03952377; SALIENT</Reference><Sponsor>SpineThera, SpineThera Australia PTY LTD</Sponsor><Trial id="380882"/><TrialStartDate>JULY     , 31, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Pain</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="106609">dexamethasone sodium phosphate (epidural steroid injectable gel, sciatia), Scilex Holding</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>SP-102</Interventions><Patients>400</Patients><ProtocolAcronym>CLEAR</ProtocolAcronym><ProtocolTitle>Corticosteroid Lumbar Epidural Analgesia for Radiculopathy</ProtocolTitle><Reference>CLEAR; NCT03372161; SP-102-02</Reference><Sponsor>Semnur Pharmaceuticals Inc</Sponsor><Trial id="322493"/><TrialStartDate>DECEMBER , 08, 2017</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><EnrollmentCount>841</EnrollmentCount><Interventions>Aerivio Spiromax; fluticasone propionate RespiClick</Interventions><Patients>841</Patients><ProtocolAcronym/><ProtocolTitle>Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler</ProtocolTitle><Reference>2016-003835-39; FSS-AS-30003; NCT02980133</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="281056"/><TrialStartDate>DECEMBER , 16, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition/><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>Qnaze; beclometasone (inhaled, CFC-free), Teva</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol</ProtocolTitle><Reference>BDP-AR-101; NCT01537692</Reference><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><Trial id="85132"/><TrialStartDate>MARCH    , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Eye pressure; HbA1C</Biomarkers><Condition/><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><EnrollmentCount>10</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Patients>10</Patients><ProtocolAcronym/><ProtocolTitle>Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema</ProtocolTitle><Reference>05-EI-0251; 050251; NCT00231023</Reference><Sponsor>National Eye Institute</Sponsor><Trial id="166130"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition/><Controls>gatifloxacin (ophthalmic), Allergan; prednisolone acetate</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="79969">gatifloxacin + prednisolone acetate (ophthalmic, bacterial infection/inflammation), Allergan</Drug><EnrollmentCount>101</EnrollmentCount><Interventions>gatifloxacin + prednisolone acetate (ophthalmic, bacterial infection/inflammation), Allergan</Interventions><Patients>101</Patients><ProtocolAcronym/><ProtocolTitle>Non-Inferiority of Gatifloxacin/Prednisolone Association Versus Isolated Administration in Prevention of Ocular Infection/Inflammation</ProtocolTitle><Reference>AG9890X-001; NCT01218737</Reference><Sponsor>Federal University of Sao Paulo</Sponsor><Trial id="89902"/><TrialStartDate>JANUARY  , 31, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition/><Controls>Rectabul</Controls><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><EnrollmentCount/><Interventions>budesonide</Interventions><Patients/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris Rectal Aerosol Foam</ProtocolTitle><Reference>NCT02800824; PRG-NY-16-007</Reference><Sponsor>Perrigo Co Ltd</Sponsor><Trial id="263269"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row></Rowset>